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Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by B cell 
dysregulation and type 1 interferon (IFN) activity. Variants in the major histocompatibility 
complex (MHC) region confer the greatest genetic risk for SLE; however, the underlying causes 
of association remain elusive. One mechanism by which causal variants may drive genetic 
associations at the MHC is through regulating gene expression in a context-specific manner. 
This project investigates the effect of (i) SLE-associated MHC haplotypes, and (ii) IFN-α 
stimulation on gene regulation in ex vivo B cells, in order to further our understanding of how 
these factors contribute to disease risk. 
 
Expression quantitative trait loci (eQTLs) were investigated for variants tagging six SLE-risk or 
-protective haplotypes: DRB1*03:01 (rs2187668), DRB1*15:01 (rs3135391), DPB1 (rs3117213, 
rs2071351, rs2071349), and MSH5 (rs409558). eQTL analyses were conducted using publicly-
available data sets. Additionally, gene expression data were generated from resting and IFN-α-
stimulated ex vivo B cells. Several cis-eQTLs were identified and replicated in the publicly-
available data sets. A novel trans-eQTL was identified for DRB1*03:01 haplotypes in the exon 
array data set, in both resting and IFN-α-stimulated cells, involving down-regulation of BTN3A2 
(P < 2.63 × 10-6). These results suggest a regulatory role for disease-associated MHC 
haplotypes, and implicate BTN3A2 as a novel candidate gene on the DRB1*03:01 haplotype.  
 
The global effect of IFN-α stimulation on the B cell transcriptome was also explored. Several 
SLE susceptibility genes outside canonical type 1 IFN signalling pathways were differentially 
expressed in response to IFN-α. The direction of effect of IFN-α on the expression of SLE 
candidate genes paralleled the known functional consequences of SLE-associated 
polymorphisms in those genes. This suggests a previously unrecognised role for SLE candidate 
genes following activation of the type 1 IFN pathway, and sheds light into the role of IFN-α in the 
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Chapter 1 -  Introduction 
 
1.1 Systemic lupus erythematosus: a clinical overview 
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that can affect multiple 
organ systems in the human body. The disease is characterized by the presence of 
autoantibodies against cellular and nuclear components, and tissue inflammation which can 
widely vary in severity. Despite the considerable advances in our understanding of disease 
pathogenesis achieved over the last few decades of research, the exact causes of SLE remain 
unknown.  
 
1.1.1 Clinical presentation 
SLE is a clinically heterogeneous disease in which patients can present a broad spectrum of 
symptoms. The manifestations of disease can range from mild to severe, typically including 
periods of relapse and remission. The most commonly reported symptoms include fatigue, joint 
pain (arthralgia), fevers, skin rashes, and photosensitivity. Some patients may also experience 
neuropsychiatric symptoms, such as seizures, strokes, migraines, and depression. More serious 
complications can arise from inflammation of vital organs, such as the kidneys (nephritis), the 
brain, and the heart (carditis), which can ultimately result in organ failure if left untreated (Lahita, 
2004, Lisnevskaia et al., 2014, Mohan and Putterman, 2015). SLE patients exhibit antinuclear 
antibodies (ANA), and may show reduced numbers of peripheral blood cells and reduced levels 
of early complement components.  
 
The presence of specific clinical manifestations (or sub-phenotypes) and autoantibody subsets 
has led many to define SLE as a spectrum of clinical syndromes, rather than a single disease. 
Lupus sub-phenotypes include the presence of renal disease (nephritis), skin involvement, and 
neurological involvement. Common subsets of ANA found in SLE include anti-double-stranded 
deoxyribonucleic acid (anti-dsDNA) antibodies, and anti-ribonuclear protein antibodies such as 
anti-Ro/SSA, anti-La/SSB, and anti-Sm (Lahita, 2004, Lisnevskaia et al., 2014). Approximately 
one third of SLE patients develop secondary autoimmune diseases – for example, thyroid 
disease, Sjӧgren’s syndrome, antiphospholipid syndrome, or rheumatoid arthritis (Lockshin et 
al., 2015). As symptoms of SLE may be unspecific, diagnosis can be based on the presence of 
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at least four of eleven clinical features listed in the American College of Rheumatology 
classification criteria (Hochberg, 1997).  
 
1.1.2 Epidemiology 
SLE has a prevalence of 1 in 2,500 individuals in the United Kingdom (U.K.), and up to 150 in 
100,000 individuals worldwide (O'Neill and Cervera, 2010, Tsokos, 2011). Disease incidence 
varies depending on ethnicity and geographical location, affecting more commonly non-
European and migrant populations (namely African-American, Afro-Caribbean, and Hispanic-
American). SLE mainly affects women of childbearing age, and may remit in patients over the 
age of 50. There is a strong gender bias towards females, with a nine to one ratio of female to 
male patients. SLE mortality rates have improved substantially in the last 60 years, with over 
85% of patients currently surviving to 10 years. However, morbidity remains a significant 
problem due to the lack of effective therapy, damage caused by disease, and side effects from 
currently administered drugs (O'Neill and Cervera, 2010).  
 
1.1.3 Aetiology 
SLE is a complex disease, whereby multiple genetic, environmental, and hormonal factors 
together contribute to disease pathogenesis. Even though the cause of SLE is unknown, some 
insight into disease triggers has been gained. Probable environmental triggers include exposure 
to ultraviolet (UV) light, viral infections (namely Epstein-Barr virus), and drug administration 
(such as hydralazine and type 1 interferon, Gourley and Miller, 2007, O'Neill and Cervera, 2010, 
Jeffries and Sawalha, 2011). Hormonal factors are also thought to act as major disease triggers, 
and may explain the marked sex and age bias in disease incidence. In particular, oestrogen has 
been shown to enhance autoimmunity, and to trigger SLE relapse (O'Neill and Cervera, 2010). 
The higher incidence of SLE in women may also be caused by an X-chromosome  dosage 
effect, as suggested by studies reporting increased disease rates in males with Klinefelter’s 
syndrome (47, XXY karyotype), compared to males with a 46, XY karyotype (Dillon et al., 2011). 
Recent advances in the genetics of SLE susceptibility are described in section 1.4. 
 
1.1.4 Current treatments 
SLE is currently incurable. Treatments administered to patients attempt to reduce inflammation 
and manage symptoms, and consist mainly of immunosuppressants. The most common 
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therapeutic agents in use are non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, 
anti-malarials (such as hydroxychloroquine), and biological agents (monoclonal antibodies). 
Therapeutic monoclonal antibodies currently in use target B cell-modulating components, such 
as the B cell-activating factor CD20 (targeted by Rituximab), or the B cell-survival factor BAFF 
(targeted by Belimumab). With the exception of Belimumab, no new drugs have been approved 
for the treatment of SLE in the last 50 years (Amissah-Arthur and Gordon, 2010). Furthermore, 
current treatments are not effective in all patients, and can cause a range of side effects, 
including infections and increased risk of cardiovascular disease. More research on the 
pathophysiology of SLE is needed to enable the development of targeted treatment for patients 
who do not respond well to conventional therapies, and for the identification of biomarkers of 
prognostic and diagnostic value (Liu and Davidson, 2012). 
 
 
1.2 Immune dysregulation in SLE 
Autoimmunity arises when an aberrant immune response to self-antigens is initiated, following a 
breakdown in immune tolerance. In healthy individuals, central and peripheral tolerance 
mechanisms ensure the deletion or inactivation of autoreactive B cells and T cells. In the 
thymus, thymic epithelial cells present self-antigens on major histocompatibility complex (MHC, 
or human leukocyte antigen) molecules to developing T cells, and signal autoreactive T cells to 
undergo apoptosis or become inactivated. Similarly, immature B cells encounter self-antigens in 
the bone marrow, where autoreactive B cells undergo apoptosis, inactivation, or B cell receptor 
(BCR) editing (central tolerance). At the periphery, autoreactive T cells become unresponsive 
following an antigen encounter in the absence of co-stimulatory signals (T cell anergy). Without 
CD4+ T cell help, autoreactive B cells cannot become activated (peripheral tolerance). In 
autoimmune disease, failure in tolerance mechanisms results in activation of autoreactive T 
cells and B cells, and the production of pathogenic autoantibodies (Liu and Davidson, 2012). 
 
SLE is characterized by cellular dysfunction in both the innate and adaptive arms of the immune 
system. Three key pathogenic mechanisms in SLE include impaired clearance of apoptotic cells 
(the “waste disposal” hypothesis), increased type 1 interferon (IFN) activity (innate immunity), 
and B cell autoreactivity (adaptive immunity). The waste disposal hypothesis posits that 
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defective clearance of apoptotic cells leads to the release and accumulation of nucleic acid-
containing self-antigens in the periphery. Presentation of self-nuclear antigens by antigen-
presenting cells (APCs) in the presence of co-stimulatory signals subsequently leads to the 
activation of autoreactive B and T cells (Kelley et al., 2010). Environmental risk factors such as 
UV rays and viral infections are also thought to trigger increased cell death in SLE, thus 
precipitating the release of self-antigens. Both nuclear antigens and environmental triggers can 
induce the production of type 1 IFNs, namely IFN-α, by plasmacytoid dendritic cells (pDCs). The 
pro-inflammatory activity of IFN-α promotes maturation of APCs, such as myeloid dendritic cells 
(mDCs). mDCs present self-antigens in the context of human leukocyte antigen (HLA) 
molecules to T cells, thereby initiating adaptive immunity. CD4+ helper T cells release signals 
that promote B cell activation and differentiation into autoantibody-producing cells (plasma 
cells). Autoantibodies and self-antigens form immune complexes (ICs), which act as 
endogenous inducers of IFN-α production, thus perpetuating a vicious cycle of inflammation. 
Impaired clearance of cellular debris results in deposition of ICs in tissues, which can cause 







Figure 1-1 Illustration of the immunopathogenesis of SLE.  
 
Environmental factors, such as viruses, trigger IFN-α production by plasmacytoid dendritic cells (PDC), 
and the release of self-antigens from apoptotic cells. IFN-α production induces maturation of dendritic 
cells, activation of T cells and B cells, and autoantibody production. Immune complexes (ICs) further 
induce IFN-α production, perpetuating a vicious cycle of inflammation.  See text for a detailed description. 
NETosis – neutrophil cell death, NK cell – natural killer cell, Mo – monocyte, DC – dendritic cell, TCR – T 




In the innate arm of the immune system, phagocytic cells such as neutrophils and macrophages 
play key roles in the clearance of cellular debris and ICs. For example, apoptotic cells are 
cleared by cross-binding to soluble phagocyte receptor ligands (such as complement factors) 
which induce phagocytosis. Similarly, Fcγ receptors (FCGRs) in phagocytic cells can induce 
phagocytosis of ICs by binding to their Fc portion, thus preventing IC accumulation and 
deposition in tissues (Pittoni and Valesini, 2002, Ronnblom, 2011). In SLE, impaired function of 
complement receptors and FCGRs in macrophages and/or neutrophils is thought to decrease 





1.3 The type 1 IFN pathway and SLE 
A role for IFNs in SLE was first established in 1979, when IFN titres were found to be elevated 
in the serum of SLE patients (Hooks et al., 1979). Since then, there has been a considerable 
amount of evidence demonstrating the central role of type 1 IFNs, particularly IFN-α, in the 
pathogenesis of SLE. Sixty to eighty per cent of SLE patients demonstrate a gene expression 
profile associated with a response to type 1 IFN (i.e. a type 1 IFN signature) in multiple cell 
types, including B cells, T cells, and myeloid cells, as well as in kidneys (Baechler et al., 2003, 
Becker et al., 2013, Berthier et al., 2012). Elevated type 1 IFN activity has been shown in the 
serum of SLE patients, and correlates with disease activity and disease sub-phenotypes (Preble 
et al., 1982, Kirou et al., 2005, Bauer et al., 2006). Additionally, the administration of therapeutic 
IFN-α in chronic viral hepatitis and cancer patients can trigger autoimmunity, including lupus-like 
symptoms, in some patients (Ronnblom et al., 1991, Niewold and Swedler, 2005). Furthermore, 
exogenous IFN-α has been shown to accelerate the onset of SLE in a mouse model (Liu et al., 
2011). The type 1 IFN signature has also been found in subsets of patients with other 
autoimmune diseases, including Sjӧgren's syndrome, rheumatoid arthritis, type 1 diabetes, 
systemic sclerosis, and idiopathic inflammatory myopathies, highlighting the importance of IFNs 
in autoimmunity (Mavragani et al., 2007, Mavragani et al., 2010, Crow, 2010, Assassi et al., 
2010, Lundberg and Helmers, 2010). 
 
 
1.3.1 The IFN family 
IFNs are pro-inflammatory cytokines of the innate immune system which play a central role in 
anti-viral defence. IFNs have a variety of other functions, including anti-tumour response, the 
conferring of immunity against bacterial and fungal parasites, and fine-tuning of immune 
responses. Human IFNs have been divided into three groups: types 1, 2, and 3. Type 1 IFNs 
include 13 IFN-α subtypes, and the single members IFN-β, IFN-ε, IFN-κ, and IFN-ω. All type 1 
IFNs share one heterodimeric receptor, the IFN-α receptor (IFNAR), which is composed of the 
IFNAR1 and IFNAR2 subunits. Differential binding of type 1 IFN subtypes to the IFNAR 
specifies the signalling cascades, and induces specific IFN signatures. Type 1 IFNs can be 
expressed by virtually any cell type, and share a degree of functional overlap with one another. 
This family of IFNs plays a central role in anti-viral defence and in the modulation of immune 
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responses. Type 2 IFN comprises a single member, IFN-γ, which signals through the IFN-γ 
receptor (IFNGR). IFN-γ is mostly expressed by natural killer (NK) cells in the innate response, 
and by activated T cells in the adaptive response. Type 3 IFNs comprise four members of the 
IFN-λ family, which are involved in anti-viral responses at mucosal surfaces. The redundancy of 
the IFN system ensures defence against pathogens, and highlights the importance of these 
cytokines in immunity (Ronnblom, 2011, Hoffmann et al., 2015). 
 
1.3.2 Type 1 and type 2 IFN signalling 
Depending on the type of antigen, type 1 IFNs can be produced via Toll-like receptor (TLR)-
dependent or TLR-independent pathways. The production of type 1 IFNs can be initiated by the 
binding of nucleic acid-containing ICs to FCGRs, which triggers endocytosis of nuclear 
antigens. dsDNA and ribonucleic acid (RNA) antigens bind to endosomal TLR7 or TLR9 
receptors, which activate a signalling cascade through MyD88, IRAK, and TRAF kinases, and 
IFN regulatory factors (IRFs) 3 and 7, which are transcriptional activators of IFN-α and IFN-β 
genes. Alternatively, cytoplasmic RNA activates the RIG-I and MDA5 cytoplasmic receptors, 
which trigger the activation of IRF3 through TLR-independent pathways, and induce type 1 IFN 
gene transcription (Bowie and Unterholzner, 2008). When type 1 IFNs bind to the IFNAR, 
downstream signalling can vary depending on cell type, antigen, and IFN subtype. IFNAR 
dimerization activates JAK1 and TYK2 kinases, which initiate a signalling cascade involving 
activation of STAT signal transducers. STAT1, STAT2, and IRF9 form the ISGF3 transcriptional 
activator complex, which binds IFN-stimulated response elements (ISREs) to induce 
transcription of type 1 IFN-inducible genes (Figure 1-2). An alternative type 1 IFN signalling 
pathway involves the direct transcription of IFN-inducible genes by STAT4 homodimers. The 
canonical pathway for type 2 IFN signals through JAK1, JAK2, and STAT1 homodimers, which 
binds IFN-γ activated site elements (GAS) in the promoter of type 2 IFN-inducible genes. 
Notably, type 1 IFNs can also activate type 2 IFN-inducible gene transcription, due to shared 
signalling mechanisms between type 1 and type 2 IFN systems (Theofilopoulos et al., 2005, 







Figure 1-2 TLR-dependent type 1 IFN pathways. 
 
Recognition of nucleic-acid-containing immune complexes by Fcγ receptors (FCGRs) trigger endocytosis 
and TLR-dependent signalling pathways that induce production of type 1 IFNs (shown on the left). Type 1 
IFNs bind to the IFN-α receptor (IFNAR) on the cell surface, and induce signal transduction cascades that 
activate the expression of several IFN-inducible genes (shown on the right). See text for a detailed 
description of each pathway. ISRE – IFN-stimulated response element. Figure adapted from Rodriguez-




1.3.3 IFN-α in the pathogenesis of SLE 
In SLE, the type 1 IFN signature found in patients is mainly associated with IFN-α activity. As 
illustrated in Figure 1-1, disease pathogenesis is characterized by sustained IFN-α production 
following antigen exposure, instead of a shutdown of the immune response. The most potent 
producers of IFN-α are pDCs, which secrete up to 1000 times more IFN-α than other cells when 
in the presence of viral antigens or ICs. IFN-α is able to breakdown immune tolerance to self by 
activating APCs (DCs and B cells) and pathways of the adaptive immune system, including up-
regulation of HLA class I and costimulatory molecules, cytotoxic CD8+ T cell differentiation, 





Furthermore, the importance of the type 1 IFN pathway in SLE has been reinforced by genetic 
studies. The first genes in the IFN-α pathway to show association with SLE were IRF5 and 
TYK2 (Sigurdsson et al., 2005). With the advent of genome-wide association studies (GWAS), 
further associations with IFN pathway genes have been reported and replicated. These are 
discussed in more detail in section 1.4.2 of this chapter. Moreover, having high levels of IFN-α is 
a trait that clusters in families, and is a heritable risk factor for SLE (Niewold et al., 2007). 
Although it is not known whether increased IFN-α levels are a cause or a consequence of SLE, 
the association of IFN-α therapy with initiation of autoimmunity, as well as the genetic 
association between IFN pathway genes and SLE susceptibility, point to a causal role for IFN-α 
in the disease.  
 
Given the importance of type 1 IFNs in SLE, clinical trials targeting the IFN-α pathway are 
currently underway, including the use of monoclonal antibodies directed against IFN-α and the 
IFNAR. A phase I clinical trial using anti-IFN-α antibodies reported a decrease in the type 1 IFN 
signature in peripheral blood mononuclear cells (PBMCs) and skin, and a reduction in disease 
activity (Merrill et al., 2011). Given the pleiotropic nature of IFNs, namely their role in anti-viral 
and anti-tumour defence, one of the potential effects of anti-IFN therapy is an increased risk of 
viral infections and tumours. Conversely, the functional redundancy between different IFN types 
and subtypes may result in non-responsiveness to therapy. Targeting molecular components 
downstream of the IFN receptor may be of more therapeutic benefit; accordingly, further 
exploration of IFN pathways in SLE is warranted. 
 
 
1.4 Genetic susceptibility to SLE 
SLE has a strong genetic component, as shown by a number of twin and familial aggregation 
studies. Monozygotic twins show higher concordance rates for the disease (25-70%) compared 
to dizygotic twins (2-5%, Deapen et al., 1992). Siblings of SLE patients have a higher disease 
risk when compared to the general population, with a sibling risk ratio (λ) between 8 and 29 
(Alarcon-Segovia et al., 2005). One study calculated a heritability of 66% for SLE; however, only 
15% of this heritability is explained by genetic factors identified to date (Lawrence et al., 1987, 
Bentham et al., 2015). In accordance with the common disease-common variant hypothesis, 
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overall genetic susceptibility to SLE is caused by a combination of multiple common risk 
variants, each of modest effect size (odds ratio, OR between 1.15 and 2.5). In a minority of SLE 
cases, genetic susceptibility is attributed to rare, highly penetrant single-gene mutations 
(monogenic SLE). 
 
The first genetic associations with SLE were identified in 1971 through serological case-control 
studies. SLE cases were shown to be enriched for the HLA class I alleles (HLA-B8 and HLA-
W15) within the MHC region on chromosome 6 (Grumet et al., 1971, Waters et al., 1971). 
Genome-wide linkage studies subsequently confirmed SLE associations within the MHC region 
(Gaffney et al., 1998, Gaffney et al., 2000, Forabosco et al., 2006). With the advent of GWAS, 
variants within the MHC region were shown to confer the greatest genetic risk for SLE (Tsao, 
2004, Graham et al., 2008, Bentham et al., 2015). The association of the MHC region with SLE 
is discussed further in section 1.5 of this chapter, and section 3.1 of Chapter 3.  
 
Over the last decade, GWAS conducted in different populations have provided further insight 
into the genetic factors conferring susceptibility to SLE, which include several non-HLA loci. 
GWAS are based on a hypothesis-free approach where the frequencies of common single 
nucleotide polymorphisms (SNPs) are compared between disease cases and unaffected 
controls. There are currently more than 40 validated common disease-associated variants, 
many of which are located within or in proximity to genes functionally involved in SLE-relevant 
pathways (Bentham et al., 2015). These pathways include clearance of apoptotic cells and ICs, 
type 1 IFN pathways, and lymphocyte signalling and function. In addition, GWAS have identified 
a previously unknown role for autophagy and ubiquitination in SLE (Sestak et al., 2007, Flesher 
et al., 2010, Liu and Davidson, 2012).  
 
1.4.1 Defective apoptosis and clearance of ICs 
The complement system is involved in the opsonization and clearance of microbes and 
apoptotic cells by phagocytosis. One of the strongest genetic associations with SLE is found 
within ITGAM, a gene encoding a subunit of complement receptor 3, CD11b. The R77H variant 
of ITGAM has been shown to impair CD11b-mediated phagocytosis of opsonized targets by 
monocytes, potentially affecting the clearance of apoptotic cells (Rhodes et al., 2012, Zhou et 
al., 2013). Furthermore, homozygous loss-of-function (LoF) mutations in several complement 
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component genes have shown association with monogenic forms of SLE, including C1Q, C1R, 
C1S, and the MHC region-linked C2 and C4 genes (Belot and Cimaz, 2012, Bryan and Wu, 
2014). The R77H variant and complement deficiency resulting from LoF mutations have been 
shown to impair the clearance of apoptotic cells and ICs, thereby exposing self-antigens to 
immune recognition by autoreactive cells (Belot and Cimaz, 2012, Zhou et al., 2013).  
 
Another group of SLE-risk genes involved in clearance of cellular debris are the FCGRs. 
FCGRs induce phagocytosis of ICs by binding to the Fc portion of ICs. A copy number variant 
(CNV) in FCGR3B is associated with reduced levels of FCGR3B in neutrophils, which may also 
impair IC clearance (Yuan et al., 2015). This CNV also generates a FCGR2C-FCGR2B hybrid 
that is expressed ectopically in NK cells, potentially inhibiting NK cell function in SLE (Mueller et 
al., 2013). 
 
1.4.2 Type 1 IFN pathways 
Several SLE susceptibility genes encode components involved in the control of type 1 IFN 
production and response. Within the pathways leading to IFN production, SLE-associated 
variants have been identified in the nucleic acid receptor genes TLR7 and IFIH1 (MDA5), and in 
the IFN regulatory factor genes IRF5, IRF7, and IRF8. In the type 1 IFN response pathway, 
genes encoding the signal transducers TYK2 and STAT4 have also shown association with SLE 
(Mohan and Putterman, 2015, Bentham et al., 2015). Many of the aforementioned SLE-risk 
variants have been shown to result in gene gain-of-function (GoF). For example, variants in 
IFIH1, IRF5, and STAT4 translate to increased serum IFN-α levels, or increased sensitivity to 
IFN-α, in either SLE patients or healthy controls (Robinson et al., 2011, Feng et al., 2010, 
Kariuki et al., 2009). 
 
1.4.3 B cell and T cell signalling 
Components of adaptive immunity pathways, particularly those involved in lymphocyte 
development and function, have also shown association with SLE. Susceptibility variants have 
been identified in genes pertaining to B cell receptor (BCR) signalling, such as BLK, LYN, 
BANK1, and CSK. The role of co-stimulatory pathways in SLE has been highlighted by the 
association of variants within TNFSF4, a gene encoding a co-stimulatory molecule, OX40L, that 
acts at the APC-T cell interface. Other variants have been identified in the gene PTPN22, which 
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encodes a protein tyrosine phosphatase that modulates the responsiveness of B cell and T cell 
receptors; and in transcription factor genes IKZF1 and IKZF3, which play a role in B and T cell 
development (Gateva et al., 2009, Mohan and Putterman, 2015, Bentham et al., 2015).  
 
1.4.4 Nucleic acid metabolism 
Nucleic acid degradation is an important step in programmed cell death (apoptosis), which 
minimizes exposure of nuclear self-antigens to the immune system. Several genes involved in 
nucleic acid degradation are associated with monogenic lupus, including the nuclease genes 
TREX1, DNASE1, DNASE1L3, and the RNASEH genes (Belot and Cimaz, 2012). Interestingly, 
single-gene mutations in components of nucleic acid metabolism are also associated with rare 
clinical syndromes characterized by high levels of type 1 IFNs. These Mendelian disorders, 
broadly termed type 1 interferonopathies, exhibit substantial clinical and genetic overlap with 
SLE, including the presence of a type 1 IFN signature, skin involvement, and inflammation of 
the central nervous system. Studies of these syndromes have established a correlation between 
increased serum type 1 IFN levels and LoF mutations in genes encoding nucleases (e.g. 
TREX1, RNASEH2C), regulators of genomic stability (e.g. SAMHD1), and GoF mutations in 
nucleic acid receptors (e.g. IFIH1, Miner and Diamond, 2014, Crow and Manel, 2015, 
Kretschmer et al., 2015, Gunther et al., 2015). Thus, these studies have identified the 
dysregulation of nucleic acid metabolism as an important trigger of IFN-α production in SLE.  
 
1.4.5 Other pathways 
Further SLE associations have been reported in other components of innate immunity. These 
include several genes encoding regulators of NFκB signalling, which occurs downstream of TLR 
engagement: the IRAK1 kinase gene, and the ubiquitination regulator genes UBE2L3, TNFAIP3 
(A20), and TNIP1. Other recently identified SLE-risk loci include the autophagy gene ATG5; and 
the NCF2 gene, which is thought to be involved in the cytotoxic activity of phagosomes (Gateva 
et al., 2009, Jacob et al., 2012). 
 
1.4.6 Epigenetics 
The epigenome consists of non-coding chromatin modifications, such as methylation and 
histone modifications, which modulate cell-specific gene expression. A recent methylation study 
reported hypomethylation of IFN-inducible genes in T cells, B cells, and monocytes from SLE 
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patients with active and inactive disease. As hypomethylation reflects an open chromatin state, 
these results indicate an increased sensitivity to IFN-α in SLE patients (Absher et al., 2013). 
One other epigenetic modification associated with active transcription, histone 4 acetylation, 
was also shown to be increased in monocytes from SLE patients (Zhang et al., 2010). Changes 
in microRNA (miRNA) activity have also been found in SLE patients; for example, miRNA-146A, 
an inhibitor of the type 1 IFN response, is decreased in PBMCs from SLE patients (Tang et al., 
2009). Epigenetic studies in SLE have contributed to the identification of relevant disease 
pathways, and future research in this field is likely to provide a better understanding of the 
pathogenesis of the disease (Costa-Reis and Sullivan, 2013). 
 
1.4.7 Missing heritability 
As most SLE susceptibility variants identified to date confer relatively small effect sizes in 
overall disease risk, a considerable portion of disease heritability remains undetected. This 
“missing heritability” may be explained by undiscovered rare variants with large effect sizes, 
and/or multiple common variants with small effect sizes. Epigenetics, gene-gene interactions 
(epistasis), and gene-environment interactions involving known and undiscovered SLE-risk 
variants are also likely to exert strong effects on overall disease risk. Furthermore, sub-
phenotype studies may enable the detection of new variants associated with specific clinical 
features that might be missed in SLE GWAS (Flesher et al., 2010). 
 
 
1.5 The MHC region 
HLA molecules consist of a group of cell surface proteins of the adaptive immune system which 
present foreign or pathogenic antigens to T cells. These molecules are also involved in 
maintaining immune tolerance against self by presenting antigens to developing B and T cells. 
Classical HLA class I molecules are expressed in all nucleated cells, and interact with CD8+ T 
cells to induce cytotoxic T cell activity. Classical class II molecules are expressed in APCs, 
namely DCs, B cells, and thymic epithelial cells, and interact with CD4+ T cells to drive 
antibody-mediated (humoral) immunity. Non-classical HLA class I and II molecules are located 
intracellularly, and are involved in antigen processing and loading onto classical HLA molecules 
(Relle and Schwarting, 2012). 
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HLA molecules are mostly encoded in the MHC region, located on the short arm of 
chromosome 6 (6p21.3). The MHC region is a gene-dense locus, harbouring 224 genes and 
pseudogenes. Approximately 40% of genes in the region encode elements involved in 
immunity. The classical MHC locus spans approximately 3.6 megabases (MB), and is divided in 
three sub-regions: class I (telomeric), class III, and class II (centromeric). The class I and class 
II regions contain the HLA genes, which encode classical and non-classical HLA molecules, 
while the class III region encodes soluble proteins involved in immunity, such as complement 
factors, cytokines, and heat shock proteins (Figure 1-3, Horton et al., 2004, Relle and 




Figure 1-3 Schematic representation of the classical MHC region. 
 
The figure shows the location of classical HLA class I and class II genes, as well a number of relevant 




The MHC region demonstrates a high degree of genetic complexity, owing to extended linkage 
disequilibrium (LD), the presence of highly polymorphic genes, and copy number variation. This 
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locus comprises one of the human genome’s regions of highest LD, which can extend to 
immune- and non-immune-related genes outside the classical MHC region. This has led to the 
characterization of an extended MHC (xMHC) region, which spans 7.6 MB across 421 loci 
(Horton et al., 2004). The MHC region also harbours the HLA genes, which include the most 
polymorphic genes in the genome. HLA polymorphism is present in the form of polygeny, allelic 
diversity, and copy number variation.  
 
Classical HLA class I and II molecules can be encoded by a number of HLA loci. HLA class I 
molecules are encoded by HLA-A, HLA-B, and HLA-C, while class II molecules are encoded by 
HLA-DR, HLA-DP, and HLA-DQ genes. Each HLA molecule is a heterodimer composed of two 
chains: the HLA class I is formed by an α chain associated with β2-microglobulin (β2m), while 
the HLA class II is formed by an α and a β chain. Whereas α and β chains are encoded by 
classical HLA genes, the β2m gene is located outside the MHC region (Figure 1-4). In HLA 
molecules, the specificity of the peptide binding groove is determined by hypervariable regions 
within the α and β chains. In HLA class I, the hypervariable regions are encoded within exons 2 
and 3 of HLA class I genes; in HLA class II, these regions are encoded within the exon 2 of HLA 
class II genes (except HLA-DRA, which is not polymorphic). The wide allelic diversity of the 
classical HLA genes means that most individuals in the population are heterozygous at each 
locus. Therefore, one individual can have up to six isotypes of HLA class I and class II 
molecules (2 alleles × 3 loci), thus enabling protection against a wide range of pathogens 







Figure 1-4 Illustration of the classical human HLA genes and molecules. 
 
The genes for classical HLA class I (A, B, and C) and class II (DP, DQ, and DR) molecules are encoded 
within the MHC region, represented at the top in centromeric to telomeric order. β2-microglobulin (β2m) is 
encoded outside the MHC region. In HLA class I, the α chain is hypervariable, whereas β2m is not 
polymorphic. In HLA class II, the α and β chains of HLA-DP and HLA-DQ, and the β chain of HLA-DR are 





The class II HLA-DRB locus is one of two regions of the MHC that exhibit gene copy number 
variation. DRB1 haplotypes can carry one or two functional DRB genes (DRB1 and DRB3, 
DRB4, DRB5, or none), and one to three pseudogenes (DRB9 and DRB2, DRB6, DRB7, DRB8, 
or none), as illustrated in Figure 1-5 (Lahita, 2004). The polymorphic nature of HLA genes is the 
result of evolutionary pressure from rapidly mutating pathogens with potential to evade the 
immune system. The current models explaining allelic diversity at the MHC postulate that 
heterozygote individuals have the ability to recognize more pathogens than MHC-homozygous 
individuals (heterozygote advantage), and that the formation of new rare allelic combinations 
provides an evolutionary advantage against pathogens at the population-level (rare allele 







Figure 1-5 Haplotypes for the class II HLA-DRB locus. 
 
The figure shows the structure of five DRB haplotypes, which include expressed genes (in green) and 




1.5.1 Disease associations with the MHC region 
The MHC region is one of the most extensively studied loci in the human genome, due to its 
strong genetic association with disease. Hundreds of diseases and traits have shown 
association with variants within the region, including multiple autoimmune diseases, 
inflammatory diseases, infectious diseases, transplant rejection, and adverse drug reactions 
(Horton et al., 2008). As previously mentioned, the MHC region confers the strongest risk for 
SLE in virtually every population studied to date, and is currently thought to explain 
approximately 4% of disease heritability (Dr David Morris, King’s College London; personal 
communication). However, the causal variants underlying disease association at the MHC are 
difficult to dissect, owing to tight LD and high polymorphism in the region, copy number 
variation, epistatic interactions between HLA and/or non-HLA alleles, and the clinical 
heterogeneity of SLE probands (Lincoln et al., 2009, Morris et al., 2012). Low recombination 
frequencies at the MHC are attributed to past selective pressures which favoured the 
preservation of specific allelic combinations that provided protection from infectious diseases 
(Gluckman and Hanson, 2004, Relle and Schwarting, 2012). This has led to the conservation of 
extended ancestral haplotypes which can span up to 4 MB, encompassing part of class I, the 
whole of class III, and part of the class II region (from HLA-B to HLA-DQ, Horton et al., 2008, 
Bishof et al., 1993). Ancestral MHC haplotypes are common in the population (frequency ≥ 
0.5%), and together they make up about half of all MHC haplotypes in Europeans. Importantly, 
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most disease associations with the MHC region involve markers of extended ancestral 
haplotypes (Larsen et al., 2014).  
 
The current human reference sequence for the MHC region is derived from a lymphoblastoid 
cell line (LCL) homozygous for the ancestral HLA-B*07-DRB1*15:01 haplotype (PGF). In order 
to characterize haplotype-specific variation, the MHC Haplotype Project annotated the 
sequences of seven additional MHC-homozygous LCLs (Table 1-1, Horton et al., 2008). The 
European ancestral MHC haplotypes harboured by these cell lines were selected for 
sequencing owing to their association with disease risk or protection, including SLE, type 1 
diabetes, and multiple sclerosis. 
 
 
Table 1-1 HLA haplotypes and alleles of eight MHC-homozygous cell lines sequenced by the MHC 
Haplotype Project (Horton et al., 2008). 
 
Cell Line Haplotype HLA-A HLA-B HLA-C HLA-DRB1 HLA-DQB1 HLA-DPB1 
PGF A3-B7-DR15 03:01 07:02 07:02 15:01 06:02 04:01 
COX A1-B8-DR3 01:01 08:01 07:01 03:01 02:01 03:01 
QBL A26-B18-DR3 26:01 18:01 05:01 03:01 02:01 02:02 
APD A1-B60-DR13 01:01 40:01 06:02 13:01 06:03 04:02 
DBB A2-B57-DR7 02:01 57:01 06:02 07:01 03:03 04:01 
MANN A29-B44-DR7 29:02 44:03 16:01 07:01 02:02 02:01 
SSTO A32-B44-DR4 32:01 44:02 05:01 04:03 03:05 04:01 
MCF A2-B62-DR4 02:01 15:01 03:04 04:01 03:01 04:02 
 
 
The most significant associations with SLE in Europeans consistently arise from the ancestral 
B*08-DRB1*03:01 haplotype, which is tagged by the DRB1*03:01 allele (Grumet et al., 1971, 
Goldberg et al., 1976). The second most consistently replicated association with SLE in 
Europeans arises from the ancestral haplotype tagged by the DRB1*15:01 allele (B*07-
DRB1*15:01, Uribe et al., 2004, International MHC and Autoimmunity Genetics Network et al., 
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2009). SLE associations with other DRB1 alleles, including DRB1*04, DRB1*08, DRB1*09:01, 
DRB1*13, and DRB1*14, have been reported in different populations (Kapitany et al., 2009, 
Uribe et al., 2004, Shimane et al., 2013, Furukawa et al., 2014, Kim et al., 2014). The 
association of classical HLA genes with SLE, as well as other autoimmune diseases, is likely to 
be explained by the role of HLA molecules in antigen presentation. Disease-associated alleles 
may translate to HLA amino acid variations that result in poor presentation of self-antigens to T 
cells during central tolerance, thereby disturbing negative selection thresholds for autoreactive T 
cells in the thymus (Wucherpfennig and Sethi, 2011). 
 
In recent years, targeted studies have attempted to fine-map MHC associations in SLE, in order 
to identify the causal variants. Implementation of high-density SNP genotyping, trans-ancestral 
mapping, and meta-analysis have enabled the identification of independent SLE associations at 
the MHC, including risk and protective variants in HLA-G (class I), HLA-DPB1 (class II), SKIV2L 
(class III), and MSH5 (class III, Fernando et al., 2007, Ruiz-Narvaez et al., 2011, Fernando et 
al., 2012). Interestingly, after conditioning on DRB1 signals, these studies identified 
associations with the classical class II DPB1 gene in Spanish (rs3117213, risk, OR = 1.76), 
Filipino (rs2071351, protective, OR = 0.48), and African-American (rs2071349, risk, OR = 1.53) 
SLE cohorts. Similarly, an SLE-protective variant at MSH5, rs409558, was associated in both 
Spanish and Filipino populations independently of DRB1 signals (OR ~ 0.56). Since the 
aforementioned variants in DPB1 and MSH5 are non-coding, the causal mechanisms 
underlying these associations are likely to be independent from HLA amino acid variation. 
However, the independence of these signals from HLA amino acids has not been yet 
established. 
 
1.5.2 DRB1*03:01 haplotypes 
The DRB1*03:01 allele is common in European populations (frequency of 10%). It tags two 
major haplotypes: one common in Northern Europeans (B*08-DRB1*03:01, present in COX cell 
lines), and the other common in Southern Europeans (B*18-DRB1*03:01, present in QBL cell 
lines, Table 1-1). DRB1*03:01 haplotypes are some of the longest haplotypes found in the 
human genome, and can span up to 4 MB of the MHC region, including the majority of class I 
and II, and all of class III. Sequencing and annotation of the B*08-DRB1*03:01 haplotype, 
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carried out by the MHC Haplotype Project revealed that this haplotype spans 311 loci and 1,191 
variants (Horton et al., 2008). 
 
In addition to SLE, DRB1*03:01 haplotypes have been associated with multiple autoimmune as 
well as non-autoimmune diseases. Among the autoimmune diseases associated with this 
haplotype are primary and secondary Sjögren’s syndrome, rheumatoid arthritis, idiopathic 
inflammatory myopathies, and type 1 diabetes. A full list of diseases associated with 
DRB1*03:01 haplotypes is presented in Table 1-2.  
 
 







Systemic lupus erythematosus 
Graham et al. (2002),     
Morris et al. (2012) 
Primary Sjögren’s syndrome Gottenberg et al. (2003) 
Rheumatoid arthritis Vignal et al. (2009) 
Multiple sclerosis de la Concha et al. (2012) 
Type 1 diabetes Noble and Valdes (2011) 
Idiopathic inflammatory myopathies 
O'Hanlon et al. (2006),     
Miller et al. (2015) 
Graves’ disease Maciel et al. (2001) 
Autoimmune hepatitis Oliveira et al. (2011) 
Celiac disease Jores et al. (2007) 
Dermatitis herpetiformis Wilson et al. (1995) 
Systemic sclerosis Kallenberg et al. (1981) 
Sarcoidosis Grubic et al. (2007) 
Myasthenia gravis Degli-Esposti et al. (1992) 
Lambert-Eaton myasthenic syndrome Parsons et al. (2000) 
Immunoglobulin A deficiency Volanakis et al. (1992) 
Non-autoimmune  
Ovarian cancer Kubler et al. (2006) 
Human immunodeficiency virus 
infection 
Steel et al. (1988) 
Common variable immune deficiency Volanakis et al. (1992) 
Non-Hodgkin lymphoma Abdou et al. (2010) 
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Several studies have demonstrated strong association between DRB1*03:01 haplotypes and 
the autoantibody subsets anti-Ro and anti-La in European SLE (OR = 3.40-7.50, Galeazzi et al., 
2002, Christian et al., 2007, Morris et al., 2014). This suggests that DRB1*03:01 haplotypes 
strongly increase the risk of specific sub-phenotypes comprising anti-Ro and anti-La antibodies, 
rather than predisposing uniformly to SLE. Given that HLA class II presentation to T cells is 
required for the initiation of antibody-mediated immunity, these findings strongly support a direct 
role for the DRB1*03:01 allele in the pathogenesis of the disease.  
 
Several non-HLA genetic variants within DRB1*03:01 haplotypes have been associated with 
SLE, suggesting that multiple risk factors within these haplotypes may contribute to increased 
susceptibility to SLE, in addition to the risk conferred by HLA alleles. Examples of such 
DRB1*03:01-linked SLE associations that may be functionally relevant include the class III TNF 
-308/G>A promoter variant, the class III TNFB*1 variant, and the C4A and C4B null alleles 
(C4A*Q0 and C4B*Q0, Wilson et al., 1993, Bettinotti et al., 1993, Boteva et al., 2012). TNF and 
TNFB (or LTA) both encode cytokines from the tumour necrosis factor (TNF) family (TNF-α and 
TNF-β, respectively). TNF has been shown to be both beneficial and aggravating in murine 
models of lupus (Aringer and Smolen, 2008). Similarly, clinical trials testing the efficacy of TNF-
α inhibition have shown contradictory outcomes in lupus; accordingly, the role of TNF in disease 
is still unclear (Takahashi et al., 2008, Aringer et al., 2009, Uppal et al., 2009). Interestingly, the 
SLE-risk -308G>A promoter variant in TNF correlates with increased expression levels of TNF 
in blood leukocytes and other cell types (Wilson et al., 1993, Helmig et al., 2011, Abraham and 
Kroeger, 1999). Complement component C4 is encoded by the copy number variable genes 
C4A and C4B. Ancestral B*08-DRB1*03:01 and B*18-DRB1*03:01 haplotypes harbour only one 
C4 copy (C4A or C4B, respectively). Even though partial genetic C4 deficiency does not 
independently predispose to SLE, complete homozygous C4 deficiency, and complete C4 
protein deficiency, are known risk factors for lupus (Boteva et al., 2012, Wu et al., 2009b, Yang 
et al., 2004). Thus, partial genetic C4 deficiency may increase disease risk when combined with 





1.6 Genetics of gene expression in immunity 
GWAS in human complex diseases have identified hundreds of associated variants, of which 
approximately 90% are non-coding (Hindorff et al., 2009). One of the possible functional 
consequences of these variants is regulation of gene expression, for example, by altering 
messenger RNA (mRNA) expression levels, alternative splicing, or miRNA activity. The level of 
expression of a transcript in cells or tissues can be considered a genetically-determined 
quantitative trait, similarly to traditional quantitative phenotypes such as weight and height. 
Genetic variants that alter gene expression levels are known as expression quantitative trait loci 
(eQTLs), and can be mapped by testing the association between transcript levels and specific 
genetic markers in a cohort of individuals. eQTLs can be analysed for a single locus, or by 
generating genome-wide expression profiles using microarray or RNA sequencing technologies. 
Commonly, a genome-wide variation profile is also generated for the cohort, using high-density 
SNP genotyping platforms. 
 
Regulatory variants are defined as cis- or trans-acting, depending on their genomic distance 
from the target gene. Cis-acting variants (or cis-eQTLs) are variants that alter the expression of 
nearby genes, and are conventionally defined as being located at a distance of up to 1 MB from 
the target gene. Trans-eQTLs are defined as variants that affect distant genes, or genes on a 
different chromosome. Genes underlying trans-eQTLs are assumed to encode trans-acting 
regulatory factors that bind cis-elements of other genes. Thus, trans-eQTLs may represent the 
location of transcription regulators (such as transcription factors) that alter the expression of one 
or more functionally-related genes, and have the potential to expose new biologically-relevant 
pathways. In the last decade, several eQTL studies have successfully identified multiple cis-
associations (Westra and Franke, 2014, Fairfax and Knight, 2014). In contrast, trans-eQTLs 
have been more difficult to detect, due to their complexity and the need to correct for large 
numbers of statistical tests. 
 
1.6.1 Context-dependency of eQTLs 
Early eQTL studies were often conducted in heterogeneous cell populations such as whole 
blood, PBMCs, or skin biopsies. These studies helped to elucidate the global eQTL landscape 
in these cell populations and tissues, as they translated in vivo cell states and cell-to-cell 
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interactions. However, the importance of biological context for the detection of eQTLs, including 
cell type, stimuli, time point, and cell environment, has recently been highlighted (Fairfax and 
Knight, 2014). eQTLs from less abundant cell types (such as B cells in whole blood or PBMC 
samples) may therefore not be detected in data sets generated from heterogeneous cell 
populations, due to signal saturation from the most common cell types. eQTL studies designed 
to explore cell type-specific eQTLs have been growing in number, and have been conducted 
using purified immune cell subsets, such as ex vivo monocytes, B cells, CD4+ T cells, CD8+ T 
cells, and neutrophils. eQTLs may be present in one cell type but not in others, or may have 
opposing effects in different cell types (Fairfax et al., 2012, Westra et al., 2015, Naranbhai et al., 
2015).  
 
Additionally, eQTLs may only be detected when cells are exposed to specific stimuli – such 
eQTLs are named response eQTLs (reQTLs). For example, one study conducted using ex vivo 
B cells found different eQTLs compared to studies using LCLs, which are derived from Epstein-
Barr virus-transformed B cells (Fairfax et al., 2012). Other studies have reported several novel 
reQTLs following stimulation with lipopolysaccharide (LPS), IFN-β, IFN-γ, and infection with the 
influenza virus in monocytes and/or DCs (Fairfax et al., 2014, Lee et al., 2014). It is possible 
that immune stimulation of cells may facilitate the discovery of eQTLs by homogenising gene 
expression. Furthermore, reQTL studies may also enable the discovery of trans-eQTLs, which 
tend to be more sensitive to context specificity than cis-eQTLs. The mechanisms underlying 
eQTLs and their regulation of gene expression may involve the formation/alteration of 
transcription factor or miRNA binding sites (Cham et al., 2012, Luo et al., 2011), non-
synonymous variants that result in a shortened transcript life-span or nonsense-mediated RNA 
decay, or splice site variants that alter the levels of spliced transcript isoforms (Lalonde et al., 
2011).  
 
1.6.2 Methods for quantifying gene expression 
The development of high-throughput genotyping and expression platforms has enabled the 
generation of high-dimensional SNP genotype and gene expression data, which can be used for 
genome-wide eQTL analyses. Several technologies can be employed to measure transcript 
levels, including quantitative reverse-transcription polymerase chain reaction (qPCR, for single 
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locus analyses), or gene expression microarrays and next generation sequencing (for 
generation of genome-wide expression profiles).  
 
Commonly used gene expression platforms include the Affymetrix GeneChip array and the 
Illumina BeadChip array (Turnbull et al., 2012). Traditional gene expression microarrays target 
the 3’ end of annotated genes to measure overall expression levels, but provide little information 
on alternatively spliced transcripts. Affymetrix platforms target each gene using multiple 25-base 
long oligodeoxynucleotide probes, in contrast to other platforms, where each gene is generally 
targeted by one probe. In principle, Affymetrix whole-transcriptome arrays provide the most 
reliable microarray technology, due to their dense genomic coverage. The Affymetrix Human 
Exon 1.0 ST array (or exon array) contains probe sets that specifically target every putative 
exon, which provides a more accurate quantification of gene expression.  
 
Seventy-five per cent of eukaryotic genes and 95% of multi-exon genes are estimated to 
undergo alternative splicing, which enables the generation of different mRNAs and, 
subsequently, protein diversity from a single gene (Pan et al., 2008, Tian et al., 2011). Exon 
arrays are one of the methods which offer insights into alternative splicing events and 
alternative transcription start sites (Lockstone, 2011). Alternatively, cell type-specific splicing 
patterns can be defined using splice junction arrays, such as the Affymetrix GeneChip Human 
Transcriptome Array 2.0, which targets annotated exon-exon junctions specific to individual 
transcript splice isoforms. RNA sequencing platforms, such as the Roche 454, Illumina HiSeq, 
and Life Technologies SOLiD platforms, are also increasingly being used to quantify gene 
expression (Wall et al., 2009). These technologies have the advantage of measuring all 
annotated and non-annotated transcripts in a given sample, thus providing unbiased 
information. However, the generation of gene expression profiles using different platforms 
raises a caveat regarding the reproducibility of gene expression data between different studies.  
 
1.6.3 Functional applications of eQTL studies 
As GWAS do not provide a functional characterization of disease-associated loci, gene 
expression levels can be used as intermediate phenotypes to investigate the genetic basis of 
complex disease. Several eQTL studies conducted in ex vivo myeloid and lymphoid cells have 
investigated eQTLs in GWAS variants associated with autoimmune and inflammatory disorders, 
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including SLE. A study by Fairfax and colleagues found that autoimmune disease-associated 
SNPs are enriched for eQTLs genome-wide, suggesting a functional role for these variants in 
disease risk (Fairfax et al., 2012). Furthermore, SLE-associated variants were found to be 
enriched for B cell-specific eQTLs compared to monocytes, which is consistent with the 
importance of B cells in the pathogenesis of the disease. Various cis-eQTLs have been reported 
for SLE-associated variants genome-wide, including those within IRF5, IRF7, BLK, and UBE2L3 
(Fairfax et al., 2012, Bentham et al., 2015). For example, an SLE-risk haplotype at IRF5 has 
been shown to correlate with increased levels of IRF5, which is potentially caused by an 
inserted transcription factor binding site for SP1 (Cham et al., 2012). This exemplifies how eQTL 
studies may help to elucidate the functional mechanisms underlying GWAS associations with 
complex disease. 
 
Since disease-causing variants might only be active in the presence of a specific cell stimulus, a 
number of studies have investigated reQTLs in disease-relevant contexts. One reQTL involving 
the IRF7 variant rs12805435, which is in moderate LD with the SLE-risk SNP rs4963128, was 
described by Lee and colleagues following stimulation of DCs with the influenza virus (Lee et 
al., 2014). After exposure, rs12805435 correlated in cis with IRF7 expression, and in trans with 
expression levels of IFN-α genes, which is consistent with the association of viral infections and 
type 1 IFNs with the development of SLE in susceptible individuals. 
 
 
1.7 Summary and project aims 
SLE is an autoimmune disease characterized by up-regulation of type 1 IFNs and B cell 
hyperactivity. Genetic association studies support the dysregulation of the IFN pathway and 
antigen presentation as the main drivers of disease pathology. The MHC region confers the 
greatest genetic risk for SLE, but fine-mapping causal variants has been challenging due to the 
presence of highly polymorphic genes and strong LD. Multiple independent associations with 
SLE risk and protection have been identified at the MHC, including the DRB1*03:01 and 
DRB1*15:01 ancestral haplotypes, DPB1 variants in class II, and MSH5 variants in class III. 
However, the most statistically significant associations with SLE in Europeans consistently arise 
within extended DRB1*03:01 haplotypes, which encompass thousands of genetic variants. 
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Several causal variants within DRB1*03:01 haplotypes may therefore contribute to disease risk, 
possibly through independent mechanisms. Furthermore, several autoimmune diseases have 
shown association with both DRB1*03:01 haplotypes and up-regulation of type 1 IFNs; hence, 
one can hypothesise a gene-environment interaction between these SLE susceptibility factors.  
 
One of the causal mechanisms underlying the aforementioned genetic associations with SLE 
may be the regulation of gene expression in specific biological contexts. B cells represent an 
ideal cell type in which to study SLE-associated eQTLs, due to their central role in the 
pathogenesis of SLE. This project aims to: 
 
i) investigate whether the MHC variants underlying the DRB1*03:01, DRB1*15:01, MSH5, 
and DPB1 SLE associations alter gene expression levels in resting LCLs and ex vivo B cells, 
using publicly-available data sets generated from healthy individuals;  
ii) explore the effects of IFN-α on gene expression and alternative splicing in ex vivo B 
cells from healthy female twins, using data generated from Affymetrix Human Exon 1.0 ST 
arrays; 
iii) validate the eQTLs identified in aim (i) for the DRB1*03:01, DRB1*15:01, MSH5, and 
DPB1 haplotypes in resting ex vivo B cells, and investigate whether these haplotypes harbour 
reQTLs following stimulation with IFN-α; 
iv) explore the effect of DRB1*03:01 haplotypes on alternative splicing in ex vivo B cells at 
rest, and following stimulation with IFN-α; 
v) investigate whether there are haplotype-environment interactions between DRB1*03:01 




Chapter 2 - Materials and methods 
 
2.1 Gene expression datasets 
Expression quantitative trait loci (eQTLs) within haplotypes associated with systemic lupus 
erythematosus (SLE) were investigated in three publicly-available gene expression data sets. 
 
2.1.1 LCL dataset from the International HapMap Project 
Gene expression data generated from lymphoblastoid cell lines (LCLs) in the study by Stranger 
and colleagues were obtained from the Gene Expression Omnibus repository (accession 
number GSE6536, Stranger et al., 2007). The samples were derived from 60 healthy individuals 
of Northern and Western European origin from Utah, U.S.A. (CEU), recruited by the 
International HapMap Project. Expression data were generated using the Illumina Sentrix 
Human-6 Expression BeadChip platform.  
 
2.1.2 LCL dataset from the MuTHER study 
Gene expression data from LCLs generated for the Multiple Tissue Human Expression 
Resource (MuTHER) study were accessed using the Genevar resource (Grundberg et al., 2012, 
http://www.sanger.ac.uk/resources/software/genevar). The samples were derived from 777 
healthy female individuals from the United Kingdom (U.K.), recruited from the TwinsUK adult 
registry (Spector and Williams, 2006). Expression data were processed using the Illumina 
Human HT-12 v3 BeadChip platform.        
 
2.1.3 Ex vivo B cell dataset 
Gene expression data generated from ex vivo B cells in the study published by Fairfax and 
colleagues were obtained from ArrayExpress (accession number E-MTAB-945, Fairfax et al., 
2012). Cells were purified by positive selection from peripheral blood mononuclear cells 
(PBMCs) of 281 healthy individuals from Oxford, U.K. The data were processed using the 






2.2 Samples for generation of gene expression data  
 
2.2.1 Cohort from the TwinsUK adult registry 
Fifty healthy female participants were recruited from the TwinsUK adult resource at St. Thomas’ 
Hospital (Spector and Williams, 2006). Genotype data were provided by the TwinsUK registry 
for 7000 individuals. Individuals were selected based on the presence of the DRB1*03:01 allele 
(using the tag single nucleotide polymorphism (SNP) rs2187668), and the MSH5 protective 
haplotype (using the tag SNP rs409558). Thus, the rs2187668 SNP (minor allele frequency of 
10%) would have approximately 70 homozygotes available for recall, and the rs409558 SNP 
(minor allele frequency of 15%) would have approximately 160 homozygotes available for recall. 
Whole blood samples from twins were collected in two different batches, one year apart. Written 
consent was obtained from all study participants prior to sample collection.  
 
2.2.2 MHC-homozygous LCLs from the MHC Haplotype Project 
Seven LCLs from the MHC Haplotype Project (Horton et al., 2008) were obtained from the 
European Collection of Authenticated Cell Cultures (https://www.phe-culturecollections.org.uk/ 
collections/ecacc.aspx). All seven LCLs are homozygous at the major histocompatibility 
complex (MHC) region. Human leukocyte antigen (HLA) genotypes for each cell line are shown 




2.3 Generation of gene expression data 
Gene expression microarray data were generated from MHC-homozygous LCLs, and from 
twins’ ex vivo B cells, both at rest and following stimulation with interferon (IFN)-α, as illustrated 
in Figure 2-1. The processing of samples prior to array hybridization for 15 of 50 individual 
twins, and from all seven LCLs, was conducted by Ms Lora Boteva under the supervision of Dr 
Michelle Fernando (Department of Medical and Molecular Genetics, King’s College London). 
For LCL samples, PGF, COX, QBL, and DBB duplicates were cultured and processed in a 
different batch to the other samples. Twins’ ex vivo B cell samples were processed in two 






Figure 2-1 Workflow demonstrating the steps taken to generate gene expression data from twins’ ex vivo B 




2.3.1 PBMC isolation 
PBMCs were isolated from 60 ml whole blood diluted 1:1 in phosphate-buffered saline (PBS, 
Sigma-Aldrich). 25 ml aliquots were layered onto 15 ml Histopaque-1077 Hybri-Max (Sigma-
Aldrich) and centrifuged with no brake at 800 × g for 20 minutes (min) at room temperature 
(RT). The layer containing PBMCs (buffy coat) was isolated and washed twice with 40 ml 
PBS/0.5% bovine serum albumin (BSA, Sigma-Aldrich) using centrifugation at 300 × g for 10 
min at RT. A final wash and centrifugation at 100 × g for 10 min, RT, was carried out to remove 
excess platelets. Around 40 - 60 million PBMCs were obtained per blood sample. 
 
2.3.2 DNA extraction 
Genomic deoxyribonucleic acid (DNA) was extracted from the cell pellets which remained 
following PBMC extraction from the 50 twins. Red blood cells were lysed by incubation with ice 
cold water for 5 min, followed by centrifugation at 300 × g for 10 min, 4 °C. The incubation and 
centrifugation steps were repeated once. White blood cells were lysed by incubation with 
hypotonic lysis buffer (1% NP-40, 50 mM Tris-Cl pH 7.5, 150 mM NaCl, Fisher Scientific) for 5 
min on ice, followed by centrifugation for 10 min, 4 °C. Pellets were washed twice with PBS, and 
incubated overnight with genomic lysis buffer (10mM Tris pH 8.0, 10mM NaCl, 10mM EDTA 




phenol (Fisher Scientific) and chloroform (Fisher Scientific), and was ethanol-precipitated 
(Fisher Scientific). DNA purity was assessed using the Nanodrop 3300 fluorospectrometer 
(Thermo Scientific).  
 
2.3.3 HLA-DRB1 typing 
Forty-six of fifty DNA samples from twins participating in the study were successfully typed for 
HLA-DRB1 by Dr Robert Collins (Clinical Transplantation Laboratory, Guy’s Hospital). Four-digit 
typing was performed using the SeCore DRB1 Locus Exon 2 & Exon 3 Sequencing Kit (Life 
Technologies). Using this kit, accurate DRB1 typing is achieved through amplification and 
bidirectional sequencing of DRB1 exon 2 and exon 3. The location of primers within the introns 
flanking exons 2 and 3 enables locus-specific amplification, and targeting of all DRB1 alleles. 
 
2.3.4 B cell isolation 
PBMCs extracted from whole blood were washed with 40 ml of B cell isolation buffer (PBS, 2% 
FBS, 2 mM EDTA), and centrifuged at 300 × g for 10 min, RT. CD19+ B cells were isolated by 
negative selection using the Dynabeads Untouched Human B Cells Kit (Invitrogen). This kit 
achieves negative selection of CD19+ B cells by depleting non-B cells from samples. Samples 
were incubated with an antibody mix designed to bind all blood cells except B cells. Antibody-
binding Dynabeads were added to samples for a short period, to allow binding to antibody-
labelled cells. Bead-bound cells were then removed using a magnet and discarded, leaving 
untouched CD19+ B cells in the samples. 
 
2.3.5 Cell culture and IFN-α stimulation 
Ex vivo B cells and LCLs were cultured in RPMI 1640 medium (GIBCO), 20% foetal bovine 
serum (FBS, Life Technologies), L-glutamine (200 µM, GIBCO) and 1% penicillin/streptomycin 
(GIBCO), in a cell culture incubator at 37°C and 5% CO2. LCLs were thawed from liquid 
nitrogen and cultured at a density of 5 × 10-5 cells/ml in T75 flasks (Nunco). After reaching 
exponential growth, 10 million LCLs at rest and 1.5 - 3 million ex vivo B cells were harvested. A 
similar number of cells were stimulated with IFN-α 2b (1000 units/ml, Bio-Techne) for 6 hours 




2.3.6 RNA extraction 
Ribonucleic acid (RNA) was isolated from 1.5 - 3 million ex vivo B cells or LCLs, using the 
RNeasy Mini kit (Qiagen), according to the manufacturer’s instructions. This RNA isolation 
procedure involves a cell lysis step, and on-column RNA-purification. Samples were first lysed, 
homogenized and mixed with ethanol to provide ideal binding conditions. The lysate was then 
loaded onto a RNeasy silica membrane, which binds and retains RNA, while allowing all other 
lysate components to wash through. To remove residual DNA contamination, an on-column 
DNase I treatment step was included, using the RNase-Free DNase Set (Qiagen). 80 µl of the 
DNase I incubation mix was added to the membrane. The RNA was then eluted from the 
membranes in RNase-free water. RNA integrity was assessed in a Nanodrop 3300 
fluorospectrometer (Thermo Scientific) and Agilent 2100 Bioanalyzer (Agilent), using the RNA 
6000 Pico Kit (Agilent). Samples with a RNA Integrity Number (RIN) > 8 were taken forward for 
analysis.  
 
2.3.7 cDNA synthesis and array hybridization 
Complementary DNA (cDNA) was synthesised from 50 ng of RNA using the High Capacity 
RNA-to-cDNA Kit (Applied Biosystems). cDNA from each sample was labelled with a 
fluorescent dye and hybridised to Affymetrix Human Exon 1.0 ST arrays. Data were processed 
using the GeneChip Scanner 3000 7G (Affymetrix), according to the manufacturer’s 
instructions. This work was performed by Mr Erick Nasser, Dr Fei Wong, and Dr Estibaliz 
Aldecoa-Otalora Astarloa, under the supervision of Dr Matt Arno (Genomics Centre, King’s 
College London). 
 
2.3.8 The Affymetrix Human Exon 1.0 ST array 
The Affymetrix Human Exon 1.0 ST array (henceforth referred to as exon array) is a platform 
suited for the analysis of gene expression and alternative splicing. The array contains over 5.5 
million probes, grouped into 1.4 million probe sets. Each exon is targeted by one probe set, 
which usually comprises a set of four probes. Longer exons or extended untranslated (UTR) 
regions may have more than one probe set. Probes are designed to target the reference human 
MHC sequence, obtained from the PGF cell line. Following hybridization of cDNA to the array, 
expression data is obtained by fluorescence-based detection. Signal intensities are captured by 
camera, quantified, and stored as .CEL files. The summarization of raw intensity data can 
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provide measures of two different kinds of information: i) overall gene expression, summarized 
as transcript cluster data (gene-level), and ii) exon-specific expression, summarized as probe 
set data (exon-level). Data quality control (QC) and final summarization were carried out using 
the probe set and transcript cluster annotation release 33.1 (annotation files dated 12/10/12, 
GRCh37 build).  
 
 
2.4 Quality control of exon array expression data 
The QC steps described in this section were applied to the raw intensity signal data from exon 





Figure 2-2 Pipeline of QC steps applied to intensity signal data obtained from Affymetrix Human Exon 1.0 





2.4.1 Probe and probe set quality control filters 
Probe and probe set filters were applied to the data, as recommended by Lockstone 
(Lockstone, 2011). All probe sets targeting RefSeq-annotated RNA transcripts (“core” probe 
sets) were included. Probes mapping to regions containing SNPs (minor allele frequency > 
0.01) or indels from the 1000 Genomes project were removed from the data. SNP and indel 
mapping was conducted by Dr Mina Ryten and Dr Adaikalavan Ramasamy (Department of 
Medical and Molecular Genetics, King’s College London). Cross-hybridizing probes, and probe 
sets containing less than three probes, were also excluded. Detection above background 
(DABG) noise was calculated for all .CEL files and probe sets were filtered using the Affymetrix 
Power Tools (Affymetrix) -a dabg command. This command calculates the probability that a 
probe set is expressed above background noise. Probe sets with DABG p-values > 0.01 in 50% 
of resting or IFN-α-stimulated samples were filtered out. Probes and probe sets that failed QC 
filters were removed from the data using the statistical package R and the --kill-list and -
-probeset-ids commands in Affymetrix Power Tools. Using data .CEL files and the final list 
of probe sets that passed QC, intensity signals were normalized at exon-level and log2-
transformed using the robust multi-array average (RMA) algorithm in the Affymetrix Expression 
Console software, build 1.2.1.20 (Affymetrix). Array hybridization quality was verified using 
Affymetrix Expression Console according to the recommendations of the Affymetrix Quality 
Assessment of Exon and Gene Arrays White Paper (http://media.affymetrix.com/support/ 
technical/whitepapers/exon_gene_arrays_qa_whitepaper.pdf), including visual inspection of 
microarray chips, intensity signal histogram and boxplots, and detection of positive and negative 
controls. 
 
2.4.2 Replicate sample correlation 
Duplicate data for COX, QBL, PGF, and DBB available from a different batch were used as 
technical replicates. For the twins’ ex vivo B cells, duplicate data for one monozygotic twin pair 
processed in both study batches were used as technical replicates. Same-batch sibling data 
from the twin pair were used as biological replicates. Correlation between replicates was 
assessed using a Spearman correlation test in R, using the following command: 




2.4.3 Principal components analysis 
Principal Components Analysis (PCA) of the twins’ ex vivo B cell and MHC-homozygous LCL 
datasets was performed in R, using the following commands: 




Data structure was visualized in a PCA plot using Partek Genomic Suite version 6.6 (Partek 
Incorporated), and sample outliers were removed from the data sets. A total of 81 samples from 
49 individual twins, and all 11 MHC-homozygous LCL samples were put forward for analysis.  
 
 
2.5 Exon array data normalization 
Intensity signals from exon array probe sets and samples that passed QC filters were 
normalized at exon level (i.e. probe set level), and gene level (i.e. transcript cluster level) in 
Partek Genomic Suite (Partek GS). Exon-level data were generated by normalization of probe 
data using the RMA algorithm and GC background correction. Probe sets were summarized to 
generate gene-level data by calculating the winsorized mean (10% and 90%), which reduces 
the effect of outlier probe sets. Both exon-level and gene-level summarization result in log2-
transformed data. Batch effects were accounted for in exon- and gene-level data sets using the 
batch-remove algorithm in Partek GS. Batch-removal was validated in R using the ComBat 
function (Leek et al., 2012). 
 
 
2.6 Data analysis 
 
2.6.1 Differential gene expression 
Differential gene expression induced by IFN-α and genotypes was calculated for MHC-
homozygous LCL and twins’ ex vivo B cell data sets using a mixed-model analysis of variance 
(ANOVA). Analysis were performed using Partek GS. For the analysis of ex vivo B cell data, 
separate models were used to calculate the effect of IFN-α stimulation (equation 1), the effect of 
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genotype at the cell resting state (equation 2), and the effect of genotype in IFN-α-stimulated 
cells (equation 3). 
 
(1) Y = µ + treatment + individual ID + twin ID + PC1 + PC3 + error 
 
(2) Yresting = µ + genotype + treatment + individual ID + twin ID + PC1 + PC3 + error 
 
(3) YIFN-α = µ + genotype + twin ID + PC1 + PC3 + error  
 
The fitted ANOVA models regressed expression levels at each gene (Y) on fixed-effect terms 
(treatment and/or genotype), and on random-effect terms denoting individual ID, family structure 
and zygosity (twin ID), and principal components (PCs) explaining most of the data variability 
(PC1 and PC3, as shown in Chapter 4, section 4.2). µ represents the intercept. The model 
testing genotypic effects at cell resting state (equation 2) was applied to all samples, and 
adjusted for the effect of IFN-α treatment. The model testing genotypic effects at IFN-α-
stimulated state (equation 3) was applied exclusively to IFN-α-stimulated samples. 
 
The ANOVA model fitted for the MHC-homozygous LCL data set is shown in equation 4. 
 
(4) Y = µ + genotype + cell line ID + error 
 
The model regressed expression levels at each gene (Y) on genotype and cell line ID (random-
effect), in order to adjust for the effect of duplicate samples. µ represents the intercept. All p-
values were corrected for multiple testing using the false discovery rate (FDR) method. 
 
2.6.2 Gene-environment interaction 
The interaction between IFN-α and DRB1*03:01 was tested in the twins’ ex vivo B cell gene-
level data set using Partek GS. To test whether genotypic effects change across different 
treatment conditions, the interaction term treatment × genotype was included in the ANOVA 








(5) Y = µ + treatment + genotype + (treatment × genotype) + individual ID + twin ID + PC1 + PC3 +  
      + error 
 
Y represents the gene expression trait and µ represents the intercept. Genes that are affected 
by one variable (genotype) differentially across a second variable (treatment condition) will have 
small p-values. All p-values were corrected for multiple testing using the FDR method. 
 
2.6.3 Alternative splicing 
Alternative splicing between samples of different treatment groups or genotypes was calculated 
in the twins’ ex vivo B cell exon-level data set using Partek GS's alternative splice ANOVA. This 
model tests the interaction between the factor of interest and exon (factor × exon). Separate 
models were used to calculate the effect of IFN-α stimulation (equation 6), the effect of 
genotype at the cell resting state (equation 7), and the effect of genotype in IFN-α-stimulated 
cells (equation 8). 
 
(6) Y = µ + sample ID + exon + treatment + (treatment × exon) + individual ID + twin ID + error 
 
(7) Yresting = µ + sample ID + exon + genotype + (genotype × exon) + treatment + individual ID + twin 
ID + error 
 
(8) YIFN-α = µ + sample ID + exon + genotype + (genotype × exon) + twin ID + error 
 
Y represents the exon expression trait, µ is the intercept, and sample ID is a sample-to-sample 
effect. Each model adjusted for the same covariates as those used in the standard ANOVA 
models (equations 1, 2, and 3, respectively); PC1 and PC3 were the exception, due to 
confounding with the factor × exon interaction terms. The splice ANOVA model testing 
genotypic effects at cell resting state (equation 7) was applied to all samples, and adjusted for 
the effect of IFN-α treatment. The model testing genotypic effects at IFN-α-stimulated state 
(equation 8) was applied exclusively to IFN-α-stimulated samples. The resulting p-value for 
each gene shows the probability that one or more exons are differentially expressed between 
treatment groups or genotypes. As alternative splicing events generally assume no changes in 
overall transcript expression levels, genes showing differential expression at P < 0.05 (gene-




2.6.4 Ingenuity Pathway Analysis 
Pathway and disease enrichment in genes showing differential expression or alternative splicing 
in the twins’ ex vivo B cell data set were calculated in Ingenuity Pathway Analysis (Qiagen), 
using a right-tailed Fisher’s Exact Test. The 2 × 2 contingency table and equation used to 








     
     




The probability of association between genes differentially regulated by IFN-α and a pathway or 





2.6.5 eQTL analysis 
eQTL analysis was performed using the Matrix eQTL R package (Shabalin, 2012). The 
correlation between SNP genotype and probe set expression levels was calculated using a 
linear regression model with additive genotype effects (Y = µ + genotype + covariates + error, 
where Y is the gene expression trait, and µ is the intercept). eQTLs were defined as cis if the 
genomic distance between the SNP and the probe set start site was less than or equal to 2.5 
MB. eQTLs were defined as trans if the distance between the SNP and probe set was greater 
than 2.5 MB, or if they were located on different chromosomes. All p-values were adjusted for 
multiple testing using the FDR correction method. The analyses were conducted for i) the ex 
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vivo B cell data set from Fairfax and colleagues, adjusting for 33 PCs as recommended by the 
authors (Fairfax et al., 2012); ii) the HapMap LCL data set; and iii) the twins’ ex vivo B cell gene-
level data set generated from exon arrays (sections 2.3, 2.4, and 2.5), adjusting for covariates 
as described in section 2.6.1. For the MuTHER LCL data set, cis-eQTL data were obtained 
through the Genevar resource, and trans-eQTL data were obtained from Dr Kerrin Small 
(Department of Twin Research and Genetic Epidemiology, King's College London; personal 
communication). SNP genotype data were available for all cohorts studied. 
 
 
2.7 TaqMan qPCR 
TaqMan quantitative polymerase chain reaction (qPCR) was used for validation of results 
obtained from array experiments, including the effects of IFN-α treatment on B cell gene 
expression, and eQTLs within DRB1*03:01 haplotypes. The principle of qPCR is based on the 
detection and quantification of a fluorescence signal that emanates during the exponential 
stages of PCR amplification. TaqMan Gene Expression Assays contain a pair of unlabelled 
PCR primers, and a TaqMan probe linked to a fluorophore and a quencher. When the probe is 
intact, the quencher inhibits any fluorescence signal emitted by the fluorophore. Quantification 
of gene expression relies on the 5´-3´ exonuclease activity of the Taq polymerase to cleave the 
dual-labelled probe during PCR amplification of the target. The resulting light emission is 
proportional to the amount of PCR product generated, thus providing a quantitative 
measurement. The presence of a probe, in addition to PCR primers, greatly increases target 
specificity of TaqMan qPCR compared to other qPCR methods. 
 
Twenty-four pre-designed TaqMan Gene Expression Assays (Life Technologies) were obtained 
for qPCR analysis, according to pre-defined criteria outlined in Chapters 4 and 5. Target genes 
included type 1 IFN signature genes, idiopathic and monogenic SLE-associated genes, and 
genes with evidence of differential expression in DRB1*03:01 haplotypes. TaqMan assays and 
their corresponding target transcripts are listed in Table 2-1. TaqMan qPCRs were prepared 
using 4 µl cDNA from twins’ ex vivo B cell samples, 0.5 µl of TaqMan assay, 5 µl of TaqMan 
Universal PCR Master Mix (Life Technologies), and 0.5 µl H2O per reaction. qPCR was 
performed in triplicate using the 7900HT Fast Real-Time PCR System (Applied Biosystems). 
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The cycle conditions were as follows: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 
95°C for 15 seconds (sec) and 60°C for 1 min. 
 
 


































































Absolute threshold cycle (Ct) values and reaction slopes were obtained from the SDS version 
2.4 software (Applied Biosystems). Within triplicate samples, those showing standard deviations 
over 0.3 were considered to be of low reproducibility, and were therefore removed from the 
analysis. Reaction efficiencies were calculated for each gene (E = 10-1/slope). The mean Ct 
values of genes of interest were normalized to the internal control genes UBB, TBP, and OAZ1, 
using ΔCt = Ctgene – Ctcontrols. The resulting ΔCt values were used to calculate differential gene 
expression. All three control genes have previously been reported to be suitable qPCR controls 
(Hruz et al., 2011, Ersahin et al., 2014), and showed similar expression levels across all 
treatment and genotype groups in the exon array data. 
 
 
2.8 Western blot 
The effect of the DRB1*03:01 haplotype on BTN3A1, BTN3A2, and BTN3A3 protein expression 
was assessed by Western blot analysis. Two DRB1*03:01-homozygote LCLs (COX and QBL) 
and three non-DRB1*03:01 LCLs (MANN, APD, and PGF) were used. LCLs were thawed and 
cultured as described in section 2.3.5. Eight million cells were harvested at resting state. Cells 
were lysed with 1 ml cold RIPA buffer (Thermo Scientific), rotated for 30 min at 4 °C and 
sonicated 3 times for 5 sec. Lysates were centrifuged for 20 min at 12,000 × g, at 4 °C, and 
protein was quantified using the Bio-Rad DC Protein Assay (Bio-Rad), according to the 
manufacturer’s instructions.  
 
Lysates were denatured for 10 min at 95 °C in 4 × loading buffer. Samples were loaded on a 
10% Mini-PROTEAN TGX Precast Protein Gel (Bio-Rad), and separation by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) was conducted at 200 volts for 45 min in 
running buffer (250 mM Tris, 1.92 M glycine, 1% SDS, Fisher Scientific). Protein was transferred 
to a nitrocellulose membrane (GE Healthcare) at 100 volts for 30 min in transfer buffer (running 
buffer with 20% methanol), and the membrane was saturated with 5% BSA/PBS for 1 h. 
Membranes were incubated with primary antibodies in 1% BSA/PBS/0.05% Tween (Sigma-
Aldrich) overnight at 4 °C. The primary antibodies used were 1.1 µg/ml anti-BTN3A2 (28010002, 
Bio-Techne), 0.9 µg/ml anti-BTN3A3 (HPA007904, Atlas Antibodies), 1 µg/ml anti-CD277 (14–
2779-82, eBioscience), and 0.05 µg/ml anti-beta-actin (sc-47778, Santa Cruz Biotechnology). 
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Membranes were washed 3 times with PBS/0.1% Tween for 5 min and incubated with 
horseradish peroxidase (HRP)-conjugated secondary antibody (0.2 µg/ml anti-mouse, W4021, 
Promega, or 0.23 µg/ml anti-rabbit, sc-2030, Santa Cruz Biotechnology) in 1% BSA/PBS/0.05% 
Tween for 1 h at RT. Membranes were again washed 3 times with PBS/0.1% Tween and 
incubated with the Luminata Crescendo Western HRP substrate (Millipore) for 3 min. Following 
membrane exposure to light-sensitive films for 30 sec or 1 min, films were developed using the 
Compact X4 film processor (Xograph Imaging Systems).  
 
Protein intensities were quantified using the ImageJ software (National Institutes of Health). 
Data were normalized to beta-actin, and differential expression was calculated using a 
Student’s t-test. Experiments were done in duplicate. 
 
 
2.9 Bioinformatic analysis 
Information on gene structure and function was explored using the Ensembl browser 
(http://www.ensembl.org/index.html), BioGPS (http://biogps.org/#goto=welcome), and the NCBI 
Entrez Gene browser (http://www.ncbi.nlm.nih.gov/gene). 
 
2.9.1 Linkage disequilibrium 
Linkage disequilibrium was calculated using Haploview version 4.2 (Broad Institute) for different 
1000 Genomes populations, and for all cohorts described in this chapter. Tag SNPs for disease-
associated variants were obtained using the Tagger algorithm in Haploview (r2 > 0.80).  
 
2.9.2 SNP functional annotations 
The HaploReg version 4.1 resource was used to access summary data for published eQTLs 
within SLE-associated haplotypes of interest (www.broadinstitute.org/mammals/haploreg, 
accessed September 2015). Regulatory features overlapping the SLE-protective MSH5 
haplotype were obtained from the ENCODE database, using the UCSC browser 
(http://genome.ucsc.edu/) and ASSIMILATOR (http://assimilator.mhs.manchester.ac.uk/cgi-
bin/assimilator.pl, accessed June 2013). Regulatory sites of interest included experimentally-
validated transcription factor binding sites (TFBS), microRNA binding sites, DNA 
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hypersensitivity sites, and methylated DNA. Predicted TFBS disruption by SNPs of interest was 
calculated using JASPAR (http://jaspar.genereg.net/, accessed June 2013). The effect of non-
synonymous SNPs on protein function was predicted using SIFT 
(http://sift.jcvi.org/www/SIFT_dbSNP.html) and Polyphen-2 version 2 
(http://genetics.bwh.harvard.edu/ pph2/).  
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Chapter 3 - eQTL analysis of MHC haplotypes associated with 




3.1.1 Genetically independent associations at the MHC in SLE 
The major histocompatibility complex (MHC) confers the strongest genetic risk for systemic 
lupus erythematosus (SLE) in all populations studied to date, with the most significant 
associations consistently arising from haplotypes harbouring the classical MHC class II genes 
HLA-DRB1, HLA-DQA1, and HLA-DQB1 (Tsao, 2004, Fernando et al., 2012, International MHC 
and Autoimmunity Genetics Network et al., 2009). The causal variants underlying MHC 
associations have remained elusive, owing to the extent of linkage disequilibrium (LD) across 
the region, the high polymorphism of classical human leukocyte antigen (HLA) genes, and copy 
number variation, as well as the heterogeneity of disease phenotype. The strongest 
associations with SLE risk in Europeans arise from the DRB1 alleles *03:01 (odds ratio, OR = 
2.10-2.70), *15:01 (OR = 1.33-1.60), and *08:01 (OR = 3.50), and their respective haplotypes 
(Graham et al., 2002, Uribe et al., 2004, International MHC and Autoimmunity Genetics Network 
et al., 2009, Fernando et al., 2012, Morris et al., 2012).  
 
The DRB1*03:01 risk allele tags an extended ancestral haplotype which is common in 
European populations (frequency ~ 10%). Association studies in European-derived populations, 
such as Mexican, Tunisian, and Hispanic, have also shown an increased frequency of 
DRB1*03:01 in SLE patients, compared to matched controls. However, in non-European 
populations, association of DRB1*03:01 with SLE have been inconsistent (Smikle et al., 2002, 
Ayed et al., 2004, Cortes et al., 2004, Uribe et al., 2004, Kim et al., 2009). The association of 
DRB1*03:01 with autoantibody subsets in SLE supports a direct role for the DRB1*03:01 allele 
itself in disease pathogenesis, given that MHC class II presentation to T cells is required for the 
initiation of antibody-mediated immunity. Furthermore, the association of the DRB1*03:01 
haplotype with several other autoimmune diseases (as previously shown in Chapter 1, Table 





The association of DRB1*15 with SLE across different populations reflects the geographical 
distribution of DRB1*15 allele frequencies. DRB1*15:01 is associated with SLE in European, 
Korean, Japanese, Taiwanese, and Thai populations; DRB1*15:02 is associated in Filipino and 
Taiwanese populations; and DRB1*15:03 is associated in African-derived populations 
(Fernando et al., 2008, Fernando et al., 2012, Cortes et al., 2004, Ayed et al., 2004, Bang et al., 
2015, Shimane et al., 2013, Lu et al., 1997, Sirikong et al., 2002, Suggs et al., 2011, Uribe et 
al., 2004). A trans-ancestral study using European and South East Asian populations 
successfully fine-mapped the DRB1*15 association to an 87 kilobases (KB) interval 
encompassing DRB1 and DQA1 (Fernando et al., 2012). In contrast to DRB1*03:01 and 
DRB1*15:01, the DRB1*08:01 allele has only shown association with SLE in some cohorts of 
Southern European ancestry (Graham et al., 2002, Uribe et al., 2004, Fernando et al., 2012).  
 
The prevailing hypothesis explaining the association of MHC haplotypes with autoimmunity risk 
proposes that amino acid variation resulting from the risk-associated HLA alleles disrupt central 
tolerance, by predisposing to aberrant HLA-T cell receptor (TCR) interactions. This may in turn 
affect the negative selection of autoreactive CD4+ T cells in the thymus and, upon encountering 
self-antigens in the periphery, result in the activation of autoantibody-mediated immunity. An 
additional hypothesis suggests that variants within disease-associated MHC haplotypes also 
contribute to disease risk through mechanisms other than HLA amino acid variation. 
Furthermore, there is increasing evidence to suggest that SLE associations at the MHC result 
from the combinatorial effects of multiple independent HLA and/or non-HLA variants (Morris et 
al., 2012). Recent case-control studies have successfully fine-mapped a number of independent 
loci at the MHC, by combining dense single nucleotide polymorphism (SNP) genotyping, HLA 
typing, and the use of multi-ethnic cohorts. A recent study by Fernando and colleagues 
conducted a trans-ancestral mapping analysis in SLE using cohorts of British (United Kingdom, 
U.K.), Spanish, and Filipino ancestry (Fernando et al., 2012). The different LD structure 
exhibited by the three populations enabled fine-mapping of MHC associations to HLA-G, HLA-
B/HLA-C, and PSORSC1 in class I; HLA-DPB1 in class II; and MSH5 in class III. Interestingly, 
both SLE-risk and SLE-protective variants were found within the MSH5 gene. The risk variant, 
rs3131379, showed association in the U.K. and Spanish cohorts, and is in moderate LD with 
DRB1*03:01 (r2 = 0.62, U.K. cohort, and r2 = 0.28, Spanish cohort). The protective SNP, 
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rs409558, showed an independent association in the Spanish and Filipino cohorts, and was 
fine-mapped to a 20 KB haplotype encompassing most of the MSH5 gene. Interestingly, 
variants within MSH5 have been associated with other autoimmune diseases, including 
rheumatoid arthritis, type 1 diabetes, and multiple sclerosis, as well as immunoglobulin A (IgA) 
deficiency, common variable immunodeficiency, and premature ovarian failure (Sirota et al., 
2009, Sekine et al., 2007, Mandon-Pepin et al., 2008). Independent associations of DPB1, a 
classical class II gene, with SLE have been reported in Spanish (rs3117213, risk), Filipino 
(rs2071351, protective), and African-American (rs2071349, risk) populations (Fernando et al., 
2012, Ruiz-Narvaez et al., 2011). The Spanish risk variant is also associated with anti-
citrullinated protein antibody (ACPA)-positive rheumatoid arthritis, whilst other SNPs within 
DPB1 have shown association with several autoimmune diseases, such as Graves' disease, 
systemic sclerosis, and multiple sclerosis (Ding et al., 2009, Takahashi et al., 2006, Zhou et al., 
2009, Wu et al., 2009a). In conclusion, fine-mapping SLE association signals arising within the 
MHC has had some success, as outlined above. However, the causal variants underlying these 
associations, and their functional consequences, are yet to be determined. 
 
3.1.2 eQTLs arising within the MHC region 
Most variants associated with complex diseases in genome-wide association studies (GWAS) 
are located in non-coding regions of the genome (Hindorff et al., 2009). There is increasing 
evidence suggesting that non-coding variants alter susceptibility to disease by regulating gene 
expression or alternative splicing. For example, SLE-associated variants within the BLK and 
STAT4 genes correlate with altered transcript levels in B cells and peripheral blood 
mononuclear cells (PBMCs) from healthy individuals (Hom et al., 2008, Abelson et al., 2009). 
Given the relatively large effect sizes of DRB1 haplotype associations with SLE and other 
autoimmune diseases, it is possible that regulatory variants within these haplotypes may 
contribute to the haplotypic disease risk, in addition to HLA amino acid variation. One example 
is the cis-expression quantitative trait locus (eQTL) identified for the TNF promoter variant, -
308/G>A, which is present in DRB1*03:01 haplotypes (Wilson et al., 1993, Helmig et al., 2011, 
Abraham and Kroeger, 1999). 
 
In order to investigate the functional impact of SLE-associated MHC haplotypes further, one 
may hypothesize that eQTLs within risk and protective MHC haplotypes contribute to disease 
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pathogenesis by altering gene expression. Recent studies have shown that carrying specific 
HLA alleles can affect gene expression MHC-wide (i.e. in cis, Vandiedonck et al., 2011) and 
outside the MHC (in trans, Fairfax et al., 2012). However, only a limited number of studies have 
investigated gene expression patterns associated with SLE-risk MHC haplotypes. An MHC-wide 
study by Vandiedonck and colleagues using lymphoblastoid cell lines (LCLs) demonstrated 
differential expression of MHC genes between two DRB1*03:01-homozygous LCLs (COX and 
QBL) and one DRB1*15:01-homozygous LCL (PGF, Vandiedonck et al., 2011). To date, there 
has not been a comprehensive investigation of cis- and trans-eQTLs within SLE-associated 
MHC haplotypes in large data sets. 
 
3.1.3 Aims and study design 
In order to gain further insight into the mechanisms underlying disease associations, the effect 
of SLE-associated MHC haplotypes on gene expression was investigated in healthy individuals, 
using published data sets. The eQTL analyses were conducted using data derived from ex vivo 
B cells and LCLs (Epstein-Barr virus (EBV)-transformed B cells), which were selected due to the 
key role of B cells in the pathogenesis of SLE, and the enrichment of SLE-associated variants in 
B cell-specific cis-eQTLs (Fairfax et al., 2012). Cis- and trans-eQTLs were investigated for 
DRB1, DPB1, and MSH5 haplotypes associated with SLE risk and protection. The potential 
functional consequences of variants within the MSH5 protective haplotype were then explored 
using bioinformatic tools, in an attempt to further elucidate the functional role of this association. 
 
eQTL analyses were conducted using tag SNPs for the European DRB1*03:01 (rs2187668, 
intronic) and DRB1*15:01 risk haplotypes (rs3135391, exonic), the Spanish DPB1 risk 
haplotype (rs3117213, intergenic), the Filipino DPB1 protective haplotype (rs2071351, intronic), 
the African-American DPB1 risk haplotype (rs2071349, intronic), and the Spanish MSH5 risk 
(rs3131379, intronic) and protective (rs409558, intronic) haplotypes. Three data sets derived 
from ex vivo B cells and LCLs of Northern European ancestry were used in this study: (i) LCLs  
from the HapMap CEU population (sample size, N = 60, Stranger et al., 2007), (ii) LCLs from 
the Multiple Tissue Human Expression Resource (MuTHER, N = 777, Grundberg et al., 2012), 
and (iii) ex vivo B cells from the study by Fairfax and colleagues (N = 281, Fairfax et al., 2012). 
eQTL analyses were performed using the HapMap LCL and the ex vivo B cell data sets. 
Available eQTL data from MuTHER LCLs were accessed from the GeneVar resource. 
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Genotype counts for each data set are detailed in Appendix A. In order to corroborate results, a 
search of the HaploReg resource for published cis-eQTLs in various cell types was carried out. 
Given the extent of LD at the MHC, cis-eQTLs for the analyses of HapMap LCLs and ex vivo B 
cells were defined as any association between SNPs and probes located at a distance of up to 
2.5 megabases (MB). All other data sets had pre-determined cis-eQTLs as associations within 1 
MB of the query SNP. The significance threshold in all published data sets was pre-set at a 
false discovery rate (FDR) of 5%. Only raw p-values are presented in this chapter, for 




3.2 The MSH5 protective haplotype 
 
3.2.1 Cis-eQTLs arising from the MSH5 protective haplotype 
In order to investigate the potential regulatory effects of the MSH5 protective haplotype, the 
SLE-associated SNP rs409558 was used to query the HapMap and MuTHER LCL data sets. As 
genotype data for rs409558 was not available in the ex vivo B cell data set from Fairfax and 
colleagues, rs2293861, a proxy SNP for rs409558, was queried instead (r2 = 1.00 in Northern 




Figure 3-1 Regional plot of cis-eQTL associations for the SLE-protective MSH5 SNP, rs409558, in LCLs 
from the MuTHER cohort (Grundberg et al., 2012).  
 
The strength of association with expression probes (lozenges) located within 1 MB of the SNP is plotted as 





Figure 3-2 Regional plot of cis-eQTL associations for the SLE-protective MSH5 SNP, rs2293861, in ex 
vivo B cells from Fairfax et al. (2012).  
 
The strength of association with expression probes (lozenges) located within 2.5 MB of the SNP is plotted 
as -log10(p-value) against genomic location. The arrows indicate the region within 1 MB of the SNP. Cis-




Cis-eQTL analysis for rs409558 in the MuTHER LCLs showed significant associations with 
three transcripts: DOM3Z (P = 4.85 × 10-10), AIF1 (P = 8.72 × 10-10), and BAT2 (P = 3.46 × 10-7, 
Figure 3-1). In contrast, analysis of HapMap LCLs showed no significant cis-eQTLs. However, 
one of five available MSH5 probes, ILMN_1810834, was differentially expressed prior to 
multiple test correction in both HapMap LCLs (P = 2.45 × 10-3, fold change (FC) = 1.13, FDR > 
5%) and MuTHER LCLs (P = 2.98 × 10-4, FC = 1.04, FDR > 5%). This probe targets the 3’ end 
of MSH5 transcripts, including a read-through transcript to the downstream gene at the 3’ end, 
SAPCD1 (Figure 3-3). Similarly, cis-association with a probe uniquely targeting SAPCD1 also 
showed suggestive association in the MuTHER LCLs (ILMN_2134765, P = 4.69 × 10-2, FC = 
1.03, FDR > 5%). In ex vivo B cells, rs2293861 was a significant eQTL for five genes (C6orf48, 
DDAH2, HSPA1B, BAT4, and DOM3Z), all of which are located within 125 KB of the MSH5 
locus (Figure 3-2). Again, the MSH5 probe ILMN_1810834 showed association prior to 
correcting for multiple testing (P = 1.43 × 10-2, FC = -1.04, FDR > 5%). Despite contradicting 
directions of effect, it is of interest that the p-values for this probe fell just under the significance 
threshold in all three data sets. Conversely, none of the other MSH5 or SAPCD1 probes present 






Figure 3-3 UCSC Genome Browser screenshot showing target locations for MSH5 and SAPCD1 probes 
from the Illumina Sentrix Human-6 BeadChip array in the reference MHC sequence.  
 
All probes shown are shared by the Illumina platforms used for the HapMap LCL data set (Stranger et al., 
2007), the MuTHER LCL data set (Grundberg et al., 2012), and the ex vivo B cell data set (Fairfax et al., 
2012). The diagram illustrates MSH5 and SAPCD1 transcripts from RefSeq gene annotations (top) and 
Sentrix Human-6 BeadChip array probes (bottom). The probes that showed suggestive associations with 
the SLE-protective haplotype tagged by rs409558 in one or more data sets are outlined in red (P < 0.05, 




The most significant cis-association with rs409558 in ex vivo B cells was to C6orf48 (P = 2.83 × 
10-11, FC = -1.06, Figure 3-4). A search using the HaploReg resource showed that the C6orf48 
cis-association was validated in ex vivo naïve monocytes (P = 1.34 × 10-21, Fairfax et al., 2014) 
and whole blood from two independent studies (P = 2.20 × 10-7, GTEx Consortium, 2015, and P 
= 2.37 × 10-15, Westra et al., 2013). Additionally, C6orf48 was also a significant cis-gene in skin 
samples from the MuTHER cohort (P = 6.92 × 10-4) and the GTEx Consortium (P = 3.4 × 10-7, 
GTEx Consortium, 2015), as well as in tibial nerve samples (P = 7.2 × 10-8, GTEx Consortium, 
2015) and testis samples (P = 1.50 × 10-6, GTEx Consortium, 2015). However, C6orf48 was not 
a significant cis-gene in the MuTHER LCLs (P = 7.21 × 10-2) and failed quality control (QC) in 
the HapMap LCL data set. The C6orf48 locus harbours two small nucleolar ribonucleic acid 
(snoRNAs) encoded within intron 1, SNORD48 and SNORD52. Accordingly, it was assessed 
whether rs409558 was also an eQTL for the two snoRNAs in LCLs and ex vivo B cells. The 
SNORD52 probe did not show a significant association with genotype, while the SNORD48 






Figure 3-4 eQTL box plot for the MSH5 protective haplotype tag SNP, rs2293861, and C6orf48 expression 
in ex vivo B cells from Fairfax et al. (2012). 
 
rs2293861 is a significant cis-eQTL for C6orf48 (P = 2.83 × 10-11, FDR < 5%). The box plot shows median, 
upper, and lower quartiles of expression levels for each genotype group. Whiskers show the maximal and 




The DOM3Z cis-association observed in MuTHER LCLs and ex vivo B cells was replicated in 
naïve monocytes (P = 1.46 × 10-6, Fairfax et al., 2014), whole blood (P = 5.21 × 10-13, Westra et 
al., 2013), and trended towards significance in HapMap LCLs (P = 2.41 × 10-2, FDR > 5%). 
HSPA1B and BAT4 were the only other cis-genes in ex vivo B cells that were validated in 
independent cohorts (LCLs from Lappalainen et al., 2013, monocytes from Fairfax et al., 2014, 
and whole blood from Westra et al., 2013). Table 3-1 summarises all cis-eQTL results that were 
replicated, or showed suggestive evidence of replication, in published data sets from LCLs, ex 
vivo B cells, ex vivo monocytes, and whole blood. Interestingly, not all cis-genes showed the 
same direction of effect in the different cell populations; for example, DOM3Z was down-







Table 3-1 Summary of cis-eQTLs for rs409558 that were replicated in independent data sets from ex vivo B cells, LCLs, ex vivo monocytes, and whole blood. 
 
The significance threshold was set to an FDR of 5% in all data sets. Italicized p-values and fold changes indicate suggestive associations (i.e. significant at P < 0.05 prior to correction 
for multiple testing, but non-significant at an FDR of 5%). All cohorts included healthy individuals of European ancestry, and data sets were corrected for population structure. 
*Cis-eQTL data accessed from the HaploReg resource.  
§ Data sets adjusted for sex. 
† Data sets generated using RNA sequencing.  
‡ Data sets generated using expression microarrays. 
N – sample size, FC – fold change (effect size per minor allele), ND – no data available. 
Correlated 
transcript 
Ex vivo B cells 











Ex vivo naïve 
monocytes 
(Fairfax et al., 
2014)*‡ 
Whole blood 
(Westra et al., 
2013)*‡ 
Whole blood (GTEx 
Consortium, 
2015)*§† 
N = 281 N = 777 N = 60 N = 462 N = 421 N = 5,311 N = 156 
C6orf48 
 
P = 2.83 × 10-11 
FC = -1.06 
 
P = 7.21 × 10-2 
FC = 1.02 
ND ND 
 
P = 1.34 × 10-21 
ND 
 
P = 2.37 × 10-15 
ND 
 
P = 2.20 × 10-7 
FC = -1.12 
DOM3Z 
 
P = 4.18 × 10-4 
FC = -1.07 
 
P = 4.85 × 10-10 
FC = 1.09 
 
P = 2.41 × 10-2 
FC = -1.11 
ND 
 
P = 1.46 × 10-6 
ND 
 





P = 1.51 × 10-8 
FC = -1.15 
ND ND ND 
 
P = 3.85 × 10-6 
ND 
 





P = 3.25 × 10-4 
FC = 1.07 
ND 
 
P = 7.24 × 10-3 
FC = 1.08 
 
P = 5.11 × 10-14 
ND 
 





3.2.2 Functional prediction of variants within the MSH5 protective haplotype 
The mechanisms that may be driving the cis-eQTLs at the MSH5 locus were investigated. The 
size of the haplotype tagged by rs409558 in European populations was first defined, and a 
search for functional annotations within this haplotype was then performed using publicly-
available data bases. To confirm the independence of the MSH5 protective signal from HLA 
haplotypes, the LD between rs409558 and HLA alleles was calculated using genotypic data 
from U.K. and Spanish populations (data obtained from Fernando et al., 2012). rs409558 
showed low LD with all typed alleles from HLA-B, HLA-DRB1, HLA-DQA1, and HLA-DQB1 in 
both populations (r2 < 0.03). As the SLE association with this haplotype could be due to either 
rs409558 itself, or a functional SNP in LD with it, the functional annotations of the SNPs within 
the protective haplotype in the Spanish (IBS) and British (GBR) populations from 1000 
Genomes (1000G) were investigated. The haplotype tagged by rs409558 was defined to a 21 
KB region flanking the MHS5 gene in both the IBS and GBR populations, using a r2 > 0.80 in 
Haploview’s Tagger algorithm. The haplotype comprises thirteen SNPs in the IBS population 
and six SNPs in the GBR population (Figure 3-5, Appendix B). All SNPs are located within 
introns of MSH5 or neighbouring genes, except for rs6905572, which is located in exon 3 of 
SAPCD1. rs6905572 results in a non-synonymous change in the SAPCD1 protein, from a 
proline to leucine at position 99 (Pro99Leu), which was predicted to be non-deleterious by the 
SIFT and PolyPhen-2 version 2 tools. 
 
A search was conducted using publicly-available data bases in order to determine whether any 
SNP within the MSH5 protective haplotype overlapped putative regulatory elements. All SNPs 
were analysed using the ASSIMILATOR tool, which queries several data bases including 
ENCODE and OpenChrom. rs409558 and rs4711279 (located upstream of C6orf48) were 
shown to overlap a high number of regulatory features relating to gene expression, including 
multiple transcription factor binding sites (TFBS), CpG islands, DNAse I hypersensitivity sites, 
and histone modifications indicative of active promoters. ASIMILATOR results are summarised 
in Table 3-2. Data obtained from chromatin immunoprecipitation-sequencing (ChIP-seq) for the 
rs409558 locus showed strong evidence for binding of E2F1 (HeLa-S3 and MC-7 cells, score of 
1000), E2F6 (K562 cells, score of 1000 and HeLa-S3 cells, score of 890), and ZFN263 (T-REx-







Figure 3-5 LD plot of the MSH5 locus.  
 
The MSH5 gene is illustrated at the top (image from Ensembl), and r2 values between common SNPs (minor allele frequency > 5%) from the GBR 1000 Genomes population are 






















SYDH UW Uniform Duke 
DNase 
Clusters 
Uniform HAIB UTA UC 
rs409558 Intronic Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
rs2293861 Intronic 
  
Yes Yes Yes 
    
Yes Yes Yes Yes  Yes 
rs2075788 Intronic 
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Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
rs116828153 Intronic 
 
Yes Yes Yes Yes 
 
Yes Yes Yes Yes Yes Yes  Yes 
 
rs116201952 3' UTR 
  




Yes Yes Yes  Yes Yes 
rs80260075 Intergenic   Yes Yes Yes           
 
HAIB Methyl450 – Illumina methyl450 array methylation data from the Hudson Alpha Institute for Biotechnology, SYDH – Stanford/Yale/Davis/Harvard, UW – University of Washington, 
UNC FAIRE – formaldehyde-assisted isolation of regulatory elements from the University of North Carolina, HS – hypersensitivity sites, TFBS – transcription factor binding sites, UTA 
– University of Texas at Austin, UC – University of Chicago, Txn Factor ChIP – transcription factor chromatin immunoprecipitation. 
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The JASPAR tool, which contains a repository of matrix-based TFBS, was used to investigate 
whether rs409558 might be expected to disrupt any TFBS. Two matrices for the sequence 
flanking rs409558 were analysed, one harbouring the ancestral allele A and one harbouring the 
minor allele G. For the E2F1 transcription factor, matrix scores predicted a higher binding affinity 
to the sequence with the G allele (77.3%) than to the sequence with the A allele (64.8%). The 
sequence containing the G allele forms a near-perfect E2F1 consensus sequence, with only 
one mismatch at the last base (Figure 3-6). Analysis of ENCODE data for the rs4711279 SNP 
within the C6orf48 promoter showed several transcription factor binding sites detected by ChIP-
seq, including E2F1 (HeLa-S3 and MCF-7 cells, score of 1000), E2F4 (HeLa-S3 and K562 cells, 
score of 1000), E2F6 (K562 cells, score of 1000), and MAX (K562 cells, score of 886). Analysis 
of the rs4711279 flanking sequence using the JASPAR tool did not reveal disrupted TFBS. 
Nevertheless, these results support a direct regulatory role for rs409558 at MSH5 and 
rs4711279 at C6orf48, which may explain the cis-associations reported for the SLE-protective 
MSH5 haplotype in section 3.2.1.  
 
 
A.     B. 
 
Figure 3-6 E2F1 consensus binding sequence. 
 
A. Sequence logo for the E2F1 consensus binding site showing the requirement for a C/G allele at position 
6 (image exported from JASPAR). B. Double stranded rs409558 flanking sequence with base position 
shown at the bottom. Presence of the minor allele G in position 6 (shown in square brackets) forms a near-
perfect E2F1 binding site. The mismatched base with the E2F1 consensus binding site at position 8 is 








5’ AAAGC[G]CT 3’ 
3’ TTTCG[C]GA 5’ 
            
         1  2  3  4  5      6      7  8 
 




3.3 HLA-DRB1 risk haplotypes 
 
3.3.1 Cis-eQTLs arising from the HLA-DRB1*03:01 risk haplotype 
To test association between the DRB1*03:01 haplotype and gene expression, the rs2187668 
SNP (located in intron 1 of HLA-DQA1) was used as a proxy, since it is in perfect LD with the 




Figure 3-7 Regional plot of cis-eQTL associations for the HLA-DRB1*03:01 tag SNP, rs2187668, in LCLs 
from the MuTHER cohort (Grundberg et al., 2012).  
 
The strength of association with expression probes (lozenges) located within 1 MB of the SNP is plotted as 





Figure 3-8 Regional plot of cis-eQTL associations for the HLA-DRB1*03:01 tag SNP, rs2187668, in ex vivo 
B cells from Fairfax et al. (2012).  
 
The strength of association with expression probes (lozenges) located within 2.5 MB of the SNP is plotted 
as -log10(p-value) against genomic location. The arrows indicate the region within 1 MB of the SNP. Cis-
associations significant at an FDR of 5% are coloured in green. 
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Cis-eQTL analysis for rs2187668 in MuTHER LCLs showed a significant association with up-
regulation of DPB1 (P = 1.20 × 10-8, FC = 1.17) and PSMB9 (P = 1.39 × 10-7, FC = 1.09, Figure 
3-7). In contrast, no significant eQTLs were found in HapMap LCLs. Ex vivo B cells showed 
several significant cis-genes for rs2187668, including VARS2 (P = 2.58 × 10-7), APOM (P = 4.40 
× 10-7), DPA1 (P = 1.06 × 10-3), and DPB1 (P = 3.84 × 10-4, FC = 1.15, Figure 3-8). Association 
with PSMB9 did not reach significance in ex vivo B cells following multiple test correction (P = 
5.73 × 10-3, FC = 1.10, FDR > 5%); however, a search for published cis-eQTLs using HaploReg 
revealed significant differential expression of PSMB9 in two monocyte data sets (P = 2.13 × 10-
4, Fairfax et al., 2014, and P = 1.87 × 10-6, Zeller et al., 2010) and two whole blood data sets (P 
= 1.34 × 10-10, Westra et al., 2013, and P = 3.10 × 10-6, Fehrmann et al., 2011).  
 
The cis-association of rs2187768 with DPB1 expression observed in MuTHER LCLs and ex 
vivo B cells was also validated in monocytes (P = 1.20 × 10-6, Fairfax et al., 2014, and P = 2.10 
× 10-15, Zeller et al., 2010). The correlation of rs2187668 genotypes with DPB1 in ex vivo B cells 
showed a heterozygote effect, rather than an additive effect (Figure 3-9). However, this 
observation is confounded by the small number of rs2187668 homozygotes in this data set (N = 
3, Appendix A). As the DPB1 gene is highly polymorphic, the observed cis-eQTL could be a 
false positive result caused by off-target probe binding. To exclude this possibility, the target 
sequence for the cis-associated DPB1 Illumina probe, ILMN_1749070, was aligned against the 
human genome sequence, using the BLAT tool from the UCSC Genome Browser. BLAT 
analysis showed that the ILMN_1749070 probe did not map to SNP-containing regions in any of 
the sequenced MHC haplotypes. Figure 3-10 illustrates the probe target site within the DPB1 
gene in the reference MHC haplotype. Table 3-3 summarises all rs2187668 cis-genes that were 
replicated, or showed suggestive evidence of replication, in published data sets from LCLs, ex 





Figure 3-9 eQTL box plot for the HLA-DRB1*03:01 haplotype tag SNP, rs2187668, and HLA-DPB1 
expression in ex vivo B cells from Fairfax et al. (2012).  
 
rs2187668 is a significant cis-eQTL for HLA-DPB1 (P = 3.84 × 10-4, FDR < 5%). The box plot shows 
median, upper, and lower quartiles of expression levels for each genotype group. Whiskers show the 





Figure 3-10 UCSC Genome Browser screenshot showing the ILMN_1749070 probe target site at the 3’ 
untranslated region of HLA-DPB1 in the reference MHC sequence.  
 
The annotation sets shown here include the BLAT search result for ILMN_1749070, the RefSeq gene 
annotation, the GenBank mRNA annotation, Illumina Sentrix Human-6 BeadChip array probes, and 











Table 3-3 Summary of cis-eQTLs for rs2187668 (DRB1*03:01 tag) that were replicated in independent 
data sets from ex vivo B cells, LCLs, ex vivo monocytes, and whole blood. 
The significance threshold was set to an FDR of 5% in all data sets. Italicized p-values and fold changes 
indicate suggestive associations (i.e. significant at P < 0.05 prior to correction for multiple testing, but non-
significant at an FDR of 5%). All cohorts included healthy individuals of European ancestry. All data sets 
were generated using expression microarrays, and were corrected for population structure. 
* Cis-eQTL data extracted from the HaploReg resource.  
§ Data sets adjusted for sex. 




A cis-eQTL analysis for the Spanish SLE-risk SNP within the MSH5 locus, rs3131379, which is 
in moderate LD with DRB1*03:01 (r2 = 0.62 in U.K. and r2 = 0.28 in Spanish populations, 
cohorts from Fernando et al., 2012) was then performed. No cis-associations passed the 
significance threshold in MuTHER LCLs. In ex vivo B cells however, cis-associations for 
rs3131379 substantially overlapped with those observed for rs2187668, as would be expected 
given the LD between these loci (Figure 3-11). Cis-association with DPB1 expression was 
significant in ex vivo B cells (P = 5.12 × 10-6, FC = 1.21, Figure 3-12), and was validated in two 
monocyte data sets (P = 1.15 × 10-8, Fairfax et al., 2014, and P = 5.90 × 10-18, Zeller et al., 
2010). rs3131379 also demonstrated additional cis-genes in ex vivo B cells and monocytes 
Correlated 
transcript 
Ex vivo B cells 





et al., 2012)§ 
Ex vivo naïve 
monocytes 




(Zeller et al., 
2010)* 
Whole blood 




et al., 2011)* 
 N = 281 N = 777 N = 421 N = 1,490 N = 5,311 N = 1,469 
HLA-DPB1 
 
P = 3.84 × 10-4 
FC = 1.15 
 
P = 1.20 × 10-8 
FC = 1.17 
 
P = 1.20 × 10-6 
ND 
 





P = 5.73 × 10-3 
FC = 1.10 
 
P = 1.39 × 10-7 
FC = 1.09 
 
P = 2.13 × 10-4 
ND 
 
P = 1.87 × 10-6 
ND 
 
P = 1.34 × 10-10 
ND 
 




P = 4.74 × 10-6 
FC = -1.61 
ND 
 
P = 3.22 × 10-9 
ND 
ND ND ND 
APOM 
 
P = 4.40 × 10-7 
FC = -1.11 
ND 
 
P = 1.30 × 10-7 
ND 
 





P = 2.58 × 10-7 
FC = -1.13 
ND 
 
P = 3.17 × 10-12 
ND 
ND ND ND 
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compared to rs2187668, including ZFP57, PSMB9, and SKIV2L (Table 3-4, Fairfax et al., 2014, 




Figure 3-11 Regional plot of cis-eQTL associations for the SLE-risk MSH5 SNP, rs3131379, in ex vivo B 
cells from Fairfax et al. (2012).  
 
The strength of association with expression probes (lozenges) located within 2.5 MB of the SNP is plotted 
as -log10(p-value) against genomic location. The arrows indicate the region within 1 MB of the SNP. Cis-




Figure 3-12 eQTL box plot for the HLA-DRB1*03:01 haplotype tag SNP, rs3131379, and HLA-DPB1 
expression in ex vivo B cells from Fairfax et al. (2012).  
 
rs3131379 is a significant cis-eQTL for HLA-DPB1 (P = 3.84 × 10-4, FDR < 5%). The box plot shows 
median, upper, and lower quartiles of expression levels for each genotype group. Whiskers show the 




Table 3-4 Summary of cis-eQTLs for rs3131379 that were replicated in independent data sets from ex vivo 
B cells, LCLs, ex vivo monocytes, and whole blood. 
 
The significance threshold was set to an FDR of 5% in all data sets. Italicized p-values and fold changes 
indicate suggestive associations (i.e. significant at P < 0.05 prior to correction for multiple testing, but non-
significant at an FDR of 5%). All cohorts included healthy individuals of European ancestry. All data sets 
were generated using expression microarrays, and were corrected for population structure. 
* Cis-eQTL data extracted from the HaploReg resource.  




3.3.2 Cis-eQTLs arising from the HLA-DRB1*15:01 risk haplotype 
eQTLs for the DRB1*15:01 risk haplotype were analysed in ex vivo cell and LCL data sets using 
the proxy SNP rs3135391 (r2 = 0.98, U.K. cohort from Fernando et al., 2012), located in exon 2 
of HLA-DRA. rs3135391 showed significant associations with BAT2 (P = 2.81 × 10-5) and 
PSMB9 (P = 3.35 × 10-5) in MuTHER LCLs (Figure 3-13). In contrast, ex vivo B cells showed 
significant associations with LOC642073 (P = 4.33 × 10-22) and ATP6V1G2 (P = 1.03 × 10-4, 
Figure 3-14), and suggestive association with BAT2 (P = 1.32 × 10-2, FDR > 5%). The cis-
eQTLs to BAT2 and LOC642073 were validated in naïve monocytes (P = 4.47 × 10-6 and P = 
2.96 × 10-15, respectively, Fairfax et al., 2014). None of the other rs3135391 cis-associations 
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 N = 281 N = 421 N = 1,490 N = 5,311 N = 1,469 
HLA-DPB1 
 
5.12 × 10-6 
FC = 1.21 
 
P = 1.15 × 10-8 
ND 
 





P = 5.73 × 10-3 
FC = 1.10 
ND 
 





P = 4.74 × 10-6 
FC = -1.61 
ND 
 





P = 4.40 × 10-7 
FC = -1.11 
ND ND 
 
P = 9.75 × 10-10 
ND 
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Figure 3-13 Regional plot of cis-eQTL associations for the HLA-DRB1*15:01 tag SNP, rs3135391, in LCLs 
from the MuTHER cohort (Grundberg et al., 2012).  
 
The strength of association with expression probes (lozenges) located within 1 MB of the SNP is plotted as 






Figure 3-14 Regional plot of cis-eQTL associations for the HLA-DRB1*15:01 tag SNP, rs3135391, in ex 
vivo B cells from Fairfax et al. (2012).  
 
The strength of association with expression probes (lozenges) located within 2.5 MB of the SNP is plotted 
as -log10(p-value) against genomic location. The arrows indicate the region within 1 MB of the SNP. Cis-









3.4 HLA-DPB1 protective and risk haplotypes 
 
3.4.1 LD analysis 
The regulatory effects of three DPB1 variants associated with SLE in different populations 
(Spanish - rs3117213, Filipino - rs2071351, and African-American - rs2071349) were 
investigated. In order to assess independence, the LD between the SLE-associated Spanish 
and Filipino DPB1 variants and HLA alleles was analysed using genotypic data from Spanish 
and Filipino cohorts obtained from Fernando and colleagues (Fernando et al., 2012). Both the 
Spanish and Filipino variants showed low LD with DRB1 alleles in the respective population (r2 
< 0.11). The independence of the African-American DPB1 variant from HLA alleles could not be 
established in the African-American population; however, the SNP was in low LD with DRB1 
alleles in the Spanish and Filipino cohorts (r2 < 0.14). Interestingly, all three DPB1 variants are 
in low LD with each other, and with DRB1*03:01 and DRB1*15:01 haplotype tag SNPs in the 




Figure 3-15 LD plot of HLA-DRB1 and HLA-DPB1 SLE-associated variants. 
 
The top bar shows the relative location of the European tag SNPs for the DRB1*03:01 and DRB1*15:01 
SLE-risk haplotypes, the Spanish DPB1 risk SNP, the Filipino DPB1 protective SNP, and the African-
American (AA) DPB1 risk SNP. r2 values from the TwinsUK cohort are displayed below. The LD plot was 






3.4.2 Cis-eQTLs arising from HLA-DPB1 haplotypes 
 
3.4.2.1 The Spanish HLA-DPB1 haplotype 
Genotypes for the DPB1 SNP rs3117213, which is associated with SLE risk in the Spanish 
population, correlated significantly with up-regulation of DPB1 in MuTHER LCLs (P = 3.08 × 10-
49) and ex vivo B cells (P = 2.10 × 10-14, Figure 3-16). This cis-eQTL was validated in LCLs (P = 
1.27 × 10-8, GTEx Consortium, 2015), monocytes (P = 2.09 × 10-24, Fairfax et al., 2014), whole 
blood (P = 9.81 × 10-198, Westra et al., 2013, and P = 3.18 × 10-27, GTEx Consortium, 2015), 
and in all other tissues tested in the GTEx Consortium study (data not shown, GTEx 
Consortium, 2015). rs3117213 was also associated at a lesser level of significance with HLA-
DOA in MuTHER LCLs (P = 9.35 × 10-7), and with the pseudogene HLA-DPB2 in MuTHER 
LCLs (P = 8.74 × 10-5), ex vivo B cells (P = 5.73 × 10-5), and whole blood (P = 5.22 × 10-29, 
GTEx Consortium, 2015). 
 
 
Figure 3-16 eQTL box plot for the Spanish SLE risk-associated HLA-DPB1 SNP, rs3117213, and HLA-
DPB1 expression in ex vivo B cells from Fairfax et al. (2012).  
 
rs3117213 is a significant cis-eQTL for HLA-DPB1 (P = 2.10 × 10-14, FDR < 5%). The box plot shows 
median, upper, and lower quartiles of expression levels for each genotype group. Whiskers show the 






3.4.2.2 The Filipino HLA-DPB1 haplotype 
The association of DPB1 with SLE protection in Filipinos is conferred by the ancestral allele of 
rs2071351. Interestingly, cis-eQTL analysis for this SNP also showed strong correlation with 
DPB1 expression. The SLE risk-associated minor allele correlated significantly with up-
regulation of DPB1 in MuTHER LCLs (P = 1.47 × 10-49), ex vivo B cells (P = 1.63 × 10-22, Figure 
3-17), monocytes (P = 6.16 × 10-29, Fairfax et al., 2014), and whole blood (P = 9.81 × 10-198, 
Westra et al., 2013, and P = 4.65 × 10-11, GTEx Consortium, 2015), as well as in all other 
tissues tested in the GTEx Consortium study (data not shown, GTEx Consortium, 2015). In 
addition to DPB1, rs2071351 genotypes also correlated with DPA1 expression in MuTHER 
LCLs (P = 6.44 × 10-7), ex vivo B cells (P = 3.44 × 10-12), and monocytes (P = 4.73 × 10-10, 
Fairfax et al., 2014). 
 
 
Figure 3-17 eQTL box plot for the HLA-DPB1 SNP associated with SLE protection in Filipinos, rs2071351, 
and HLA-DPB1 expression in ex vivo B cells from Fairfax et al. (2012). 
 
rs2071351 is a significant cis-eQTL for HLA-DPB1 (P = 1.63 × 10-22, FDR < 5%). The box plot shows 
median, upper, and lower quartiles of expression levels for each genotype group. Whiskers show the 







3.4.2.3 The African-American HLA-DPB1 haplotype 
In contrast with rs3117213 and rs2071351, the DPB1 SNP associated with SLE risk in African-
Americans, rs2071349, was moderately associated with down-regulation of DPB1 in MuTHER 
LCLs (P = 2.87 × 10-6). In ex vivo B cells however, association with DPB1 was not significant 
after multiple test correction (P = 6.66 × 10-3, FDR > 5%, Figure 3-18). rs2071349 was also 
associated with expression of the pseudogene DPB2 in MuTHER LCLs (P = 1.01 × 10-7). Table 
3-5 summarises all cis-associations with DPB1 expression that were identified in MuTHER LCLs 
and ex vivo B cells arising from SLE-risk and -protective haplotypes.  
 
 
Figure 3-18 eQTL box plot for the African-American SLE risk-associated HLA-DPB1 SNP, rs2071349, and  
HLA-DPB1 expression in ex vivo B cells from Fairfax et al. (2012).  
 
rs2071349 is not a significant cis-eQTL for HLA-DPB1 (P = 6.66 × 10-3, FDR > 5%). The box plot shows 
median, upper, and lower quartiles of expression levels for each genotype group. Whiskers show the 












Table 3-5 Summary of cis-associations with DPB1 expression levels for the SLE-associated DRB1*03:01 
haplotype (tagged by rs2187668), and the DPB1 haplotypes tagged by rs3117213, rs2071351 and 
rs2071349 in MuTHER LCLs (Grundberg et al., 2012) and ex vivo B cells from Fairfax et al. (2012). 
 
The significance threshold was set to an FDR of 5% in all data sets. Italicized p-values and fold changes 
indicate non-significant p-values.  




3.5 Trans-eQTLs within risk and protective MHC haplotypes 
Trans-eQTL analysis of DRB1, DPB1, and MSH5 SLE haplotypes showed few and inconsistent 
associations with gene expression in different cell types. In MuTHER LCLs, the DRB1*03:01 tag 
SNP showed a significant trans-effect to the pseudogene RNF5P1, located on chromosome 8 
(P = 1.00 × 10-9, FC = 1.10). However, the peak expression SNP (eSNP) for this gene was the 
MHC class II SNP rs3132965 (P = 7.61 × 10-20, FC = 1.17), which is in moderate LD with the 
DRB1*03:01 haplotype (r2 = 0.31, TwinsUK cohort). In contrast, no significant trans-eQTLs for 
the DRB1*03:01 haplotype were detected in ex vivo B cells. 
 
The DRB1*15:01 tag SNP showed a significant trans-association with ERG, located in 
chromosome 21, in MuTHER LCLs (P = 5.98 × 10-23, FC = -1.10). The peak trans-signal for 
ERG was to the class II SNP rs7194 (P = 5.41 × 10-50, FC = -1.12). This SNP is in low to 
moderate LD with the DRB1*15:01 haplotype (r2 = 0.25, TwinsUK cohort). The DRB1*03:01 and 
DRB1*15:01 trans-associations with RNF5P1 and ERG expression may therefore result from 
LD with the causal variants rs3132965 and rs7194, respectively. Trans-eQTL analyses in ex 














LCLs 1.20 × 10-8 1.17 13.50% 




LCLs 3.08 × 10-49 1.36 27.02% 




LCLs 1.47 × 10-49 1.43 17.46% 






LCLs 2.87 × 10-6 -1.14 12.27% 
ex vivo B cells 6.66 × 10-3  -1.10 13.52% 
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chromosome 1 (P = 1.93 × 10-6, FC =-1.06) and FAM98B in chromosome 15 (P = 2.25 × 10-6, 
FC = 1.12). Interestingly, the trans-association to ZNF672 was replicated in naïve monocytes (P 
= 2.11 × 10-22, Fairfax et al., 2014). The peak trans-signal for ZNF672 in this monocyte data set 
was to the class II SNP rs3104369 (P = 3.75 × 10-31), which is in moderate LD with the 
DRB1*15:01 haplotype (r2 = 0.23, TwinsUK cohort). None of the tag SNPs for DRB1*03:01, 
DRB1*15:01, DPB1 (rs3117213, rs2071351, rs2071349), or MSH5 (rs409558, rs3131379) 




This chapter describes a comprehensive investigation of cis- and trans-eQTLs within SLE-
associated MHC haplotypes in LCLs and ex vivo B cells, using publicly-available data sets. The 
DRB1*03:01 risk haplotype and the MSH5 protective haplotype in class III were significant cis-
eQTLs for multiple transcripts, which were validated in monocytes and whole blood. The 
DRB1*03:01 haplotype, and two DPB1 risk and protective SNPs, showed robust cis-
associations with the classical HLA class II gene DPB1 in LCLs, ex vivo B cells, and whole 
blood. In contrast, cis-eQTLs arising from the DRB1*15:01 haplotype, and trans-eQTLs arising 
from all analysed MHC haplotypes, were inconsistent between the different data sets.  
 
Genotypes of the SLE-protective MSH5 SNP, rs409558, correlated significantly with expression 
levels of the class III genes DOM3Z and C6orf48 in LCLs, ex vivo B cells, monocytes, and 
whole blood, suggesting an unprecedented role for these genes in SLE. The functions of 
DOM3Z (also known as decapping exoribonuclease, or DX0) and C6orf48 are currently 
unknown (Entrez Gene). C6orf48 is moderately expressed in human B cells and highly 
expressed in lymphoma tumours, whereas DOM3Z is thought to be a housekeeping gene (Pan 
et al., 2012, BioGPS, Entrez Gene). Furthermore, the cis-association with C6orf48 was 
replicated in skin samples from two independent cohorts, which is of interest given the 
cutaneous clinical manifestations sometimes observed in lupus patients. In ex vivo B cells, 
monocytes, and whole blood, rs409558 was also a significant cis-eQTL for the class III gene 
HSPA1B, which has previously shown association with SLE risk independently of DRB1*03:01 
in Europeans and African Americans (Furnrohr et al., 2010, Jarjour et al., 1996). The suggestive 
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cis-eQTL to the MSH5 gene itself in B cells and LCLs is of interest, given the association of 
variants near this gene with autoimmune diseases, and the role of MSH5 in pathways relevant 
to SLE (such as deoxyribonucleic acid (DNA) repair, Bannwarth et al., 2012). However, the cis-
association to MSH5 was only suggestive for two of five available MSH5 probes. The lack of 
power to detect very small fold changes, as well as the presence of potential spliced transcripts 
not targeted by the Illumina array, may explain the lack of significance for these cis-
associations.  
 
The SLE-protective MSH5 haplotype was defined by thirteen SNPs, and was shown to be 
independent of HLA alleles in European populations. Bioinformatic analysis of the thirteen SNPs 
delineating the haplotype indicated that both rs409558 at MSH5 and rs4711279 at C6orf48 
were the best functional SNP candidates within the haplotype. The overlap of rs409558 and 
rs4711279 with high numbers of regulatory features, including elements indicative of active 
promoters, may explain the cis-eQTLs observed for the MSH5 protective haplotype, particularly 
to C6orf48. The rs409558 minor allele (G) was predicted to increase binding affinity of E2F1, 
suggesting that this transcription factor may be functionally involved in regulating gene 
expression within the protective haplotype. Altogether, the cis-eQTLs and functional annotations 
here presented support a direct regulatory role for non-coding SNPs within the protective MSH5 
haplotype, which could underlie its association with SLE. Following these analyses, a large SLE 
GWAS was conducted in a cohort of Northern and Southern European ancestry (Bentham et 
al., 2015). The independent association of rs409558 with SLE could not be validated in this 
study, due to the SNP failing quality control (Dr David Morris, King’s College London; personal 
communication). Provided that the rs409558 association with SLE protection is validated in 
independent data sets, the regulatory role of this haplotype could be further investigated using 
functional studies. For example, differential binding of E2F1 to rs409558 allelic variants may be 
validated by electrophoretic mobility shift assay (EMSA), and the regulatory role of variants in 
weak LD with rs409558 could be assessed. 
 
Whereas the cis-eQTLs for the MSH5 protective haplotype were confined to the class III region, 
the cis-eQTL landscape for the ancestral DRB1*03:01 haplotype spanned both class III and 
class II regions in ex vivo B cells, reflecting the large size of the haplotype. The DRB1*03:01 
haplotype demonstrated reproducible cis-eQTL for DPB1 in LCLs, ex vivo B cells, and 
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monocytes. Furthermore, this cis-eQTL showed a possible heterozygote effect in ex vivo B 
cells. This may have been an artefact resulting from the low number of DRB1*03:01 
homozygote samples in the ex vivo B cell data set (Appendix A); however, it was not possible to 
access genotypic data from additional data sets to confirm this. Up-regulation of DPB1 in 
DRB1*03:01 haplotypes is of great interest, given the independent association of the DPB1 
gene with SLE, as well as other autoimmune diseases, in different populations. Interestingly, 
Spanish and Filipino SLE-associated SNPs in DPB1, which are independent of the DRB1*03:01 
haplotype, were also strongly associated with DPB1 expression in ex vivo B cells (up-
regulation), LCLs, and whole blood. Furthermore, the cis-eQTL within the DPB1 and 
DRB1*03:01 haplotypes showed similar fold changes for differential expression of DPB1 (FC ~ 
1.3, Table 3-5). Since both the Spanish and Filipino DPB1 SNPs were shown to be in low LD 
with HLA alleles (including DRB1*03:01), the cis-associations of SLE-risk haplotypes with 
increased DPB1 expression suggest an important role for this class II gene in susceptibility to 
autoimmune disease. One can hypothesise a plausible pathogenic mechanism for these 
disease-associated cis-eQTLs that would decrease tolerance to self: up-regulation of DPB1 
expression in autoreactive B cells harbouring DRB1*03:01 or DPB1 risk haplotypes would result 
in increased MHC class II presentation of self-antigens to T cells. In the presence of co-
stimulatory signals, T cell recognition of self-antigen-MHC class II complexes induces plasma 
cell differentiation and, subsequently, autoantibody production. Further fine-mapping of the 
SLE-associated Spanish and Filipino DPB1 signals is required in order to find the causal 
regulatory variants. 
 
The DRB1*03:01 haplotype was also a significant cis-eQTL for PSMB9 in LCLs, monocytes, 
and whole blood, at similar fold changes. Interestingly, this gene showed additional cis-
associations with the SLE-risk MSH5 SNP, rs3131379, which is in moderate LD with 
DRB1*03:01, and with the DRB1*15:01 haplotype. PSMB9 is a type 1 interferon (IFN)-inducible 
gene which encodes a proteasome subunit involved in antigen processing. Further investigation 
of PSMB9 cis-associations with SLE-risk DRB1 and MSH5 haplotypes may be more relevant in 
the context of type 1 IFN stimulation, given the role of PSMB9 and the importance of IFN-α in 
the pathogenesis of lupus. In ex vivo B cells and monocytes, the MSH5 risk SNP, rs3131379, 
showed additional cis-associations with SKIV2L in class III, which has previously shown an 
independent association with SLE (Fernando et al., 2007), and to ZFP57 in class I. Increased 
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levels of ZFP57 expression have been previously reported in B*08-DRB1*03:01-homozygous 
LCLs (COX), compared to other MHC-homozygous LCLs (including B*18-DRB1*03:01, 
Vandiedonck et al., 2011). This suggests that the rs3131379 and B*08-DRB1*03:01 cis-eQTLs 
to ZFP57 are tagging an effect from causal variants in the class I region, which has been shown 
to harbour regulatory cis-SNPs in ZFP57 (Plant et al., 2014).  
 
Trans-eQTLs within the DRB1*03:01 and DRB1*15:01 haplotypes showed significant but 
inconsistent associations with gene expression in ex vivo B cells and LCLs. These associations 
may result from weak LD between the peak eSNPs for the trans-associated genes and DRB1 
haplotypes. With the exception of the trans-association of DRB1*15:01 to ZNF672, none of the 
trans-signals were replicated in other data sets, rendering these results inconclusive. 
Replication of trans-signals in different cell types is difficult due to the high context-specificity of 
trans-eQTLs. This was exemplified in an eQTL study by Fairfax and colleagues showing low 
overlap of trans-eQTLs in ex vivo B cells and monocytes (N = 120), compared to cis-eQTLs (n = 
17,962,  Fairfax et al., 2012). 
 
This study has highlighted some of the caveats of conducting eQTL analyses using expression 
arrays, particularly with respect to the MHC region. Firstly, the sample size in the data sets 
investigated in this study may have been too low to enable detection and replication of cis- and 
trans-associations of small effect size (particularly for DRB1*03:01 and DRB1*15:01 haplotypes, 
for which the number of homozygotes was low). Failure to replicate cis- and trans-associations 
may also be due to the differences in cell type and activation states. The ex vivo B cell data set 
was derived from positively selected B cells, so it is possible that the cells may have been 
partially activated during the selection process. LCLs are immortalized via EBV-transformation, 
which also results in cell activation. As eQTLs are highly sensitive to the cellular context, 
comparing eQTLs between the B cell, LCL, monocyte, and whole blood data sets will fail to 
replicate cell state- and cell type-specific effects. Furthermore, most of the eQTL data sets 
investigated in this study were not adjusted for sex, which is another factor known to influence 
eQTLs. Another limitation to the study of gene expression at the MHC and genome-wide is the 
use of Illumina expression arrays for the generation of the LCL and ex vivo cell data sets. 
Current Illumina arrays are designed to target the 3’ untranslated region of genes and a limited 
number of annotated spliced transcripts, therefore any cis- and trans-effects on spliced 
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transcript variants may be missed. Detection of gene expression at the MHC by microarray or 
RNA sequencing methods is also limited by the high polymorphism and sequence homology in 
the region. As conventional microarrays are designed to target the reference human genome 
MHC sequence (which harbours the B*07:02-DRB1*15:01 haplotype), this results in the 
exclusion of several HLA genes, as well as copy number variable genes, from most RNA 
sequencing and non-custom array studies.  
 
One other important caveat in this study is that the SLE-associated signals in MSH5 and DPB1 
here investigated may be erroneous, due to the relatively small size of the cohorts in which they 
were identified. Therefore, these associations require validation in independent cohorts of the 
relevant ancestry, prior to any further functional investigations. Furthermore, the use of 
European gene expression data to annotate eQTLs for SNPs associated with SLE in non-
European populations (such as Filipino and African-American populations) may result in 
inaccurate eQTL signals, due to differences in eQTL landscape between populations. 
Importantly, the SNPs here investigated may not be the peak eSNPs for the genes where a 
probe association was found. In order to identify the most likely causal variants for the eQTL 
signals identified in this chapter, the peak cis-eQTL for each cis-transcript here reported, as well 
as their LD with the SLE-associated SNPs under investigation, should also be explored. 
 
In conclusion, this study demonstrates eQTLs within SLE-associated DRB1, DPB1, and MSH5 
haplotypes in LCLs and B cells, which were reproducible in different blood cell types. These 
eQTLs suggest that SLE-risk and -protective haplotypes affect disease risk through gene 
regulatory mechanisms, and highlight new candidate genes in SLE. Thus, the regulatory role of 
disease-associated variants at the MHC here presented supports the hypothesis that disease 
associations arising from the MHC region, particularly DRB1 haplotypes, result from the 




Chapter 4 - The effect of IFN-α on the B cell transcriptome 
 
4.1 Introduction 
It is well established that type 1 interferons (IFNs), particularly IFN-α, are central to the 
pathogenesis of systemic lupus erythematosus (SLE). Many of the immunological and clinical 
features of the disease are attributed to an autoimmune response driven by type 1 IFNs. As 
mentioned in Chapter 1, multiple lines of evidence support a role for type 1 IFNs in triggering, 
amplifying, and maintaining inflammation in lupus and in other autoimmune diseases, but the 
underlying mechanisms remain unclear. Over the past few years, genetic studies have identified 
signalling components of the type 1 IFN pathway and regulators of nucleic acid metabolism as 
key players in the pathogenesis of lupus and other systemic autoimmune diseases (Crow, 
2010).  
 
B cell dysfunction is also critically implicated in the pathophysiology of SLE. B cell functions 
thought to be important in SLE have been postulated to include self-antigen presentation to 
CD4+ T cells, production of pathogenic auto-antibodies, and secretion of pro-inflammatory 
mediators. Given that IFN-α is a trigger of autoimmunity, it is likely to contribute significantly to B 
cell-mediated pathology in SLE. Type 1 IFNs are important mediators between the innate and 
adaptive immune systems, and direct type 1 IFN stimulation of B cells has been shown to be 
crucial for antibody-mediated response to viral and microbial infections in mice (Coro et al., 
2006, Swanson et al., 2010). The effects of IFN-α and IFN-β stimulation on gene and protein 
expression have been extensively studied in dendritic cells (DCs) and murine B cells (Braun et 
al., 2002, Hervas-Stubbs et al., 2011), whilst studies in human B cells have looked only at the 
effects of IFN-α on a limited number of gene transcripts (de Goer de Herve et al., 2011, 
Giordani et al., 2009). To date, no studies have investigated the impact of IFN-α on global gene 
expression in human B cells. 
  
Illumina expression microarrays have been a popular choice for transcriptomic data analysis, as 
exemplified by the study from Fairfax and colleagues, and the Multiple Tissue Human 
Expression Resource (MuTHER) study, discussed earlier in Chapter 3 (Fairfax et al., 2012, 
Grundberg et al., 2012). Among the limitations of the Illumina platform design are the targeting 
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of gene 3’ untranslated regions (UTRs), and restricted coverage of annotated splice variants. 
The Affymetrix Human Exon 1.0 ST array (here referred to as exon array) provides an attractive 
alternative, due to its high-density gene coverage. The probes are designed to detect individual 
exons, enabling the quantification of both whole gene expression and alternatively spliced 
transcripts (Clark et al., 2007).  Alternative splicing, like gene expression, is tissue- and context-
specific, and can therefore be modulated by pro-inflammatory cytokines (Le et al., 2004). 
 
Investigating the consequences of type 1 IFN stimulation on gene regulation (i.e. gene 
expression and alternative splicing) in the context of B cells is important to further our 
understanding of the pathways and mechanisms that are dysregulated in antibody-mediated 
autoimmune diseases. The work described here seeks to investigate the effect of IFN-α 
stimulation on the regulation of SLE-associated genes in B cells, in order to elucidate the 
functional mechanisms underlying these associations. 
 
This chapter describes the first transcriptomic analysis of human B cells following stimulation 
with IFN-α. First, changes in genome-wide gene expression between resting and IFN-α-
stimulated B cells were analysed. Secondly, the differential expression of genes associated with 
autoimmune and non-autoimmune diseases was investigated, with a particular focus on genes 
within SLE-associated loci, and within the major histocompatibility complex (MHC) region. 
Lastly, the impact of IFN-α on alternative splicing in B cells was explored. Given the gender bias 
of SLE incidence, and the influence of hormonal factors on gene expression, the study cohort 
comprised 49 healthy women of European ancestry from the TwinsUK registry. Transcriptomic 
data were generated from negatively selected ex vivo CD19+ B cells at rest, and following 
stimulation with IFN-α for 6 hours. This time point was previously shown to induce the highest 
expression of four type 1 IFN-inducible genes in a multi-time point assay (work conducted by Ms 
Lora Boteva, under the supervision of Dr Michelle Fernando, King’s College London). Gene 
expression data from CD19+ B cells were then processed using the Affymetrix exon array. P-
values were considered significant if they fell below a false discovery rate (FDR) < 1% or 5%, 







4.2 Quality control of exon array data 
The quality of the expression data obtained from exon arrays was first investigated using the 
Affymetrix Expression Console software, build 1.2.1.20. Visualization of the quality control (QC) 
metrics described in Chapter 2, section 2.4.1, revealed that all arrays generated from ex vivo B 
cells had high hybridization quality, and showed normal distribution of probe intensity signals 




Figure 4-1 Histogram showing the normal distribution of exon array probe set intensity signals for ex vivo B 
cell samples.  
 




Two technical replicates derived from a single monozygotic twin pair in each experimental batch 
were available. Within a batch, each twin from the pair was used as a biological replicate. A 
Spearman correlation test showed high correlation between biological replicates (r2 = 0.98), and 





Principal component analysis (PCA) of the raw data showed that three principal components 
(PCs) explained most of the data variability (Figure 4-2). Data structure was investigated using a 
PCA plot. Samples from different batch years clustered distinctly along PC1 and PC3, and 
samples from different treatment groups clustered along PC2 (Figure 4-3 A and B). The PCA 
plot also identified four outlier samples, which were removed from the data prior to analysis. 
Following adjustment for batch effects, samples from different treatment groups still clustered 



















A.      B. 
PCA mapping of raw data   PCA mapping of raw data 
 
               
 
 
C.       D. 
PCA mapping of batch-adjusted data  PCA mapping of batch-adjusted data 
 
 
                 
Figure 4-3 PCA plots for exon-level array data from ex vivo B cells.  
 
Plot A shows samples clustering by batch year in the raw data, and plot B shows samples clustering by 
treatment group in the raw data. Sample outliers are indicated. Plots C and D show the data structure 






4.3 Global effect of IFN-α on gene expression 
Gene-level analysis of B cell expression data revealed that IFN-α significantly affected genome-
wide gene expression, with 40% of annotated transcripts (6,018 out of 15,510) differentially 
expressed between resting and IFN-α-stimulated cells (FDR < 1%, Figure 4-4). Of these, 1,126 
genes had fold changes ≥ 2 or ≤ -2 (which equates to log2 fold changes ≥ 1 or ≤ -1). As 
expected, the most significantly up-regulated genes were IFN response genes, and the most 
down-regulated genes were primarily involved in cell cycle regulation (e.g. MOB3B, DUSP1), 
tumour suppression (e.g. PLPP5, FCRL1), or innate and adaptive immunity (LYZ, BIN2, CD1C).  
 
Enrichment analysis of the differentially expressed data using Ingenuity Pathway Analysis (IPA) 
identified B cell receptor (BCR) signalling as the top canonical pathway (56%, P = 2.13 × 10-12), 
followed by phosphoinositide 3-kinase (PI3K) signalling in B lymphocytes (57%, P = 1.54 × 10-
9), which occurs downstream of the type 1 IFN receptor. The IFN signalling pathway was also 
significantly enriched in cells stimulated with IFN-α (48%, P = 3.39 × 10-2). The top five enriched 
canonical pathways in the gene set are listed in Table 4-1. The most significant upstream 
regulators of differential expression predicted by IPA were IFN-λ (IFNL1, P = 3.47 × 10-14), IFN-




Figure 4-4 Volcano plot showing the effect of IFN-α stimulation on global gene expression in ex vivo B 
cells. 
 
Global gene expression was quantified using the Affymetrix Exon 1.0 ST array. Up-regulated genes with 
log2 fold changes ≥ 1 are highlighted in red. Down-regulated genes with log2 fold changes ≤ -1 are 
highlighted in blue. Gene labels indicate the top ten up-regulated and down-regulated transcripts. The red 
line indicates the significance threshold at an FDR of 1%.  
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B Cell Receptor Signalling 141 79 56.0% ND 2.13 × 10⁻¹² 
PI3K Signalling in B Lymphocytes 96 55 57.3% -3.159 1.54 × 10⁻⁹ 
Role of NFAT in Regulation of the 
Immune Response 
116 61 52.6% -3.015 1.83 × 10⁻⁸ 
CD28 Signalling in T Helper Cells 84 47 56% -2.846 6.48 × 10⁻⁸ 
Molecular Mechanisms of Cancer 297 125 42.1% ND 9.51 × 10⁻⁸ 
 
Gene transcripts differentially expressed by IFN-α (FDR < 1%) were put forward for IPA analysis of 
canonical pathways. Z-scores denote the predicted direction of change, with significance considered at an 
absolute z-score of ≥ 2. Pathway enrichment was considered significant if P < 0.05 at an FDR < 5%. DE – 
differentially expressed, PI3K – phosphoinositide 3-kinase, NFAT – nuclear factor of activated T cells, ND 




4.3.1 Type 1 IFN signature 
The presence of a type 1 IFN signature was detected in IFN-α-stimulated B cells. Five IFN-
inducible genes commonly used to characterize the signature, IFIT1, IRF7, ISG15, IFI44, and 
IFI44L (Greenberg et al., 2012, Kyogoku et al., 2013, Ferreira et al., 2014), were up-regulated in 
the exon array data (FDR < 1%). The direction of effect for these genes was validated by 
quantitative reverse-transcription polymerase chain reaction (qPCR), using complementary 
deoxyribonucleic acid (cDNA) from the exon array samples (Table 4-2). Interestingly, exon array 
data showed that down-regulation of the IFN-α receptors 1 (IFNAR1) and 2 (IFNAR2) 
messenger ribonucleic acid (mRNA) transcripts on IFN-α stimulation trended towards 
significance, suggesting a negative feedback loop (PFDR = 0.074, fold change (FC) = -1.16 and 























4.3.2 Differential expression of B cell markers by IFN-α 
Given that IFN-α strongly affected global gene expression, and that stimulation with cytokines is 
known to modify the cell phenotype, the biological state of ex vivo B cells following stimulation 
with IFN-α was assessed. B cell development and differentiation occurs in stages, each of 
which is characterized by different sets of markers expressed at the cell surface. In line with the 
activation of BCR signalling highlighted above, transcripts of the B cell activation markers CD25 
(IL2RA), CD40, and CD80 (Chang et al., 2008, Gantner et al., 2003, Gupta et al., 2013, Breen 
et al., 2011) were up-regulated by stimulation with IFN-α (Table 4-3). In contrast, other known B 
cell activation markers, such as the co-stimulatory markers CD86 and CD69, or the memory B 
cell marker CD27, were down-regulated, or not differentially expressed. Interestingly, IFN-α 
induced differential expression of markers associated with a transition into plasmablasts (CD20-
CD38++CD45++CD126++CD138- cells, De Vos et al., 2006), such as down-regulation of CD20 
(MS4A1) and CD22, and up-regulation of CD38 transcripts (Table 4-4). Similarly, the data 
showed differential expression of a number of plasma cell markers (CD20-
CD38++CD45weakCD54+CD126+CD130+138++ cells, De Vos et al., 2006), including down-
regulation of CD45, and up-regulation of CD54 (ICAM1) and CD130 (IL6ST) transcripts. 
Differential gene expression did not correlate with B effector cell polarization, as there was no 
up-regulation of B effector 1 (Be1) or Be2-associated cytokines (de Goer de Herve et al., 2011, 
Lund and Randall, 2010, Table 4-4). Transcripts were considered significantly differentially 
expressed at an FDR < 1% for all aforementioned genes. 
Type 1 IFN 
response gene 
Exon array qPCR 
Fold change PFDR Fold change PFDR 
IFIT1 172.87 2.66 × 10-16 1254.43 5.63 × 10-18 
IRF7 5.31 5.10 × 10-13 40.53 2.23 × 10-18 
ISG15 45.01 7.39 × 10-15 20.80 3.98 × 10-5 
IFI44 26.04 2.48 × 10-13 13.99 2.35 × 10-5 
IFI44L 50.24 1.90 × 10-12 12.08 4.65 × 10-5 
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CD25 (IL2RA) 6.11 8.00 × 10-11 
CD40 1.67 4.74 × 10-5 
CD80 1.47 5.37 × 10-3 
CD69 1.15 2.12 × 10-1 
CD27 -1.16 1.64 × 10-1 
CD86 -1.13 1.10 × 10-1 
101 
 
Table 4-4 The effect of IFN-α stimulation on the expression of plasmablast, plasma cell, and B effector cell 
differentiation markers. 
 





Plasmablast and plasma cell markers 
CD130 (IL6ST) 3.62 2.60 × 10-10 
CD22 -3.43 1.02 × 10-9 
CD38 4.16 2.21 × 10-8 
CD45 (PTPRC) -1.64 1.89 × 10-8 
CD54 (ICAM1) 6.20 4.73 × 10-6 
CD20 (MS4A1) -1.35 4.25 × 10-3 
CD138 (SDC1) -1.41 4.94 × 10-2 
CD126 (IL6R) -1.12 8.67 × 10-2 
Be1 polarization marker 
IFNG -1.55 3.77 × 10-3 
IL12RB1 -1.14 3.82 × 10-2 
IL12RB2 1.05 1.14 × 10-1 
IFNGR1 1.08 1.72 × 10-1 
IL12B -1.05 2.04 × 10-1 
IL12A 1.01 3.17 × 10-1 
Be2 polarization marker 
IL4R -3.75 1.38 × 10-8 
IL5RA -1.45 8.89 × 10-3 
IL13 1.01 3.00 × 10-1 
 





4.3.3 Differential expression of apoptotic markers by IFN-α 
In light of the role of IFNs in the induction of programmed cell death during the course of viral 
infection, the effect of IFN-α stimulation on cell survival was assessed. The lymphocytic 
apoptotic markers CD45 and CD28 (Vigano et al., 2001) were down-regulated following IFN-α 
stimulation, at a significant and a suggestive level of significance, respectively (Table 4-5). 
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Furthermore, the transcripts for the anti-apoptotic markers c-Myc (MYC) and Bcl-2 (BCL2) were 
up-regulated on IFN-α stimulation (Hoffman and Liebermann, 2008). Transcripts were 
considered significantly differentially expressed at an FDR < 1%. 
 
 

















Acute IFN-α stimulation of B cells had a significant effect on global gene expression, including 
the induction of a type 1 IFN signature, and the differential expression of several B cell markers. 
The magnitude of effect of IFN-α stimulation reflects the importance of this cytokine in 
transcriptome modulation. 
 
Stimulated B cells showed transcriptional changes indicative of antiviral response, 
immunoregulation, partial B cell activation and differentiation, and increased cell survival. This 
corroborates data from previous reports describing the downstream effects of IFN-α in murine 
and human B cells (Braun et al., 2002, Gujer et al., 2011, Apelbaum et al., 2013). Up-regulation 
of transcripts for the co-stimulatory molecules CD40 and CD80 is consistent with data from a 
mouse study (Braun et al., 2002), and supports at least partial activation of B cells by IFN-α 
stimulation. Failure to detect up-regulation of additional activation markers reported in the 
literature, such as CD86, CD69, and CD27, may be due to time point-dependent effects of the 
IFN-α response, heterogeneity of CD19+ B cell sub-populations, and differences between 
Apoptosis marker Fold change PFDR 
Pro-apoptotic markers 
CD45 (PTPRC) -1.64 1.89 × 10-8 
CD28 -1.20 5.55 × 10-2 
Anti-apoptotic markers 
BCL2 3.12 4.06 × 10-10 
MYC 1.64 1.61 × 10-3 
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murine and human biology. The cytokine-secreting role of B cells is effected through 
polarization into Be1 or Be2 cells, which secrete a panel of cytokines similar to that of T helper 
type 1 (Th1) and Th2 cells, respectively. IFN-α has been shown to trigger Be1 commitment after 
18-24 hour stimulation of human naïve B cells, through increased production of IFN-γ and IL-12 
(de Goer de Herve et al., 2011). The lack of change in gene expression patterns associated 
with Be1 (or Be2) polarization in the data presented here suggests that IFN-α priming for Be1 
differentiation may occur after 6 hours of stimulation or, alternatively, may be concealed by the 
presence of multiple B cell sub-populations. 
 
The effect of type 1 IFNs on cell survival is still unclear, with some studies reporting a role in 
induction of apoptosis, and others reporting proliferative effects and/or increased survival 
(Braun et al., 2002, Apelbaum et al., 2013). Type 1 IFN stimulation is generally insufficient to 
induce apoptosis in most cell types (Trinchieri, 2010), and is therefore likely to be dependent on 
cellular context. Tanaka and colleagues showed that type 1 IFN stimulation of murine primary 
embryonic fibroblasts selectively induced apoptosis in virally-infected cells, whilst promoting 
inhibition of viral replication and cell survival in uninfected cells (Tanaka et al., 1998). The data 
presented here show that B cells stimulated with IFN-α up-regulate pro-survival markers, but not 
apoptotic markers, further supporting the view that IFN-induced apoptosis in humans only 
occurs within a context of infection or prolonged IFN-α stimulation. Using evidence from 
previous studies reporting the effects of IFN-α in B cells, this work has shown that genome-wide 




4.4 Enrichment of disease-associated loci in the gene set 
differentially expressed by IFN-α 
As summarised in Chapter 1, there is overwhelming evidence supporting a pathogenic role for 
IFN-α in a number of autoimmune diseases, particularly SLE, Sjögren’s syndrome, and 
idiopathic inflammatory myopathies. Accordingly, an analysis was carried out to determine 
whether genes differentially expressed by IFN-α in B cells were enriched for complex disease-
associated loci. Susceptibility genes for 13 complex diseases previously identified by genome-
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wide association studies (GWAS) were tested for enrichment in the gene set differentially 
expressed by IFN-α. The diseases included eight autoimmune and five non-autoimmune 
diseases, of which a number have shown evidence of altered IFN activity. Disease-associated 
genes for SLE, rheumatoid arthritis, Sjögren’s syndrome, idiopathic inflammatory myopathies, 
multiple sclerosis, inflammatory bowel disease (IBD), type 1 diabetes, psoriasis, osteoarthritis, 
type 2 diabetes, bipolar disorder, schizophrenia, and hypertension were curated from the 
National Human Genome Research Institute (NHGRI) catalogue of published GWAS 
(http://www.genome.gov/gwastudies/; dates accessed September 2014). The analysis included 
all disease-associated loci which passed a genome-wide significance threshold of 5 × 10-8, and 
excluded intergenic and MHC loci (Appendix C). Section 4.5.5 describes the analysis of the 
extended MHC (xMHC) region.  
  
Two datasets for SLE susceptibility genes were created: one curated from the NHGRI database 
for purposes of comparison with the other diseases (Appendix C, Table C1), and one derived 
from an updated PubMed search of all published SLE-associated genes (January 2016, 
Appendix D, Table D1). Over 40% of genes associated with SLE, rheumatoid arthritis, IBD, and 
multiple sclerosis were enriched in the gene set differentially expressed by IFN-α, at a 
significant (FDR < 5%) or suggestive level of significance (FDR < 7%, Table 4-6). In contrast, 
there was no significant enrichment for genes associated with psoriasis, type 1 diabetes, or the 
non-autoimmune diseases osteoarthritis, type 2 diabetes, bipolar disorder, schizophrenia, and 
hypertension. The small number of genes for Sjögren’s syndrome and idiopathic inflammatory 












Table 4-6 Enrichment analysis for loci associated with 13 complex diseases in the gene set differentially 
expressed by IFN-α (FDR < 1%).  
               
 
Disease-associated loci were curated from the NHGRI GWAS database. An additional comprehensive 
gene list for SLE was also analysed (SLE (all published loci)). Disease enrichment was considered 
significant if P < 0.05 at an FDR < 5%. Significant p-values are displayed in bold type. P-values with 
suggestive significance (P < 0.05, FDR < 7%) are displayed in italic type. DE – differentially expressed, 






Disease enrichment analysis of genes differentially expressed by IFN-α in ex vivo B cells 
showed an overlap with susceptibility loci for the autoimmune diseases SLE, rheumatoid 
arthritis, IBD, and multiple sclerosis. This suggests a role for type 1 IFN in these diseases, 
which is discussed further below. Almost half of all psoriasis susceptibility genes also 













Autoimmune diseases  
Rheumatoid arthritis 45 42 57.1% (24/42) 3.83 × 10-5 4.98 × 10-4 
SLE                         
(all published loci) 
83 74 43.0% (34/79) 8.88 × 10-4 5.77 × 10-3 
IBD 227 188 41.4% (77/188) 2.57 × 10-2 8.35 × 10-2 
Multiple sclerosis 63 56 40.0% (22/56) 2.80 × 10-2 8.35 × 10-2 
SLE 40 35 41.7% (15/36) 3.21 × 10-2 8.35 × 10-2 
Psoriasis 20 15 46.7% (7/15) 9.98 × 10-2 0.22 
Type 1 diabetes 60 43 30.2% (13/43) 3.31 × 10-1 0.54 
Sjögren's syndrome 4 4 25.0% (1/4) 1.00 1.00 
IIM 1 1 100.0% (1/1) 1.00 1.00 
Non-autoimmune diseases  
Osteoarthritis 8 6 16.6% (1/6) 4.96 × 10-1 0.72 
Type 2 diabetes 76 62 30.5% (18/59) 2.73 × 10-1 0.51 
Bipolar disorder 9 5 20.0% (1/5) 1.00 1.00 
Schizophrenia 122 97 28.8% (28/97) 7.52 × 10-1 0.98 
Hypertension 15 13 0.0% (0/13) - - 
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diseases, including type 2 diabetes, schizophrenia, bipolar disease, and hypertension, were not 
enriched. The small number of susceptibility genes for Sjögren’s syndrome and idiopathic 
inflammatory myopathies available in the NHGRI data base resulted in a lack of power to detect 
disease enrichment in the IFN-α data set, given that these diseases also demonstrate a type 1 
IFN signature (Mavragani et al., 2007, Lundberg and Helmers, 2010).  
 
Administration of therapeutic type 1 IFN for hepatitis C and certain cancers has been reported 
to induce SLE, inflammatory arthritis, multiple sclerosis, psoriasis, and type 1 diabetes in a 
minority of patients (Crow, 2010, Afshar et al., 2013). A subset of patients with rheumatoid 
arthritis, and patients with relapsing remitting multiple sclerosis (RRMS), demonstrate a type 1 
IFN signature, albeit less intense than that found in SLE (Crow, 2010). In contrast to SLE, both 
IFN-α and IFN-β have been found in the rheumatoid arthritis signature (Mavragani et al., 2010), 
and in brain lesions of RRMS patients (Traugott and Lebon, 1988). IFN-β was proposed to have 
a regulatory role in multiple sclerosis, which led to the administration of this cytokine as a 
therapeutic agent in patients (Buttmann and Rieckmann, 2007). Similarly, IFN-β is associated 
with disease improvement in the joints of murine arthritis models and rheumatoid arthritis 
patients, further supporting a protective role for this cytokine (Crow, 2010). The suggestive 
enrichment of rheumatoid arthritis and multiple sclerosis candidate genes following IFN-α 
stimulation may indicate a role for IFN-α in these diseases, but may also reflect the redundancy 
of the IFN-α and IFN-β signalling pathways. 
 
Interestingly, type 1 diabetes susceptibility genes were not enriched in the IFN-α data set. The 
type 1 IFN signature is not a hallmark of type 1 diabetes, although a recent study reported 
presence of the signature in peripheral blood preceding the onset of type 1 diabetes (Ferreira et 
al., 2014). Type 1 diabetes patients given low-dose IFN-α (5000 units) demonstrate less severe 
disease than patients given a placebo or high-dose IFN-α (30,000 units, Rother et al., 2009). 
Altogether, these observations support a small role for this cytokine in the pathogenesis of type 
1 diabetes in B cells. Studies in other relevant cell types for type 1 diabetes, such as pancreatic 
β cells, may help to clarify the role of IFN-α in this disease. Similarly, the effect of type 1 IFNs in 
IBD is controversial, with one report claiming both regulatory and inflammatory roles in different 
phases of the disease (Rauch et al., 2014). Finally, therapeutic IFN-α administration has also 
been reported to trigger or exacerbate neuropsychiatric symptoms, including bipolar disorder 
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and depression (Mustafa et al., 2014). Various studies have shown a decreased IFN-α 
response in schizophrenia patients; however, the role of IFN-α in schizophrenia is still unclear 
(Inglot et al., 1994, Hornberg et al., 1995, Katila et al., 1989). The data presented in this chapter 
suggest that genetic susceptibility loci for both schizophrenia and bipolar disease may not 
interact directly with the IFN-α pathway, such that alterations of IFN-α levels in these patients 
may result from an epiphenomenon.  
 
As loci identified by GWAS are often located in non-coding genic or intergenic regions of the 
genome, gene annotations from the NHGRI database have been established according to the 
gene most proximal to the associated marker. The annotated genes in the NHGRI data base 
may not correspond to actual disease-causing genes, as the molecular mechanisms underlying 
disease associations may involve loci located in proximity (cis) or distant (trans) to the 
associated marker. A causal regulatory locus can act on a different locus through expression 
quantitative trait loci (eQTLs), epigenetic changes, chromatin conformation changes, or by 
affecting microRNA sites (Pai et al., 2015, Voisin et al., 2015). Some of the disease-associated 
loci described in this chapter may therefore not be biologically relevant in SLE. Since GWAS do 
not reveal the functional context for genetic associations, the information gained from GWAS 
needs to be combined with regulatory and functional data generated in disease-relevant 
conditions, such as the gene expression data here described. This will enable fine-mapping and 
identification of the causal genes and functional mechanisms underlying disease associations. 
 
In summary, the work described here shows that IFN-α stimulation of B cells regulates the 
expression of candidate genes for SLE and rheumatoid arthritis, and possibly candidate genes 
for multiple sclerosis and IBD, implicating a role for this cytokine in these autoimmune diseases. 
Since few studies have addressed the role of type 1 IFN in perpetuating inflammation and tissue 







4.5 Differential expression of genes associated with idiopathic and 
monogenic lupus by IFN-α  
 
4.5.1 Idiopathic SLE susceptibility genes 
Based on the comprehensive PubMed literature search described in section 4.4, as of January 
2016, 83 genes were associated with susceptibility to idiopathic SLE (using a statistical 
threshold of 5 × 10-8, Appendix D, Table D1). Of these 83 genes, 74 transcripts were expressed 
in the ex vivo B cell data set studied. However, the mechanisms underlying their association 
with disease remain largely unknown. I therefore sought to explore how the expression of SLE 
susceptibility genes is regulated by IFN-α stimulation in B cells (Table 4-7). As expected, 
significantly differentially expressed SLE candidate genes included those functionally involved in 
canonical Toll-like receptor (TLR) and type 1 IFN pathways, such as FCGR2B and IFIH1 
(MDA5) receptors, the signalling molecules STAT4 and TYK2, and the IFN inducible genes 
IRF5 and IRF7. Several of the genes differentially expressed by IFN-α encode BCR signalling 
components, including BANK1, BLK, LYN, and PRKCB, which are known to cross-talk with the 
type 1 IFN pathway (Delgado-Vega et al., 2010).  
 
Curiously, a number of SLE candidate genes outside canonical type 1 IFN and BCR signalling 
pathways (henceforth referred to as non-canonical genes) were also differentially expressed 
following IFN-α stimulation. These include moderately expressed genes (mean log2 expression 
values between 4 and 5) whose function in B cells is unknown or poorly characterised (e.g. 
NCF2, FCGR2A, and ITGAM), and genes of unknown function (e.g. PXK and TMEM39A). 
Differential expression of two canonical and six non-canonical SLE candidate genes was 
validated by qPCR, using cDNA from the exon array samples (FDR < 1%, Table 4-8). These 
eight genes were selected for qPCR validation, given the ongoing functional studies on their 

















Strong evidence of DE (FDR < 1%) 
IFIH1 (MDA5) 2584207 9.82 6.09 × 10-16 Type 1 IFN pathway 
FLI1 3355733 -3.33 1.03 × 10-14 Lymphoid Txn Factor 
CIITA 3647993 -3.23 1.12 × 10-13 
Transcriptional activator of HLA 
class I and class II 
IKZF1 3001479 -4.25 2.88 × 10-13 Lymphocyte development 
IRF7 3358174 5.31 5.10 × 10-13 Type 1 IFN pathway 
SMG7 2371255 2.30 5.15 × 10-13 Nonsense-mediated mRNA decay 
TLR7 3969081 8.41 4.91 × 10-12 Type 1 IFN pathway 
STAT4 2592356 7.24 1.31 × 10-11 Type 1 IFN pathway 
TNPO3 3072014 1.98 1.64 × 10-10 Nuclear import receptor 
BLK 3085990 -2.69 3.07 × 10-10 BCR signalling 
SH2B3 3431892 2.78 6.27 × 10-10 Hematopoiesis 
NADSYN1 3338968 -1.66 1.17 × 10-9 Metabolic redox reactions 
PRKCB 3653123 -3.61 2.23 × 10-9 BCR signalling 
ELF1 3511031 1.73 3.66 × 10-9 Lymphoid Txn Factor 
SOCS1 3680213 3.96 4.92 × 10-9 Cytokine signalling regulator 
CSK 3601840 -1.73 1.26 × 10-8 BCR signalling 
CXorf21 4003895 2.41 3.69 × 10-8 Unknown 
ITGAM 3656990 -2.80 5.24 × 10-8 
Phagocytosis in neutrophils and 
monocytes/macrophages 
PTPN22 2428796 -2.15 8.89 × 10-8 Lymphoid signalling 
IKZF2 2597867 2.32 9.06 × 10-8 Lymphocyte development 
TREX1 2621705 1.48 1.23 × 10-7 Nucleic acid metabolism 
PLD2 3707214 -1.44 3.46 × 10-7 Phospholipase 
FCGR2B 2363808 -2.54 4.12 × 10-7 B cell Fc receptor (inhibitory) 
BANK1 2737596 -1.83 6.76 × 10-7 BCR signalling 
RASGRP3 2476671 1.72 1.83 × 10-6 Energy metabolism 
KIAA0319L 2406139 -1.44 2.14 × 10-6 Unknown 






DE – differential expression, BCR – B cell receptor, Txn Factor – transcription factor, NK – natural killer, 









ICAM1 3820443 6.20 4.73 × 10-6 Cell adhesion 
ETS1 3397589 -1.80 4.91 × 10-6 Type 1 IFN response inhibitor 
NCF2 2447414 -1.78 9.20 × 10-6 
Phagosome function in 
neutrophils 
PXK 2626167 -1.69 2.92 × 10-5 Unknown 
TMEM39A 2690850 1.36 2.95 × 10-5 Unknown 
LYN 3098977 1.49 1.27 × 10-4 BCR signalling 
CDKN1B 3405440 -1.31 1.45 × 10-4 Cell cycle 
MECP2 4027056 1.62 1.96 × 10-4 DNA methylation 
DHCR7 3380697 -1.45 4.21 × 10-4 Cholesterol production 
FCGR3B 2440943 -1.94 1.20 × 10-3 NK cell receptor 
RAD51B 3541497 -1.25 1.90 × 10-3 DNA repair 
TCF7 2829171 -1.41 2.79 × 10-3 Lymphocyte differentiation 
TNFSF4 2444283 1.63 3.71 × 10-3 BCR signalling 
TYK2 3850278 -1.16 3.87 × 10-3 Type 1 IFN pathway 
CD80 2690900 1.47 5.37 × 10-3 BCR signalling 
TNFAIP3 2927506 1.93 6.25 × 10-3 Type 1 IFN pathway 
IRF5 3023246 1.29 7.05 × 10-3 Type 1 IFN pathway 
UHRF1BP1 2904270 -1.11 7.39 × 10-3 Unknown 
UBE2L3 3938175 -1.25 9.78 × 10-3 NFκB pathway 
Suggestive evidence of DE (FDR < 5%) 
SPRED2 2556752 -1.18 1.02 × 10-2 Growth factor signalling 
SKP1 2876011 -1.32 1.15 × 10-2 Ubiquitination 
TET3 2489071 1.24 1.19 × 10-2 DNA methylation 
ZPBP2 3720543 -1.21 1.38 × 10-2 Unknown 
ATG5 2967550 1.15 1.77 × 10-2 Autophagy 
DRAM1 3428783 1.28 2.30 × 10-2 NFκB pathway and autophagy 
IRF8 3672489 1.25 3.81 × 10-2 Type 1 IFN pathway 
IL21 2784279 -1.21 4.12 × 10-2 
















    
     




4.5.2 Monogenic lupus susceptibility genes 
An investigation of the effect of IFN-α on genes that cause rare monogenic forms of lupus was 
carried out. Eighteen genes associated with monogenic lupus were identified from a PubMed 
literature search (Appendix D, Table D2), of which 16 transcripts were expressed in the B cell 
expression data set. Seven monogenic lupus genes (46%) showed strong or suggestive 
evidence of differential expression by IFN-α (FDR < 1% or < 5%, respectively, Table 4-9). 
These included genes involved in nucleic acid metabolism (SAMHD1, TREX1, DNASE1L3), the 
complement components C1R, C1S and C2, and acid phosphatase 5 (ACP5 or TRAP). In 
addition, differential expression of PRKCD (PFDR = 0.08) and RNASEH2C (PFDR = 0.06) 
demonstrated a trend towards significance. Differential expression five transcripts, including 
PRKCD and RNASEH2C, was validated by qPCR, using cDNA from the exon array samples 












IFIH1 (MDA5) 10.96 6.58 × 10-20 
ITGAM -7.95 4.03 × 10-18 
IRF7 40.53 2.23 × 10-17 
IKZF1 -3.35 1.18 × 10-16 
FCGR2A -9.65 1.02 × 10-9 
PTPN22 -2.25 1.02 × 10-9 
TNPO3 1.50 1.85 × 10-8 
FCGR3B -2.97 5.41 × 10-5 
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Table 4-9 The effect of IFN-α stimulation on the expression of genes associated with monogenic lupus. 
 
 


































Strong evidence of DE (FDR < 1%) 
SAMHD1 3904691 3.76 2.14 × 10-8 Nucleic acid metabolism 
TREX1 2621705 1.48 1.23 × 10-7 Nucleic acid metabolism 
DNASE1L3 2678298 -1.93 1.09 × 10-4 Nucleic acid metabolism 
C1R 3442475 -1.22 3.58 × 10-4 Complement 
Suggestive evidence of DE (FDR < 5%) 
C1S 3403168 -1.21 1.12 × 10-2 Complement 
ACP5 (TRAP) 3851072 2.01 2.56 × 10-2 Type 1 IFN regulator 
C2 2902804 -1.22 3.00 × 10-2 Complement 
No evidence of DE (FDR > 5%) 
PRKCD 2624291 -1.12 8.03 × 10-2 Apoptosis of B cells 








Strong evidence of DE (FDR < 1%) 
SAMHD1 6.01 5.26 × 10-15 
PRKCD -1.31 2.20 × 10-4 
ACP5 (TRAP) 1.61 4.84 × 10-4 
DNASE1L3 -2.93 1.12 × 10-3 
Suggestive evidence of DE (FDR < 5%) 
RNASEH2C 1.10 1.87 × 10-2 
113 
 
4.5.3 IFN-α effects mirror the functional consequences of SLE polymorphisms 
Several studies have investigated the functional consequences of established SLE-associated 
polymorphisms, such as differential transcript and protein expression, or altered cellular 
function. Interestingly, the direction of effect of IFN-α on transcript levels (increasing or 
decreasing) of several SLE susceptibility genes mirrored the functional effects of gain-of-
function (GoF) and loss-of-function (LoF) SLE polymorphisms reported in the literature 
(summarized in Table 4-11). Differentially expressed SLE genes within canonical type 1 IFN 
and BCR pathways which harbour GoF (IFIH1, IRF7, STAT4, TNFSF4) and LoF (BLK, 
FCGR2B, TYK2) polymorphisms were respectively up- and down-regulated by IFN-α. The same 
pattern was observed for nine non-canonical SLE genes, and five monogenic lupus-associated 
























Table 4-11 Differential expression of canonical and non-canonical SLE-associated genes by IFN-α mirrors 
the effect of GoF and LoF polymorphisms within those genes. 
 









Functional effect of 
polymorphism 
Reference 






Increased sensitivity to IFN-α 
in SLE PBMCs 





Elevated IRF7 activity in 
reporter cells 
Fu et al. (2011) 
STAT4  rs7582694 
Increased STAT4 expression 
in healthy PBMCs 




Reduced BLK expression in 
healthy B cells 
Hom et al. (2008), 





expression in healthy B cells; 
protein LoF 
Bentham et al. 
(2015), Floto et al. 
(2005) 
TNFSF4  rs2205960 
Increased TNFSF4 
expression in SLE blood 
lymphocytes 
Cunninghame 
Graham et al. (2008),        
Manku et al. (2013) 
TYK2  rs2304256 
Reduced TYK2 expression in 
healthy monocytes 
Bentham et al. (2015) 
IRF5  rs10488631 
Increased IRF5 transcript 
and protein expression in 
SLE PBMCs 
Feng et al. (2010) 
Non-canonical SLE genes  
SOCS1  rs9652601 
Increased SOCS1 
expression in healthy B cells 
Bentham et al. (2015) 
ITGAM  R77H Protein LoF Rhodes et al. (2012) 
PTPN22  R620W Conflicting 
Holmes et al. (2015), 
Wang et al. (2015) 
FCGR2A  H166R, R131H Reduced protein function  
Tada et al. (2012), 




Reduced ETS1 expression 
Lu et al. (2015),     
Yang et al. (2010) 
NCF2  H389Q, R395W Protein LoF Jacob et al. (2012) 
DHCR7  rs3794060 
Reduced DHCR7 expression 
in healthy stimulated 
monocytes 
Bentham et al. (2015) 
FCGR3B  CNV Reduced protein expression Willcocks et al. (2008) 
SKP1  rs7726414 
Reduced SKP1 expression 
in healthy B cells 
Bentham et al. (2015) 
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Table 4-12 Differential expression of monogenic lupus-associated genes by IFN-α mirrors the effect of LoF 
polymorphisms within those genes. 
 
 




4.5.4 Type 1 interferonopathy susceptibility genes 
Genetic studies of type 1 interferonopathies, which comprise clinical syndromes characterized 
by high levels of type 1 IFN, have advanced our understanding of the molecular pathways 
involved in triggering type 1 IFN production. Studies in patients with Aicardi-Goutières 
syndrome, a neurodegenerative type 1 interferonopathy, have identified LoF mutations in genes 
involved in nucleic acid metabolism and recognition (such as TREX1, SAMHD1, RNASEH2C, 
and IFIH1), which correlate with increased serum type 1 IFN levels (Miner and Diamond, 2014, 
Kretschmer et al., 2015, Gunther et al., 2015). Gene expression data showed that IFN-α 
stimulation resulted in the up-regulation of eight out of 13 genes associated with the type 1 
interferonopathies (FDR < 5%, Appendix E). Interestingly, five of the up-regulated genes 
overlapped with idiopathic and monogenic lupus susceptibility genes (Figure 4-5).  Out of a total 












Functional effect of 
polymorphism 
Reference 
Monogenic lupus genes 












Protein deficiency Bryan and Wu (2014) 
PRKCD  G510S 
Reduced PRKCD 
expression and activity 







Figure 4-5 Venn diagram showing differentially expressed susceptibility genes for lupus and type 1 
interferonopathies following IFN-α stimulation. 
 
The diagram demonstrates shared and unique susceptibility loci for idiopathic SLE (top 21 differentially 
expressed genes shown), monogenic lupus, and type 1 interferonopathies. Genes differentially expressed 




4.5.5 xMHC region genes 
The strongest genetic risk for SLE in Europeans arises from the MHC region, with a substantial 
contribution from extended ancestral human leukocyte antigen (HLA) haplotypes. Given the 
extent of linkage disequilibrium (LD) in the region, and the challenges this poses for fine-
mapping disease associations, the effect of IFN-α on gene expression within the xMHC region 
was examined separately from that on SLE-associated genes outside the xMHC.  
 
IFN-α significantly affected the expression of 56% of xMHC genes (110 out of 197 genes, FDR 
< 1%, Figure 4-3), which are listed in Appendix F, Table F1. The most significantly up-regulated 
genes were located within the class III region, and include tumour necrosis factor (TNF) family 
members (TNF, LTA), antigen processing genes for HLA class I presentation (TAP1, TAP2, 










HLA genes, many of the exon array probes targeting these genes were removed from the data 
during QC. Excluded probes included those for the classical class I HLA-A, HLA-B, HLA-C, and 
classical class II HLA-DRB and HLA-DPB1 transcripts. Nevertheless, IFN-α up-regulated two 
non-classical HLA class I transcripts (HLA-E and HLA-F). In contrast, HLA class II transcripts 
were down-regulated, including classical antigen presenting molecules (HLA-DRA, HLA-DPA1), 
non-classical HLA molecules involved in peptide loading (HLA-DMA, HLA-DMB, HLA-DOA, 
HLA-DOB), and the pseudogene HLA-DPB2. Down-regulation of the classical class II gene 
DPB1 was demonstrated by qPCR (PFDR = 4.05 × 10-3, FC = -1.67). Additional genes down-
regulated by IFN-α in the exon array data included several members of the histone family 
located in the xMHC class I (14 out of 36 histone genes).  
 
Several of the xMHC genes differentially expressed by IFN-α stimulation have been associated 
with SLE in GWAS and candidate locus studies (as detailed in Chapter 3, section 3.1, and 
Chapter 5, section 5.1). These included genes which have shown single nucleotide 
polymorphism (SNP) associations with SLE independently of extended ancestral HLA 
haplotypes (MICB, MSH5, and DPB1), and genes in strong LD with extended ancestral HLA 
haplotypes, such as HLA-DRB1*03:01 (NCR3, AIF1, TNF, LTA, LTB, C6orf10, TRIM27, and 




Figure 4-6 Effect of IFN-α stimulation on differential gene expression in the xMHC region. 
 
The plot shows that genes with the largest fold changes are located within the MHC class III region. Genes 
with the smallest fold changes are located within the xMHC class I and MHC class III regions. The top 






Investigation of SLE candidate genes differentially expressed by IFN-α revealed that multiple 
transcripts were positively or negatively regulated in ex vivo B cells. Differentially expressed 
genes included both canonical and non-canonical SLE candidate genes, and genes within the 
xMHC region. This suggests a direct role for these genes in the pathogenesis of SLE through 
the activation of the type 1 IFN pathway. Furthermore, the effect of IFN-α on the expression of 
several idiopathic and monogenic lupus candidate genes mirrors the genetic consequences of 
risk polymorphisms reported in functional studies.  
 
As expected, SLE susceptibility genes differentially expressed by IFN-α included those 
functionally involved in canonical TLR, type 1 IFN, and BCR signalling pathways. Up-regulation 
of TLR pathway genes indicate that IFN-α might possibly induce a positive feedback loop in 
type 1 IFN production. Differential expression of BCR signalling pathway genes was likely to 
result from the crosstalk between type 1 IFN signalling and BCR signalling, as previously 
mentioned. Functional studies on the IFN signalling genes STAT4, IRF5, IRF7, and IFIH1 have 
demonstrated that SLE risk GoF polymorphisms correlate with increased transcript expression 
or protein activity, as well as an exacerbated response to IFN-α (Abelson et al., 2009, Kariuki et 
al., 2009, Feng et al., 2010, Niewold et al., 2008, Fu et al., 2011, Salloum et al., 2010, Robinson 
et al., 2011). Up-regulation of these genes by IFN-α mirrors the genetic effects of functional 
polymorphisms, and again suggests a positive feedback loop induced by IFN-α. Similarly, down-
regulation of the canonical genes BLK and FCGR2B by IFN-α parallels the effect of reported 
LoF polymorphisms in these genes. Furthermore, SLE-associated LoF polymorphisms in 
FCGR2B have been shown to result in increased pro-inflammatory signalling (Floto et al., 
2005). These canonical SLE candidate genes may therefore play a role not only in inducing the 
type 1 IFN response, but are also likely to perpetuate it via an IFN-α positive feedback loop.  
 
Many of the differentially expressed idiopathic and monogenic SLE candidate genes were not 
previously known to be functionally associated with the type 1 IFN or BCR signalling pathways 
following stimulation with IFN-α (i.e. non-canonical genes). Interestingly, these included SLE 
genes whose function in B cells is poorly characterised or unknown, such as ITGAM, FCGR2A, 
FCGR3B, and NCF2, as well as genes conventionally expressed in B cell, such as ETS1, 
PTPN22, and IKZF1. Again, down-regulation of several of these genes by IFN-α parallels the 
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functional effects of SLE risk polymorphisms. The implications of these observations for the 
pathogenesis of SLE are discussed further below, and are illustrated in Figure 4-7 and Figure 
4-8 for a number of SLE candidate genes.  
 
ITGAM encodes a complement component 3 receptor subunit, CD11b, which acts as an anti-
inflammatory mediator by inducing phagocytosis of immune complexes (ICs). Recently, an SLE-
associated LoF polymorphism in ITGAM was shown to decrease the phagocytic activity of 
macrophages, which is thought to affect the uptake of ICs (Rhodes et al., 2012). CD11b is 
abundantly expressed in monocytes and neutrophils; however, its expression and function in 
human B cells is not well characterized, except in B1 and memory (CD27+) B cell sub-
populations (Griffin et al., 2012, Kawai et al., 2005). The work here described confirms 
moderate expression of ITGAM in CD19+ B cells, and reports, for the first time, down-regulation 
of ITGAM transcripts by IFN-α stimulation. Interestingly, CD11b expression is reduced in T cells, 
monocytes, and neutrophils from SLE patients (Zhou et al., 2014). Furthermore, CD11b was 
recently shown to negatively regulate the survival of murine autoreactive B cells (Ding et al., 
2013). Based on these data, it is possible to hypothesise that IFN-α increases the survival of 
autoreactive B cells through the down-regulation of ITGAM, thereby predisposing to 
autoimmunity. However, one study reported that type 1 IFN stimulation mediated conversion of 
plasmacytoid DCs (pDCs) into CD11b+ DCs (Liou et al., 2008), implying an increase in ITGAM 
expression in pDCs. The effect of IFN-α on ITGAM expression may therefore be cell type-
dependant.  
 
Other differentially expressed SLE candidate genes poorly characterized in B cells include the 
Fcγ receptors FCGR2A and FCGR3B. These are activating receptors which induce endocytosis 
of ICs. FCGR2A is mainly expressed in phagocytic cells (macrophages, neutrophils, and pDCs), 
and harbours LoF polymorphisms associated with SLE (Tada et al., 2012). The copy number 
variable gene FCGR3B is constitutively expressed in neutrophils, and low copy number is 
associated with risk of SLE (Yuan et al., 2015). Functional studies of the risk polymorphisms in 
both FCGR2A and FCGR3B have shown that cells exhibit decreased IC clearance (Deng and 
Tsao, 2010). This chapter reports a decrease in expression of both FCGR2A and FCGR3B 
transcripts by IFN-α, which may translate to decreased activity of these receptors in B cells. 
However, FCGR3B mRNA expression in B cells has not been previously confirmed in the 
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literature, due to high sequence similarity within copy number variable loci, and flow cytometric 
data have suggested that it is not expressed at protein-level in B cells (Dr Ruth Tarzi, Imperial 
College London; personal communication). In order to validate the results presented here, 
protein-level expression of FCGR3B in B cells would need to be demonstrated. Conversely, 
transcriptional changes may not be translated at protein-level, due to additional regulatory 
mechanisms, such as nonsense-mediated mRNA decay or translational repression. 
 
ETS1 encodes a transcription factor highly expressed in lymphoid tissues, which binds the IFN-
stimulated response element (ISRE), and acts as a repressor of IFN-α production and B cell 
development (Flesher et al., 2010). SLE-associated polymorphisms in ETS1 correlate with 
decreased mRNA expression and increased IFN signalling in Asian populations (Lu et al., 2015, 
Yang et al., 2010). Furthermore, ETS1 transcript levels are decreased in peripheral blood 
mononuclear cells (PBMCs) from SLE patients compared to controls (Li et al., 2010). The data 
presented here showed that IFN-α stimulation also down-regulated ETS1 expression, which 
suggests that reduced levels of this transcript in SLE patients may be due to environmental as 
well as genetic factors. 
 
PTPN22 encodes a lymphoid tyrosine phosphatase, Lyp, which is involved in immune cell 
development and function, and is an inhibitor of immune cell signalling (Bottini and Peterson, 
2014). The non-synonymous polymorphism R620W is associated with SLE, as well as various 
other autoimmune diseases (Gregersen et al., 2012). Functional studies have shown conflicting 
results regarding the effect of R620W, with reports showing both an increase (due to LoF) and a 
decrease (due to GoF) in T cell and B cell signalling. A study by Holmes and colleagues 
(Holmes et al., 2015) showed that Lyp-deficient mice exhibited increased serum IFN-α, as did 
SLE patients carrying the risk polymorphism. The study concluded that Lyp negatively regulates 
IFN-α signalling, and that the PTPN22 risk variant results in LoF. In contrast, a different group 
demonstrated that SLE patients carrying the R620W variant show reduced IFN-α signalling in 
PBMCs (Wang et al., 2015). The effect of this PTPN22 polymorphism may be dependent on cell 
sub-populations, specific immune pathways, or biological state (Burn et al., 2011, Bottini and 
Peterson, 2014). The data presented in this chapter showed that IFN-α down-regulated 
PTPN22 in B cells, compounding the observations of Holmes and colleagues (Holmes et al., 
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2015), and may therefore help to clarify the functional role of this archetypal autoimmune gene 
within the context of B cells. 
 
IKZF1 encodes a member of the Ikaros family of transcription factors (Ikaros), which is involved 
in lymphocyte differentiation (Hu et al., 2013). Reports of the functional effect of the SLE-
associated SNP, rs4917014, on IKZF1 expression levels are contradictory. One study reported 
a correlation between the risk allele and up-regulation of IKZF1 transcripts in cis, and up-
regulation of IFN-α-inducible transcripts in trans, in peripheral blood cells (Westra et al., 2015). 
However, the cis-eQTL has not been replicated in other gene expression cohorts (Bentham et 
al., 2015). The down-regulation of IKZF1 by IFN-α here reported is of interest, given that IKZF1 
is also down-regulated in the serum of SLE patients (Costa-Reis and Sullivan, 2013). It has 
been suggested that low levels of IKZF1 expression activate IFN-α production through 
regulation of STAT4 transcription (Dang et al., 2014). In contrast, the data presented here 
showed that the SLE-associated Ikaros family members IKZF2 (Helios) and IKZF3 (Aiolos) were 
not down-regulated by IFN-α. Taken together, these observations support a direct relationship 
between levels of IKZF1 in SLE and IFN-α activity, and suggest that IKZF1 may play a role in a 



























Figure 4-7 Differential expression of genes associated with idiopathic SLE by IFN-α stimulation.  
 
SLE candidate genes within canonical TLR and type 1 IFN pathways are coloured in blue and those within 
non-canonical pathways are coloured in orange. Non-differentially expressed genes relevant to the 
pathways are coloured in grey. The activating and inhibitory effects of SLE genes on IFN-α production are 




















Figure 4-8 Potential consequences of IFN-α on the function of genes associated with idiopathic SLE.  
 
Associated genes within canonical TLR and type 1 IFN pathways are coloured in blue and those within 
non-canonical pathways are coloured in orange. Non-differentially expressed genes relevant to the 
pathways are coloured in grey. Black arrows indicate the direction of effect on gene expression levels 
following IFN-α. The resulting hypothetical increase and decrease in protein function is indicated by thick 
green arrows and red crosses, respectively. Changes in the expression of these genes may increase the 
IFN-α response through reduced clearance of immune complexes and apoptotic debris, increased TLR-










Monogenic (or familial) lupus comprise rare inherited forms of lupus caused by highly penetrant, 
single-gene mutations. IFN-α induced differential expression of a range of monogenic lupus-
associated genes, including nucleic acid metabolism genes, complement components, and type 
1 IFN signalling genes (Figure 4-9). IFN-α had a minimal negative effect on complement 
expression, which had been previously demonstrated in PBMCs (Colten et al., 1986, Sánchez-
Pernaute et al., 2015). Deficiencies in components of the early classical complement pathway, 
including C1Q, C1R, C1S, and C2, have long been associated with an increased risk of lupus 
(Bryan and Wu, 2014). However, due to the high LD between C2 and other MHC genes, 
independence of this signal from HLA haplotypes has not been confirmed. Complement 
deficiency results in impaired clearance of ICs and apoptotic cells, which provide a source of 
self-antigens to autoreactive cells, and activate type 1 IFN production (Belot and Cimaz, 2012). 
One can hypothesise that down-regulation of complement components by IFN-α, combined with 
a genetically-driven decrease in immune regulation, may result in the breakdown of tolerance 
and transition to autoimmunity (Figure 4-10). 
 
Similarly, several LoF mutations in the nuclease genes TREX1, DNASE1L3, and RNASEH2C, 
and in the genome-stabilising gene SAMHD1, have been shown to impair clearance of 
intracellular nucleic acids and induce type 1 IFN activation (Fye et al., 2011, Al-Mayouf et al., 
2011, Gunther et al., 2015, Kretschmer et al., 2015). Up-regulation of TREX1, RNASEH2C, and 
SAMHD1 transcripts by IFN-α further supports a role for these genes in immune tolerance, by 
preventing the accumulation of interferogenic nucleic acids. Of note, TREX1 was also recently 
associated with complex SLE in a large case-control study (Namjou et al., 2011), so it is 
plausible that additional monogenic lupus genes may show an association with idiopathic SLE 
in future larger GWAS. IFN-α also regulated the expression of ACP5 (up-regulated) and PRKCD 
(down-regulated), both of which interact with type 1 IFN signalling components. Interestingly, 
functional studies in mice have shown that PRKCD, which encodes an isoform of protein kinase 
C, induces apoptosis of autoreactive B cells, and is therefore a crucial regulator of immune 
tolerance (Belot et al., 2013). As with the complement genes, down-regulation of DNASE1L3 
and PRKCD by IFN-α paralleled the genetic effects of the lupus-associated LoF variants within 





In addition to monogenic SLE, studies of various forms of syndromic lupus have advanced our 
understanding of the pathways that can activate type 1 IFN production. The so-called type 1 
interferonopathies are a group of rare monogenic syndromes which include chilblain lupus, 
Aicardi-Goutières syndrome, and spondyloenchondrodysplasia. These syndromes are 
characterized by overproduction of IFN-α, and show a degree of clinical overlap with SLE (Crow 
and Manel, 2015). Studies in patients have identified LoF mutations in nucleic acid metabolism 
genes (including those also associated with monogenic lupus) and GoF mutations in nucleic 
acid sensors (IFIH1, RIG-I (DDX58), and STING), type 1 IFN inducers (ACP5), and IFN-
inducible genes (ISG15 and PSMB8). All interferonopathy genes differentially expressed by 
IFN-α were up-regulated, including those shared with monogenic and idiopathic SLE, which 













Figure 4-9 Differential expression of genes associated with monogenic lupus by IFN-α stimulation.  
 
Monogenic lupus genes are coloured in purple. Non-differentially expressed genes relevant to the 
pathways are coloured in grey. The activating and inhibitory effects of lupus genes on IFN-α production 




Figure 4-10 Potential consequences of IFN-α on the function of genes associated with monogenic lupus.  
 
Associated genes are coloured in purple. Non-differentially expressed genes relevant to the pathways are 
coloured in grey. Black arrows indicate the direction of effect on gene expression levels following IFN-α 
stimulation. The resulting hypothetical increase and decrease in protein function is indicated by thick green 
arrows and red crosses, respectively. Changes in the expression of these genes may increase the IFN-α 
response through the accumulation of endogenous nucleic acids in the cytoplasm, decreased 
complement-mediated clearance of apoptotic debris, and increased type 1 IFN signalling. 
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Analysis of gene expression at the MHC showed a strong effect of IFN-α in the region, 
particularly on xclass I histone genes, class I and class II antigen processing and presentation 
genes, and class III cytokine genes. Up-regulation of HLA class I transcripts replicated previous 
studies in murine B cells (Braun et al., 2002, Descotes, 2004). Induction of the HLA class I in 
response to IFN-α is consistent with its role in anti-viral immunity, where early production of 
IFNs is key (Fink et al., 2006). Furthermore, IFN-α down-regulated HLA class II transcripts, 
including the SLE-associated DPB1 gene. However, based on reports in the literature, the effect 
of IFN-α on class II molecules remains unclear, with one study showing that IFN-α up-regulated 
the HLA class II in buccal epithelial cells (Smith et al., 1996). In contrast, a different study 
reported that IFN-γ, but not IFN-α, up-regulated class II molecules in keratinocytes 
(Niederwieser et al., 1988).  
 
Differential expression at the MHC also included several genes that have shown independent 
and non-independent associations with SLE. MICB (class I) and MSH5 (class III) were the only 
genes regulated by IFN-α that have shown independent SNP associations with lupus (Barcellos 
et al., 2009, Fernando et al., 2012, Morris et al., 2012). Many reported MHC associations with 
SLE were no longer significant after accounting for DRB1 alleles, due to strong LD between the 
loci (Clancy et al., 2010, Morris et al., 2012, Fernando et al., 2007, Barcellos et al., 2009). 
Interestingly, the results presented here showed that several loci within the DRB1*03:01 
extended haplotype were differentially expressed by IFN-α, including NCR3, AIF1, the TNF 
cytokine family genes TNF, LTA, and LTB, C6orf10 (class II), TRIM27 (xclass I), and HSD17B8 
(xclass II). The heat shock protein gene HSPA1B (class III), also differentially expressed by IFN-
α, has previously shown an association with SLE independently from a DRB1*03:01 tag SNP, 
but the study in question did not confirm independence from other HLA alleles (Furnrohr et al., 
2010). Taken together, these data suggest that SLE-associated loci within extended MHC 
haplotypes may still play a biological role in the disease in the context of IFN-α activation. 
 
It should be noted that most classical HLA class I and II genes failed QC, which highlights one 
of the drawbacks of using pre-designed expression arrays for highly polymorphic regions such 
as the MHC. qPCR analysis of DPB1 demonstrated that this method was a reliable alternative 




In summary, the work described in this chapter has shown that IFN-α regulates the expression 
of several lupus candidate genes, including those involved in type 1 IFN signalling, BCR 
signalling, the classic complement pathway, nucleic acid metabolism, and HLA class I and class 
II antigen presentation. Differential expression of non-canonical SLE candidate genes following 
IFN-α stimulation suggests that they may play a previously unrecognised role in disease 
pathogenesis. The direction of effect of IFN-α on the expression of several non-canonical 
candidate genes was similar to that of functional SLE polymorphisms within those genes. In 
addition, the effects of IFN-α and functional risk polymorphisms also mirrored the difference in 
gene transcript levels between SLE patients and controls in some cases. Importantly, IFN-α 
decreased expression of regulators of type 1 IFN and genes involved in clearing apoptotic cell 
debris, ICs, and endogenous nucleic acids, all of which contribute to immune tolerance during 
inflammation. Based on these observations, it is possible to hypothesise that exposure to IFN-α 
in genetically susceptible individuals may trigger autoimmunity by altering the expression of 
genes involved in maintaining tolerance to self. For example, in individuals carrying an SLE risk 
variant that marginally decreases cellular function, IFN-α exposure could further reduce protein 
levels below the threshold required to sustain health, leading to the development of SLE. 
Altogether, these data complement ongoing functional studies of individual SLE-associated 
genes, and uncover potentially novel mechanisms underlying disease susceptibility. 
 
 
4.6 Alternative splicing induction by IFN-α 
The effects of IFN-α on gene expression so far described in this chapter have been observed in 
data normalized at gene level. However, analysis of gene-level data will not detect any effects 
on exon expression in genes where the overall transcript levels remain unchanged. Accordingly, 
a further analysis was performed to determine whether IFN-α affected alternative splicing in 
non-differentially expressed (NDE) genes. In addition, the effect of IFN-α in alternative splicing 
of SLE candidate genes, type 1 interferonopathy candidate genes, and genes within the xMHC 
region, was also investigated. 
 
Following normalization at exon level, differential gene expression and alternative splicing 
between resting and IFN-α-stimulated samples was calculated. As the exon-level and gene-
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level datasets were generated using different normalization methods (robust multi-array 
average (RMA) and winsorized mean, respectively), the list of differentially expressed genes in 
the two data sets was similar, but not identical (6,018 differentially expressed transcripts at 
gene-level compared to 7,902 transcripts at exon-level, FDR < 1%).  
 
4.6.1 Global alternative splicing 
Analysis of the global exon-level data showed that 8,708 out of 13,394 multi-exon transcripts 
(65%) were alternatively spliced between resting and IFN-α samples. After excluding 
differentially expressed transcripts (differential expression PFDR < 0.05), 1,383 transcripts (10% 
of all multi-exon transcripts) were alternatively spliced. 
 
4.6.2 Alternative splicing of SLE susceptibility genes 
Out of 16 NDE SLE-associated genes, nine transcripts showed evidence of alternative splicing 
following IFN-α stimulation (FDR < 1%, Table 4-13, Figure 4-11). These included the canonical 
type 1 IFN pathway genes IRAK1, TNIP1 and IRF8, and non-canonical genes. Interestingly, 
IRF8 was the only alternative spliced gene exhibiting conflicting differential expression status 
between the exon-level data set (NDE, PFDR = 0.28) and the gene-level data set (differentially 
expressed at an FDR < 5%, Table 4-7). Of the nine NDE genes associated with monogenic 
lupus, two genes showed evidence of alternative splicing, C1QC and DNASE1 (FDR < 1%, 
Table 4-14, Figure 4-12). In contrast, none of the type 1 interferonopathy-associated genes 
showed evidence of alternative splicing. At the xMHC region, 14 out of 36 NDE transcripts 
(24%) were alternatively spliced, including the SLE-associated genes NOTCH4 and SKIV2L 





































Figure 4-11 Differential exon expression in the SLE susceptibility gene IRAK1 between resting and IFN-α-
stimulated B cells.  
 
The top panel shows exon expression levels (y axis) plotted for each probe set (x axis). A UCSC 
screenshot with GENCODE version 24 transcript variants is shown below. Alternative splicing of IRAK1 







Strong evidence of alternative splicing (FDR < 1%) 
IRAK1 4027009 7.11 × 10-7 TLR pathway 
WDFY4 3245783 6.09 × 10-5 Unknown 
SLC15A4 3477917 4.53 × 10-4 Peptide Transporter 
FAM167A 3124388 7.24 × 10-4 Unknown 
TNIP1 2881672 1.05 × 10-3 Type 1 IFN pathway 
LRRC18 3288482 1.19 × 10-3 Unknown 
ICAM5 3820469 1.56 × 10-3 Cell adhesion 
IRF8 3672489 1.99 × 10-3 Type 1 IFN pathway 
WDFY4 3245881 2.42 × 10-3 Unknown 
Suggestive evidence of alternative splicing (FDR < 5%) 
DDA1 3824212 1.24 × 10-2 Unknown 
PRDM1 2919669 1.69 × 10-2 IFN-β inhibition 
VKORC1 3688197 1.88 × 10-2 Vitamin K metabolism 
SPRED2 2556752 2.10 × 10-2 Growth factor signalling 
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Strong evidence of alternative splicing (FDR < 1%) 
C1QC 2324873 2.09 × 10-4 Complement 
DNASE1 3646000 4.68 × 10-4 Nucleic acid metabolism 
Suggestive evidence of alternative splicing (FDR < 5%) 
PRKCD 2624291 1.10 × 10-2 BCR-induced apoptosis 



















Figure 4-12 Differential exon expression in monogenic lupus susceptibility genes between resting and IFN-
α-stimulated B cells.  
 
The top panels show exon expression levels (y axis) plotted for each probe set (x axis). UCSC 
screenshots with GENCODE version 24 transcript variants are shown below each plot. Evidence of 
treatment-specific alternative splicing is shown for C1QC (P = 2.09 × 10-4, panel A) and DNASE1 (4.68 × 
10-4, panel B). Alternative splicing events were considered significant at an FDR < 1%. Error bars 




Genome-wide alternative splicing was shown to be significantly modified in ex vivo B cells 
following exposure to IFN-α, reflecting an additional level of molecular regulation of B cell 
function. Interestingly, NDE genes associated with idiopathic and monogenic SLE showed 
evidence of alternative splicing between resting and stimulated cells. These data implicate NDE 
SLE candidate genes in the type 1 IFN response, thus complementing the gene-level 
expression results previously presented in section 4.5. Microarray studies have previously 
shown that changes in alternative splicing following B cell and T cell activation can result in 
increased transcript diversity, or altered protein function (Grigoryev et al., 2009). The role of 
alternative splicing in the development of autoimmune disease has attracted increasing 
attention in recent years, with several studies indicating a role for alternative splicing in SLE 
susceptibility, as well as in disease pathogenesis (Evsyukova et al., 2010). In accordance with 
these observations, the data here reported implicate alternative splicing as an additional 
mechanism controlling the response of SLE candidate genes to IFN-α stimulation. As alternative 
splicing data obtained using splice ANOVA have low reproducibility, these results will require 
subsequent validation using different algorithms, such as splicing index (SI) or finding of 
isoforms using Robust Multichip Analysis (FIRMA), to detect splicing events (Srinivasan et al., 




Chapter 5 - eQTL analysis of MHC haplotypes in resting and 




5.1.1 Fine-mapping SLE associations at the MHC 
The most consistent genetic association with systemic lupus erythematosus (SLE) in European 
populations arises from the human leukocyte antigen (HLA) class II allele HLA-DRB1*03:01, 
and variants in linkage disequilibrium (LD), at the major histocompatibility complex (MHC) 
region (Tsao, 2004, Fernando et al., 2012, International MHC and Autoimmunity Genetics 
Network et al., 2009). The DRB1*03:01 allele is mainly present in two ancestral haplotypes, the 
B*08:01-DRB1*03:01 haplotype (B8, common in Northern Europeans) and the B*18:01-
DRB1*03:01 haplotype (B18, common in Southern Europeans). This allele can also be found in 
partially-conserved B8 and B18 haplotype fragments that form due to recombination. The B8 
haplotype is characterized by the specific HLA allele combination HLA-A*01:01-Cw*07:01-
B*08:01-DRB1*03:01-DQA1*05:01-DQB1*02:01. The conservation of such extended 
haplotypes at the MHC is thought to have resulted from positive selection of specific HLA alleles 
and other variants that confer protection against infectious disease (Gluckman and Hanson, 
2004, Relle and Schwarting, 2012). The B8 haplotype is associated with several autoimmune 
diseases in addition to SLE (Chapter 1, Table 1-2), hence its designation as the “autoimmune 
haplotype” (Lie and Thorsby, 2005). As the DRB1*03:01 association with SLE has not been 
fine-mapped to less than ~1 megabase (MB), the causal variants underlying this signal remain 
to be fully elucidated (Graham et al., 2002, Fernando et al., 2012).  
 
The identification of disease-causing variants arising from MHC haplotypes has been 
challenging, due to the high polymorphism of HLA genes, copy number variation, the complex 
LD structure in the region, and epistatic interactions between HLA and/or non-HLA alleles 
(Lincoln et al., 2009, Morris et al., 2012). Furthermore, the clinical heterogeneity of SLE may 
hamper the detection of sub-phenotype-specific associations. In order to overcome these 
issues, recent studies have attempted to fine-map associations at the MHC using a variety of 
targeted methods, such as high-density single nucleotide polymorphism (SNP) studies, trans-
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ancestral analyses, meta-analyses, and sub-phenotype association studies (Barcellos et al., 
2009, Fernando et al., 2012, Morris et al., 2012, Morris et al., 2014). As discussed in Chapter 3, 
section 3.1.1, SLE associations at the MHC have been successfully fine-mapped to a number of 
loci independently of DRB1 haplotypes, including the HLA class II gene HLA-DPB1 and the 
class III gene MSH5 (Fernando et al., 2012). Despite the successful fine-mapping of a number 
of SLE signals arising within the MHC region, the molecular mechanisms underlying these 
associations have not been fully elucidated. 
 
The current hypothesis explaining the association of DRB1 haplotypes with SLE is that HLA 
class II alleles play a direct role in disease pathogenesis by affecting HLA-T cell interactions. As 
mentioned in previous chapters, it is possible that multiple risk factors within DRB1 haplotypes 
jointly contribute to SLE susceptibility, in addition to the risk conferred by HLA alleles. This 
hypothesis is supported by the identification of non-HLA risk factors within DRB1*03:01 
haplotypes which may be functionally relevant to disease, such as the -308/G>A TNF promoter 
variant, or partial C4 deletion (Abraham and Kroeger, 1999, Helmig et al., 2011, Boteva et al., 
2012). Since DRB1*03:01 haplotypes span over 1000 coding and non-coding polymorphisms, it 
is plausible that regulatory variants within these haplotypes may predispose to disease by 
altering gene expression. A number of studies have shown cis and trans regulatory effects 
emanating from specific HLA alleles/haplotypes (Vandiedonck et al., 2011, Fairfax et al., 2012). 
In addition, I have shown in Chapter 3 that SLE-associated haplotypes at the MHC harbour 
reproducible cis- and trans-expression quantitative trait loci (eQTLs) in B cells, lymphoblastoid 
cell lines (LCLs), and other blood cell populations from published studies. 
 
5.1.2 Limitations of existing eQTL data sets 
One of the weaknesses of the study conducted in Chapter 3 was the comparison of eQTLs 
between data sets of different cell types and cell activation states, given the context-specificity 
of eQTLs. Many of the early eQTL studies were performed in heterogeneous cell populations, 
such as whole blood and peripheral blood leukocytes; therefore, cell type-specific eQTLs may 
have been missed in these studies due to signal saturation from other cell populations. Other 
eQTL studies have used LCLs, which are cell lines derived from Epstein-Barr virus (EBV)-
transformed B cells, and may therefore be partially activated. Furthermore, since B cells exhibit 
a high degree of cross-talk with other immune cells, analysing gene expression in ex vivo B 
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cells is more physiologically relevant than using LCLs. One of the potential issues with the ex 
vivo B cell data set of Fairfax and colleagues is the positive selection of B cells, which may have 
also activated the cells (Fairfax et al., 2012). Finally, the DRB1*03:01 haplotype cis-eQTL to 
DPB1 reported in Chapter 3 showed a heterozygote effect in the ex vivo B cell data set from 
Fairfax and colleagues; however, this may have been an artefact caused by the low number of 
DRB1*03:01 homozygote samples in this data set (N = 3, Fairfax et al., 2012). For the 
aforementioned reasons, the eQTLs identified in B cells and LCLs described in Chapter 3 
warrant further validation in B cells from healthy individuals. 
 
One commonality between the microarray-based eQTL studies investigated in Chapter 3 was 
the use of Illumina platforms for gene expression quantification. Illumina arrays target the 3’ 
untranslated region (UTR) of genes, and a limited number of annotated spliced transcripts. In 
contrast, the Affymetrix Human Exon 1.0 ST array (or exon array) comprises probes designed to 
target every exon (which together make up a probe set), thereby providing higher overall gene 
coverage compared to Illumina arrays. Gene-level expression data are obtained by 
summarising probe set data into transcript clusters. The exon array design enables a more 
accurate estimation of gene expression, as well as the detection of alternative splicing events 
that would otherwise be missed in Illumina arrays.  
 
5.1.3 Response eQTLs 
Recent eQTL studies have highlighted the importance of defining eQTLs within the context of 
cell stimulation, the so-called response eQTLs (reQTLs). Following exposure to a stimulus, cells 
exhibit more uniform global gene expression, which facilitates the discovery of trans-eQTLs 
(Fairfax et al., 2014). Furthermore, response-specific eQTLs enable the identification of gene-
environment interactions that may be informative for disease. Two studies have reported an 
overlap between disease-associated variants and reQTLs following stimulation of immune cells 
with interferon (IFN)-β and IFN-γ (Lee et al., 2014, Fairfax et al., 2014). Given that IFN-α 
therapy is a known trigger of autoimmunity, and that type 1 IFNs play a major pathogenic role in 
SLE, it is plausible that SLE-associated variants may act as reQTLs in cells stimulated with IFN-
α. In addition to SLE, several other autoimmune diseases have shown a type 1 IFN signature. 
Interestingly, of those diseases showing the signature, SLE, Sjögren's syndrome, rheumatoid 
arthritis, type 1 diabetes, systemic sclerosis, and idiopathic inflammatory myopathies all show 
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genetic association with DRB1*03:01 haplotypes (Chapter 1, Table 1-2). Thus, the association 
of DRB1*03:01 haplotypes and the type 1 IFN signature with multiple autoimmune diseases 
suggests that there may be a haplotype-environment interaction (H × E). 
 
5.1.4 Aims and study design 
The first aim of this study was to validate cis- and trans-eQTLs arising from SLE-associated 
MHC haplotypes in ex vivo B cells from healthy individuals, using Affymetrix exon arrays and 
TaqMan quantitative reverse-transcription polymerase chain reaction (qPCR). eQTLs were 
investigated for DRB1*03:01 haplotypes, as well as for tag SNPs of the Spanish SLE risk DPB1 
haplotype (rs3117213), the Filipino protective DPB1 haplotype (rs2071351), and the MSH5 
protective haplotype (rs409558), using genotype data from the TwinsUK resource.  
 
The second aim was to investigate reQTLs in the context of IFN-α stimulation, and assess 
whether there are any haplotype-environment interactions between DRB1*03:01 and IFN-α. 
Finally, the effects of DRB1*03:01 haplotypes on alternative splicing were evaluated both in 
basal and in IFN-α-stimulated states. Study participants comprised 49 healthy European women 
from the TwinsUK registry. Gene expression data were obtained from negatively-selected ex 
vivo CD19+ B cells at rest and after stimulation with IFN-α for 6 hours. To increase power, 
analyses for resting B cells were conducted using all study samples and adjusting for IFN-α 
stimulation (Table 5-1).  
 
In order to validate any eQTLs found in the CD19+ B cell data set, expression levels of relevant 
genes were also investigated in seven MHC-homozygous LCLs, using data obtained from exon 
arrays (data generated by Ms Lora Boteva and Dr Michelle Fernando, King’s College London). 
This data set comprised two DRB1*03:01-homozygous LCLs (COX and QBL), and five non-
DRB1*03:01 LCLs (APD, MANN, SSTO, PGF, and DBB). The MHC haplotypes for each LCL 
are described in Chapter 1, Table 1-1. For all analyses, p-values were considered significant if 







Table 5-1 Sample numbers by DRB1, rs3117213, rs2071351, and rs409558 genotypes used for the reQTL 












Resting 28 3 18 49 
IFN-α 21 2 9 32 
Total 49 5 27 81 
rs3117213 
minor allele 
Resting 8 12 5 25 
IFN-α 11 5 0 16 
Total 19 17 5 41 
rs2071351 
minor allele 
Resting 13 11 1 25 
IFN-α 11 5 0 16 
Total 24 16 1 41 
rs409558 
minor allele 
Resting 34 4 11 49 
IFN-α 19 3 10 32 
Total 53 7 21 81 
  
The study included a total of 49 participants. The reduced number of IFN-α-stimulated samples in the 
data set was due to sample loss during the experimental procedure. Genotype data for rs3117213 

















5.2 Quality control of exon array data 
Quality control (QC) analysis of the expression data generated from twin’s ex vivo B cells 
showed that the data were of good quality, as described in Chapter 4, section 4.2. For the MHC-
homozygous LCL data, visualization of QC metrics using the Affymetrix Expression Console 
software, build 1.2.1.20 (as described in Chapter 2, section 2.4.1) revealed that all arrays had 
high hybridization quality, and showed normal distribution of probe intensity signals (Figure 5-1). 
A Spearman correlation test showed high correlation between technical replicates available for 




Figure 5-1 Histogram showing the normal distribution of exon array probe set intensity signals for MHC-
homozygous LCL samples.  
 




Principal component analysis (PCA) of the LCL data showed that one principal component (PC) 
explained most of the data variability (Figure 5-2). A PCA plot revealed that batch was the 






























A.      B. 
PCA mapping of raw data          PCA mapping of raw data 
 
                   
C.      D. 
PCA mapping of batch-adjusted data  PCA mapping of batch-adjusted data 
 
                   
 Figure 5-3 PCA plots for exon-level array data from MHC-homozygous LCLs. 
 
Plot A shows raw data samples clustering by batch. Plot B shows raw data coloured by cell line ID. Plots C 




5.3 Characterization of HLA-DRB1*03:01 haplotypes in the study 
cohort 
DRB1 genotypes for each study participant were initially identified using genotypic data for the 
DRB1*03:01 tag SNP, rs2187668, provided by the TwinsUK resource. DRB1 genotypes were 
subsequently confirmed by DRB1 typing at four-digit resolution. In order to characterize the 
DRB1*03:01 haplotypes of the study participants, the genotypes for HLA-A, -C, -B, -DPB1, and 
-DQB1 were established using imputed HLA data, and compared to ancestral B8 and B18 
haplotypes. Imputed genotypes were available for 13 DRB1*03:01 homozygotes and one 
DRB1*03:01 heterozygote. All DRB1*03:01 haplotypes harboured the DQB1*02:01 allele. For 
the HLA-C and HLA-B loci, nine DRB1*03:01 homozygotes were B*08-Cw*07:01 homozygotes, 
two were B*08-Cw*07:01/B*18-Cw*05:01 heterozygotes, and two were B*08-Cw*07:01/other 
heterozygotes. For HLA-A and DPB1, recombinants from the ancestral B8 and B18 haplotypes 
were more frequent, reflecting the LD breakdown of the DRB1*03:01 haplotype between HLA-A 
and HLA-C, and between DQB1 and DPB1. The HLA allelic composition of DRB1*03:01 
haplotypes for each individual can be found in Appendix G. These data show that the 
DRB1*03:01 haplotypes included in the study cohort are almost identical between HLA-B in 
class I and DQB1 in class II. 
 
 
5.4 Cis-eQTLs arising from SLE susceptibility MHC haplotypes 
 
5.4.1 No cis-eQTLs arising from HLA-DRB1*03:01 haplotypes 
Due to the low number of DRB1*03:01 heterozygotes in the exon array data set, gene 
expression levels were first compared between DRB1*03:01 homozygotes and non-
DRB1*03:01 samples. A mixed-model analysis of variance (ANOVA) was performed separately 
for basal and IFN-α-stimulated B cells. No significant cis-eQTLs were found following multiple 
test correction in either basal or IFN-α-stimulated samples.  
 
In Chapter 3, DRB1*03:01 haplotypes were consistently shown to be associated in cis with up-
regulation of DPB1 and PSMB9 in publicly-available data sets. Validation of these cis-eQTLs 
was therefore attempted in ex vivo basal and IFN-α-stimulated B cells from TwinsUK. DPB1 
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expression could not be investigated using the exon array data set, as all probe sets for this 
gene failed QC. Differential expression of DPB1 was therefore investigated by TaqMan qPCR, 
using complementary deoxyribonucleic acid (cDNA) from study samples. The pre-designed 
TaqMan assay for DPB1 does not target regions harbouring common SNPs. The number of 
remaining cDNA samples was smaller than the original cohort used for the exon array 
experiment (N = 32 non-DRB1*03:01 samples, N = 3 DRB1*03:01 heterozygotes, and N = 13 
DRB1*03:01 homozygotes). DRB1*03:01 homozygote and non-DRB1*03:01 haplotypes did not 
show significant differential expression of DPB1 in resting cells (P = 0.22, fold change (FC) = 
1.14, ANOVA). However, there is a clear trend towards up-regulation of DPB1 in DRB1*03:01 
homozygotes, as shown in Figure 5-4, with a similar fold change to that reported in Chapter 3, 
section 3.3 (FC ~ 1.3). Since there was only one remaining DRB1*03:01 homozygote sample 
from IFN-α-stimulated cells in sufficient amount for qPCR, the analysis could not be carried out 
in this group. For PSMB9, neither the exon array data nor the qPCR analysis suggested 
differential expression in basal or IFN-α-stimulated cells (P > 0.98).  
 
 
HLA-DPB1 qPCR in resting B cells       
 
Figure 5-4 qPCR analysis of HLA-DPB1 expression in HLA-DRB1*03:01 haplotypes in resting ex vivo B 
cells. 
 
The plot shows a trend for up-regulation of DPB1 in DRB1*03:01 homozygotes and heterozygotes, 
compared to non-DRB1*03:01 samples (FDR > 5%). Expression levels were normalized against the 
control genes UBB, TBP, and OAZ1. The box plots show median, upper, and lower quartiles of expression 
levels for each genotype group. Whiskers show the maximum and minimum non-outlying data points. 
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5.4.2 No cis-eQTLs arising from HLA-DPB1 and MSH5 haplotypes 
Cis-eQTL analyses were performed for the SLE-associated DPB1 Spanish (rs3117213) and 
Filipino (rs2071351) SNPs using qPCR data, in an attempt to validate cis-associations with 
DPB1 expression described in Chapter 3. Out of the 48 available qPCR samples, only 41 had 
genotype data for rs3117213 and rs2071351 (Table 5-1). Cis-eQTL analysis showed that there 
were no significant eQTLs for either rs3117213 or rs2071351; however, the eQTL plots 
revealed a clear trend for up-regulation of DPB1 in rs3117213 heterozygotes, compared to 
homozygotes for the ancestral allele, in both resting and IFN-α-stimulated cells (P > 0.29, FC = 
1.05, Figure 5-5). For rs2071351, this trend was only observed in IFN-α-stimulated cells (P = 
0.45, FC = 1.08, Figure 5-6). Similarly, analysis of the exon array data showed that there were 
no significant cis-eQTLs with the SLE-protective MSH5 SNP, rs409558, in either resting or IFN-
α-stimulated B cells. 
 
 
A.      B. 
      HLA-DPB1 qPCR in resting B cells HLA-DPB1 qPCR in IFN-α-stimulated B cells 
   
Figure 5-5 qPCR analysis of HLA-DPB1 expression for rs3117213 genotypes in resting and IFN-α-
stimulated ex vivo B cells. 
 
The plots show a trend for up-regulation of HLA-DPB1 in heterozygotes, compared to homozygotes for the 
ancestral allele, in B cells at rest (A) and following stimulation with IFN-α (B, FDR > 5%). Expression levels 
were normalized against the control genes UBB, TBP, and OAZ1. The box plots show median, upper, and 
lower quartiles of expression levels for each genotype group. Whiskers show the maximum and minimum 




A.      B. 
      HLA-DPB1 qPCR in resting B cells HLA-DPB1 qPCR in IFN-α-stimulated B cells 
  
Figure 5-6 qPCR analysis of HLA-DPB1 expression for rs2071351 genotypes in resting and IFN-α-
stimulated ex vivo B cells. 
  
 
A. No evidence of differential expression between rs2071351 genotypes was found in resting B cells.  
B. The plot shows a trend for up-regulation of HLA-DPB1 in rs2071351 heterozygotes, compared to 
homozygotes for the ancestral allele, in IFN-α-stimulated B cells (FDR > 5%). Expression levels were 
normalized against the control genes UBB, TBP, and OAZ1. The box plots show median, upper, and lower 
quartiles of expression levels for each genotype group. Whiskers show the maximum and minimum non-




5.5 Trans-eQTLs arising from HLA-DRB1*03:01 haplotypes 
 
5.5.1 Association between HLA-DRB1*03:01 and BTN3A2 expression 
Trans-eQTL analysis for the DRB1*03:01 haplotype in basal cells revealed two significantly 
differentially expressed transcript clusters, both of which mapped to the BTN3A2 gene (Figure 
5-7). These two transcript clusters, TC_2899298 and TC_2899333, showed under-expression in 
DRB1*03:01 homozygote samples, compared to non-DRB1*03:01 samples (P < 2.34 × 10-8, FC 
< -2.00, Figure 5-8, Table 5-2). In IFN-α-stimulated cells, only TC_2899298 showed significant 
down-regulation following multiple test correction (P = 2.63 × 10-6, FC = -2.10, Table 5-3). 
Differential expression of BTN3A2 was then analysed using a linear regression for comparison 
between DRB1*03:01 homozygotes, heterozygotes, and non-DRB1*03:01 samples. Differential 
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expression of BTN3A2 was significant prior to multiple test correction in basal cells (P = 9.31 × 
10-3 for TC_2899298, P = 2.05 × 10-2 for TC_2899333, FDR > 5%), but not in IFN-α-stimulated 




Figure 5-7 Volcano plot showing trans-eQTLs for the HLA-DRB1*03:01 haplotype in resting ex vivo B cells. 
 
Trans-associations are plotted as -log10(p-values) against log2(fold change). Two BTN3A2 transcript 
clusters from the Affymetrix Human Exon 1.0 ST array showed significant differential expression between 
DRB1*03:01 homozygotes and non-DRB1*03:01 samples. The red line indicates the significance threshold 



















A.      B. 
TC_2899298 expression in resting B cells         TC_2899333 expression in resting B cells 
          
Figure 5-8 The HLA-DRB1*03:01 haplotype is an eQTL for BTN3A2 in resting ex vivo B cells.  
 
The Affymetrix Human Exon 1.0 ST array transcript clusters for BTN3A2, TC_2899298 (A) and 
TC_2899333 (B), were significantly down-regulated in DRB1*03:01 homozygotes, compared to non-
DRB1*03:01 samples (FDR < 5%). In contrast, there was no significant differential expression between 
non-DRB1*03:01 and DRB1*03:01 heterozygotes, or between DRB1*03:01 heterozygotes and 
homozygotes (FDR > 5%). The box plots show median, upper, and lower quartiles of expression levels for 




Table 5-2 ANOVA results for BTN3A2 expression between HLA-DRB1*03:01 and non-DRB1*03:01 











*03:01 homozygotes vs. 
non-*03:01 samples 
-2.60 2.34 × 10-8  1.90 × 10-4 -2.00 3.82 × 10-10 6.19 × 10-6 
*03:01 heterozygotes vs. 
non-*03:01 samples 
-1.67 5.10 × 10-2 0.99 -1.52 2.61 × 10-2 0.99 
*03:01 homozygotes vs. 
*03:01 heterozygotes 
-1.59 8.67 × 10-5 0.35 -1.34 6.46 × 10-6 5.23 × 10-2 
 
BTN3A2 expression levels were quantified using the Affymetrix Exon 1.0 ST array, and summarised as 
two transcript clusters, TC_2899298 and TC_2899333. The significance threshold was established at an 





Table 5-3 ANOVA results for BTN3A2 expression between HLA-DRB1*03:01 and non-DRB1*03:01 











*03:01 homozygotes vs. 
non-*03:01 samples 
-2.10 2.63 × 10-6 4.26 × 10-2 -1.96 1.20 × 10-5 0.10 
*03:01 heterozygotes vs. 
non-*03:01 samples 
-1.11 0.70 0.80 -1.85 7.75 × 10-2 0.57 
*03:01 homozygotes vs. 
*03:01 heterozygotes 
-1.54 1.80 × 10-4 0.48 -1.74 6.36 × 10-3 0.86 
 
BTN3A2 expression levels were quantified using the Affymetrix Exon 1.0 ST array, and summarised as 
two transcription clusters, TC_2899298 and TC_2899333. The significance threshold was established at 




The two BTN3A2 transcript clusters target different regions of the gene: TC_2899298 targets 









Figure 5-9 UCSC Genome Browser screenshot showing the BTN3A2 target sites for the Affymetrix Human 
Exon 1.0 ST array probe sets included in the ex vivo B cell analysis.  
 
Probe set sequences for each BTN3A2 transcript cluster were aligned to the genome using the BLAT tool, 
and are shown above BTN3A2 transcripts from RefSeq. A. The TC_2899298 transcript cluster comprises 
six probe sets, which target the 5’ UTR, exons 4, 6, 9, and the 3’ UTR, and detect both full-length and 
truncated transcripts. B. TC_2899333 comprises five probe sets, which target the 3’ UTR, and detect all 
full-length BTN3A2 transcripts. 
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The BTN3A2 gene is located in the extended MHC (xMHC) class I region, within a cluster of 
butyrophilin 3 (BTN3) genes: BTN3A1, BTN3A2, and BTN3A3 (Figure 5-14). Clustal alignment 
of the cDNA sequences for all three BTN3 genes revealed high sequence homology between 
them (89-94%, Table 5-4, Appendix H). 
 
 
Table 5-4 Clustal alignment scores for the coding sequences of the paralogue butyrophilin genes BTN3A1, 
BTN3A2, and BTN3A3.  
 
Gene BTN3A1 BTN3A2 BTN3A3 
BTN3A1 - 88.86% 89.69% 
BTN3A2 88.86% - 94.13% 
BTN3A3 89.69% 94.13% - 
 




As a result of the high sequence homology between the three BTN3 genes, quantification of 
BTN3A2 expression by conventional Illumina arrays and RNA sequencing (RNA-seq) data sets 
is not reliable. The Illumina probes annotated for BTN3A2 cross-hybridize to BTN3A1 and 
BTN3A3, and therefore fail QC in eQTL studies using Illumina platforms (including LCL, ex vivo 
B cell, monocyte, and whole blood data sets investigated in Chapter 3). Additionally, due to the 
technical challenges of processing RNA-seq data from highly homologous genes, the eQTL for 
BTN3A2 could also not be validated in publicly-available RNA-seq data sets. To confirm that the 
BTN3A2 eQTL identified using the exon array was not an artefact, validation of the results by 
TaqMan qPCR was attempted, using cDNA from the study samples. A pre-designed TaqMan 
qPCR assay specific for BTN3A2 transcripts was obtained from Life Technologies. The assay 
target region did not map to common SNP-harbouring regions, and spanned a sequence of low 
homology to BTN3A1 and BTN3A3 (Figure 5-10). Down-regulation of BTN3A2 in DRB1*03:01 
homozygotes compared to non-DRB1*03:01 samples was validated by qPCR in basal B cells (P 
= 2.06 × 10-3, FC = -2.88, FDR < 5%). In IFN-α-stimulated B cells, this eQTL trended towards 







BTN3A1      GATGGAGAAGTATCCAGTATGCATCTCGGGGAGAGAGACATTCAGCCTATAATGAATGGAAAAAGGCC 
BTN3A2      AGAGGAAAAAAATCCAGTACTTGACTCGTGGAGAGGAGTCTTCGTCCGATACCAATAAGTCAGCCTGA 
BTN3A3      AGTGGAGGAAAATCCAGTACATGGCTCGTGGAGAGAAGTCTTTGGCCTATCATGAATGGAAAATGGCC 
            ****   ***  *  ******** **** ******     **   ** **    *   *  *   
 
 
Figure 5-10 Location of the BTN3A2 region targeted by the TaqMan qPCR assay Hs00389328_m1.  
 
A. The Hs00389328_m1 assay (shown in green) targets a region within exons 8 and 9 of the BTN3A2 
gene, represented below (image obtained from Life Technologies). The exact assay target sequence is not 
specified by Life Technologies. B. Clustal cDNA sequence alignment showing the comparison of exons 8 
and 9 of BTN3A2 with BTN3A1 and BTN3A3. BTN3A2 exon 8 is highlighted in yellow and exon 9 is 





A.      B.  
         BTN3A2 qPCR in resting B cells                   BTN3A2 qPCR in IFN-α-treated B cells 
   
Figure 5-11 qPCR analysis validated the down-regulation of BTN3A2 in DRB1*03:01 homozygotes 
compared to non-DRB1*03:01 samples from ex vivo B cells.  
 
BTN3A2 down-regulation in resting cells was significant at an FDR < 5% (A), but not in IFN-α-stimulated 
cells (FDR > 5%, B). Expression levels were normalized against the control genes UBB, TBP, and OAZ1. 
The box plots show median, upper, and lower quartiles of expression levels for each genotype group. 
Whiskers show the maximum and minimum non-outlying data points. 
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Validation of the eQTL for BTN3A2 in MHC-homozygous LCLs at the protein-level was then 
attempted. First, BTN3A2 messenger ribonucleic acid (mRNA) levels were assessed in seven 
LCLs using data obtained from exon arrays. This data set comprised two DRB1*03:01-
homozygous LCLs (COX, N = 2, and QBL, N = 2), and five non-DRB1*03:01 LCLs (APD, N = 1; 
MANN, N= 1; SSTO, N = 1; PGF, N = 2; and DBB, N = 2), including technical replicates. 
Differential expression of BTN3A2 between DRB1*03:01 and non-DRB1*03:01 LCLs was not 
significant (P > 0.13, FC = -2.53, ANOVA). Interestingly, down-regulation of BTN3A2 in COX 
(B*08-DRB1*03:01) compared to other LCLs showed a trend towards significance 
(TC_2899298, P = 8.37 × 10-2, FC = -3.76, FDR > 5%, Figure 5-12).  
 
Given the effect sizes found for the DRB1*03:01 trans-eQTL to BTN3A2 in exon array and 
qPCR experiments, the translation of this eQTL to protein level was investigated in MHC-
homozygous LCLs. A Western blot was performed to detect protein expression in two 
DRB1*03:01-homozygous LCLs (COX and QBL) and three non-DRB1*03:01 LCLs (APD, 
MANN, and PGF). The BTN3A1 and BTN3A3 gene products (BT3.1 and BT3.3, respectively) 
were also examined for comparison with the BTN3A2 gene product (BT3.2). Antibodies for each 
of the butyrophilin proteins were specific for the C terminus regions. The amino acid antigen for 
the BT3.2 antibody encompassed the same exons targeted by the TaqMan qPCR assay (exons 
8 and 9, Appendix I). Protein levels were quantified by normalization against β-actin, and levels 
were compared between LCLs using a Student’s t-test. BT3.2 showed evidence of down-
regulation in COX and QBL, compared to non-DRB1*03:01 LCLs (P = 3.88 × 10-2, Figure 5-13). 













A.      B. 
TC_2899298 expression in resting LCLs  TC_2899333 expression in resting LCLs 
        
Figure 5-12 BTN3A2 expression in seven MHC-homozygous LCLs at rest, quantified by Affymetrix Human 
Exon 1.0 ST arrays.  
 
Expression levels for the TC_2899298 transcript cluster are shown in A, and expression levels for 
TC_2899333 are shown in B. BTN3A2 was not significantly differentially expressed between DRB1*03:01-
homozygous LCLs (COX and QBL) and non-DRB1*03:01 LCLs (APD, MANN, PGF, DBB, and SSTO, P > 
0.13). TC_2899298 showed a trend towards being down-regulated in COX (B*08-DRB1*03:01) compared 
to other LCLs (P = 8.37 × 10-2, non-significant). Error bars represent the standard error of the mean for 





Figure 5-13 BT3.1, BT3.2, BT3.3, and β-actin protein expression detected by Western blotting in five MHC-
homozygous LCLs.  
 
Western blot analysis showed evidence of down-regulation of BT3.2 in two DRB1*03:01 LCLs (COX and 
QBL), compared to three non-DRB1*03:01 LCLs (APD, MANN, and PGF, P = 3.88 × 10-2). In contrast, 
BT3.1 and BT3.3 protein levels were not significantly altered between DRB1*03:01 and non-DRB1*03:01 








Interestingly, the BTN3A2 gene in xMHC class I is approximately 6 MB from the DRB1 gene in 
class II (Figure 5-14). To investigate whether the DRB1*03:01 eQTL with BTN3A2 is caused by 
LD with a cis-eQTL at BTN3A2, a cis-eQTL analysis was performed for BTN3A2 on resting B 
cells. Out of 47 tested SNPs, none were significant eQTLs after multiple test correction. Thirty-
six SNPs, however, correlated with decreased BTN3A2 levels at p-values of less than 0.05 prior 
to multiple test correction (best SNP P = 1.85 × 10-4, FDR > 5%, FC = -1.36). All SNPs are in 
low LD with the DRB1*03:01 proxy SNP rs2187668 (r2 < 0.09, TwinsUK cohort).  Thus, it is 
unclear whether the DRB1*03:01 eQTL with BTN3A2 is a true trans-eQTL, or whether it is 
tagging a cis-eQTL that was not genotyped in the cohort.  
 
 
     




5.5.2 No evidence of interaction between HLA-DRB1*03:01 haplotypes and IFN-α 
An interaction ANOVA was performed to test whether DRB1*03:01 homozygotes and non-
DRB1*03:01 individuals responded differently to IFN-α stimulation at the mRNA level. The 
analysis showed no evidence of interaction at gene level between the two factors (PFDR > 0.46).   
 
 
5.6 Effect of HLA-DRB1*03:01 haplotypes on alternative splicing 
The effect of harbouring DRB1*03:01 haplotypes on alternative splicing was assessed, as 
described in Chapter 4, section 4.5. Partek’s splice ANOVA in resting B cell samples did not 
show evidence of alternative splicing between DRB1*03:01 homozygotes and non-DRB1*03:01 
samples (using a significance threshold of FDR < 5%). In contrast, analysis of IFN-α-stimulated 
154 
 
cells revealed that 30 out of 13,543 multi-exon transcript clusters were alternatively spliced 
between DRB1*03:01 and non-DRB1*03:01 haplotypes at significant levels (FDR < 5%, Table 
5-5). Interestingly, a great portion of the alternatively spliced genes are type 1 IFN-inducible 
genes, such as STAT1 and OAS2. Ingenuity pathway analysis (IPA) of alternatively spliced 
genes confirmed enrichment of IFN signalling (P = 1.55 × 10-7) and bacteria and virus pattern 
recognition receptor pathways (P = 1.48 × 10-8). Additionally, the IFN-α gene IFNA2 was 
predicted as the top upstream regulator (P = 4.54 × 10-26). There was no significant enrichment 
of idiopathic or monogenic SLE-associated genes in the data set (P > 0.19). Alternative splicing 


























Table 5-5 Alternatively spliced genes between HLA-DRB1*03:01 and non-DRB1*03:01 haplotypes in IFN-
α-stimulated ex vivo B cells. 
 
 








STAT1 2592268 3.11 × 10-8 Type 1 IFN pathway 
DDX58 (RIG-I) 3203086 3.85 × 10-6 Type 1 IFN pathway 
IFIT1 3257246 3.97 × 10-6 Type 1 IFN response 
SEPT9 3735847 3.73 × 10-5 Cell cycle 
HERC6 2735362 3.73 × 10-5 Type 1 IFN response 
SBF2 3362468 4.64 × 10-4 Unknown 
ISG15 4053534 4.83 × 10-4 Type 1 IFN response 
MX2 3922037 6.05 × 10-4 Type 1 IFN response 
PLSCR1 2699726 6.05 × 10-4 Type 1 IFN response 
TARS 2805786 6.05 × 10-4 tRNA synthesis 
OAS2 3432514 7.42 × 10-4 Type 1 IFN response 
EIF2AK2 2548402 1.14 × 10-3 Type 1 IFN response 
TDRD7 3181193 1.21 × 10-3 Type 1 IFN response 
TLR7 3969081 1.31 × 10-3 Type 1 IFN pathway 
TIMM10 3373946 1.34 × 10-3 Mitochondrial transport 
SP100 2531377 5.46 × 10-3 Type 1 IFN response 
IFIH1 2584207 5.54 × 10-3 Type 1 IFN pathway 
MX1 3922100 5.54 × 10-3 Type 1 IFN response 
CD4 3402786 6.85 × 10-3 T cell activation 
PNPT1 2553970 8.72 × 10-3 Type 1 IFN response 
GBP4 2421995 1.10 × 10-2 Type 1 IFN response 
NMI 2580955 1.29 × 10-2 Type 1 IFN response 
OAS3 3432467 1.43 × 10-2 Type 1 IFN response 
RNF138 3783749 1.43 × 10-2 Unknown 
INPP4B 2787459 1.50 × 10-2 Glycerophospholipid signalling 
MFAP1 3621692 1.70 × 10-2 Unknown 
LCK 2328841 1.82 × 10-2 T cell development 
ZFP36L1 3569754 1.84 × 10-2 Unknown 
LOC100862671 3656418 2.01 × 10-2 Unknown 






















Figure 5-15 Differential exon expression in two IFN-inducible genes between HLA-DRB1*03:01 
homozygotes and non-DRB1*03:01 samples.  
 
The top panels show exon expression levels (y axis) plotted for each probe set (x axis). UCSC 
screenshots with RefSeq-annotated transcript variants are shown below each plot. A. Evidence of 
haplotype-specific cassette exon usage (boxed region) in NMI (P = 2.11 × 10-5, FDR < 5%). B. Evidence of 
haplotype-specific expression of a truncated splice transcript variant (boxed region) in OAS2 (P = 6.05 × 






In this chapter, gene expression patterns for SLE-risk DRB1*03:01 haplotypes were 
characterized in ex vivo B cells from healthy women, using the Affymetrix Human Exon 1.0 ST 
array. Cis-eQTL analysis did not validate differential expression of DPB1, or any other gene, in 
DRB1*03:01 haplotypes at a significant level, despite a clear trend for up-regulation of DPB1 in 
this cohort. Trans-eQTL analysis of basal and IFN-α-stimulated B cells showed significant 
down-regulation of BTN3A2 in B*08-DRB1*03:01 haplotypes, at both mRNA- and protein-level. 
There was no evidence of haplotype-environment interaction between DRB1*03:01 haplotypes 
and IFN-α stimulation at gene level. Interestingly, DRB1*03:01-homozygous samples showed 
alternative splicing of several IFN-inducible genes following IFN-α-stimulation, but not in resting 
cells, suggesting a haplotype-environment interaction at exon-level.  
 
None of the previously reported cis-eQTLs for DRB1*03:01 haplotypes were validated in this 
study, despite a clear trend towards up-regulation of DPB1 in resting B cells, at a similar fold 
change as that found in other data sets in Chapter 3, section 3.3. Similarly, cis-eQTLs reported 
for the rs3117213 and rs2071351 DPB1 variants (section 3.4), and the rs409558 MSH5 variant 
(section 3.2), were not validated. Again, a trend towards up-regulation of DPB1 was observed 
for rs3117213 and rs2071351 in resting and IFN-α-stimulated B cells. These negative results 
suggest that, despite the fact that there is a larger number of DRB1*03:01 homozygotes in this 
study than in any of the previously studied data sets, there was insufficient power to detect all 
true eQTLs for DRB1*03:01, rs3117213, rs2071351, or rs409558 haplotypes.  
 
Association of DRB1*03:01 haplotypes with down-regulation of BTN3A2 was the only significant 
trans-eQTL detected in this study. This eQTL was found in both resting and IFN-α-stimulated B 
cells using the exon array, and was validated by qPCR in resting B cells. The trend for down-
regulation of BTN3A2 observed in qPCR data from IFN-α-stimulated B cells supports the 
robustness of this eQTL. Exon array quantification of BTN3A2 expression in MHC-homozygous 
LCLs showed a trend towards decreased BTN3A2 expression levels in COX (B*08-DRB1*03:01 
haplotype), compared to six other LCLs. Western blot analysis validated down-regulation of 
BTN3A2 at the protein-level in both COX and QBL (B*18-DRB1*03:01 haplotype), compared to 
non-DRB1*03:01 LCLs. Since most ex vivo B cell samples were B*08-DRB1*03:01 
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homozygotes, these results strongly support a correlation between this haplotype and BTN3A2 
expression. Given the location of BTN3A2 in the xMHC class I region, and the high LD 
encompassing the region, it is possible that the reported eQTL may be tagging a cis-eQTL at 
BTN3A2. Due to the low BTN3A2 genotype coverage available for this cohort, cis-eQTLs within 
BTN3A2 could not be identified; therefore, the mechanism underlying the eQTL for the 
DRB1*03:01 haplotype remains unclear.  
 
Expression of BTN3A2 could not be reliably detected in previous eQTL studies, due to the high 
sequence homology between the BTN3 genes. However, eQTL analysis of two Illumina array 
studies in blood cells, and one RNA-seq study in LCLs, showed trans-association between the 
DRB1*03:01 European tag SNP, rs2187668, and BTN3A2 expression at an FDR < 5%, despite 
being potentially confounded by signals from BTN3A1 and BTN3A3 (Zeller et al., 2010, Westra 
et al., 2013, Lappalainen et al., 2013). The validity of the results here presented is supported by 
the specific targeting of BTN3A2 by the exon array probe sets, the qPCR assay, and the 
Western blot antibody. Furthermore, no differential expression of BTN3A1 or BTN3A3 was 
detected in the exon array and Western blot analyses. Future work would be required to 
replicate this eQTL in ex vivo B cells from an independent cohort, ideally by qPCR analysis. 
 
As alterations in mRNA levels do not always translate to protein level due to translational 
repression mechanisms, validation of eQTLs at the protein level has been challenging, 
particularly for trans-eQTLs (Parts et al., 2014, Albert and Kruglyak, 2015). Therefore, the 
validation of the BTN3A2 eQTL at protein-level here described is of great interest, and puts 
forward BT3.2 as a plausible target protein for treating autoimmune disease. 
 
BTN3A2 encodes one of three isoforms of CD277 (BT3), an immunoglobulin-like cell surface 
receptor belonging to the B7 family of co-stimulatory molecules. There are a total of seven 
butyrophilin genes in humans, which are positioned in tandem across the xMHC class I region: 
BTN1A1 (single-copy), BTN2 genes (BTN2A1, BTN2A2, and BTN2A3), and BTN3 genes 
(BTN3A1, BTN3A2, and BTN3A3); and one butyrophilin-like (BTNL) gene located in the MHC 
class II (BTNL2, Rhodes et al., 2001). Despite having undergone gene duplication, butyrophilin 
gene numbers are stable in humans (Salomonsen et al., 2014). Butyrophilins have attracted 
strong interest in recent years due to their role as T cell-regulating molecules (Arnett et al., 
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2009, Abeler-Dorner et al., 2012). CD277 molecules have been shown to act as co-inhibitors of 
T cell proliferation and T helper type 1 (Th1) cytokine production when expressed by antigen-
presenting cells (Cubillos-Ruiz and Conejo-Garcia, 2011). Other reports have shown that these 
molecules play a role in the recognition of stress responses by γδ T cells (Harly et al., 2012, 
Vavassori et al., 2013); however, the individual function of each butyrophilin member has not 
yet been fully elucidated. The CD277 isoforms BT3.1 (BTN3A1) and BT3.3 (BTN3A3) contain a 
cytoplasmic domain (B30.2), whereas BT3.2 (BTN3A2) lacks this domain, and is thought to act 
as a decoy receptor (Rhodes et al., 2001). BT3.2 is expressed in lymphocytes and natural killer 
(NK) cells, and is the only CD277 isoform that can inhibit NK cell-induced production of 
cytokines (Messal et al., 2011). BTN3A2 has not previously shown genetic association with 
SLE; however, variants within various butyrophilin and butyrophilin-like genes have been linked 
with several autoimmune and inflammatory diseases, including lupus (BTNL2), anti-citrullinated 
protein antibody (ACPA)-positive rheumatoid arthritis (BTN2A2 and BTN3A1), type 1 diabetes 
(BTN3A2), myositis (BTNL2), sarcoidosis (BTNL2), and inflammatory bowel disease (BTNL2, 
Orozco et al., 2005, Orozco et al., 2011, Viken et al., 2009, Scott et al., 2011, Spagnolo et al., 
2007, Pathan et al., 2009), and also with chronic kidney disease (BTN2A1, Yoshida et al., 
2011). Given the role of co-inhibitory molecules in the prevention of autoimmunity (Watanabe 
and Nakajima, 2012), the down-regulation of BTN3A2 in SLE-risk DRB1*03:01 haplotypes 
reported here is of functional interest. Hypothetically, down-regulation of BT3.2 at the cell 
surface could result in decreased T cell inhibition and, consequently, lower the threshold for 
autoimmune responses in the presence of self-antigens.  
 
Haplotype-environment interaction analysis showed that DRB1*03:01 and non-DRB1*03:01 
haplotypes did not respond differently to IFN-α stimulation at gene level, suggesting a lack of 
interaction between haplotype and cell stimulus. Conversely, there may be insufficient power to 
detect an interaction. Interestingly, DRB1*03:01 homozygote samples showed evidence of 
alternative splicing following IFN-α stimulation, which involved several IFN-inducible genes. 
These results demonstrate that DRB1*03:01-homozygous and non-DRB1*03:01 individuals 
respond differently to IFN-α, i.e., there is a haplotype-environment interaction at exon level, but 
not at gene level. Alternatively, these results could be explained by the increased expression 
levels of IFN-inducible genes following IFN-α stimulation, which may have provided greater 
sensitivity to detect changes in gene splicing. As most existing alternative splicing analysis 
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pipelines (including splice ANOVA) do not provide high true-positive detection rates, these 
results require validation using different alternative splicing calculation methods, such as the 
splicing index (SI) and finding of isoforms using Robust Multichip Analysis (FIRMA) algorithms 
(Srinivasan et al., 2005, Purdom et al., 2008). 
 
The use of ex vivo B cells from healthy female individuals, both at rest and after IFN-α 
stimulation, provided a disease-relevant context for the exploration of eQTLs in SLE-risk 
haplotypes, given the interaction between genetic, hormonal, and environmental factors in 
disease pathogenesis. However, one of the major drawback of this study is its limited power, 
which may have prevented the identification of highly significant signals. The limitations 
highlighted in section 3.6 of Chapter 3 regarding the use of SLE signals derived from non-
European cohorts, and the use of expression data sets generated from European populations to 
functionally annotate these SLE signals, also apply to the study described in this chapter. 
Furthermore, given the strong effect of gender on gene expression, the use of females in this 
study may have also limited the replication of eQTLs found in publicly-available data bases, 
since most of these studies were not adjusted for gender (Chapter 3, Table 3-1 and Table 3-3). 
An additional limitation of the study relates to the potential effects of age and medication, for 
which data were not available. 
 
Despite these limitations, the use of the Affymetrix exon expression array proved to be effective 
for the identification of a novel eQTL in ex vivo B cells. The wide gene coverage provided by 
exon arrays enabled quantification of gene expression for BTN3A2 and its paralogous genes, 
which could not be reliably detected using Illumina arrays or RNA-seq. However, one major 
caveat to the use of microarrays, including the exon array, is the high polymorphism and copy 
number variation at the MHC, which challenge accurate detection of gene expression in the 
region. Since conventional microarrays are designed to target the reference human genome 
MHC sequence (obtained from the PGF cell line), expression levels of most HLA genes, 
including DPB1, could not be quantified in this study. RNA-seq provides an alternative method 
for the detection of genome-wide gene expression; however, the method faces similar 
challenges to those involved in the use of microarrays when resolving expression data at the 
MHC. In addition, the processing of RNA-seq data is computationally intensive, and short read 
lengths generated by RNA-seq hamper the resolution of copy number variable regions, such as 
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the MHC. The challenges of reliably detecting gene expression at the MHC may be overcome 
with the use of targeted qPCR assays (as shown in this study), custom microarrays, or 
fluorescence-activated cell sorting (FACS). The detection of DPB1 expression by qPCR 
described in this chapter demonstrates that this method is a reliable alternative to measure the 
expression levels of this classical HLA gene.  
 
One final limitation of the study design is that the comparison between DRB1*03:01 and non-
DRB1*03:01 haplotypes may hinder the identification of true eQTLs, due to the length and 
variability of MHC haplotypes. The majority of non-DRB1*03:01 individuals are heterozygous for 
classical HLA genes. As HLA genes can have large numbers of existing alleles in the 
population, the non-DRB1*03:01 haplotypes included in this study will be highly variable. Most 
of the DRB1*03:01 haplotypes from the study cohort were almost identical between HLA-C in 
class I and DQB1 in class II, and demonstrated LD breakdown between HLA-A and HLA-C, and 
between DQB1 and DPB1, which is typical of DRB1*03:01 haplotypes in the British population 
(Bishof et al., 1993). Therefore, the lack of homogeneity between the haplotypes tested in the 
study may affect the detection of eQTL signals. Despite these caveats, the data generated for 
this study may be used in future eQTL meta-analysis studies of B cells, given the large number 
of DRB1*03:01-homozygous samples in the cohort. 
 
In conclusion, this study supports a regulatory role for the DRB1*03:01 haplotype in B cells, and 
implicated BTN3A2 as a novel candidate gene underlying the association of the DRB1*03:01 
haplotype with autoimmunity. In addition, this study implicates DPB1 as a highly likely cis-eQTL, 
further supporting the results presented in Chapter 3. The study also highlights the importance 
of specifically targeting paralogous genes, such as the BTN3 genes, as well as the need for 
large sample sizes, in order to detect and corroborate eQTL signals at the MHC. Investigating 
the effects of disease-associated haplotypes on gene regulation under relevant cellular 
contexts, such as the study here presented, will further our understanding of the molecular 




Chapter 6 - Conclusions 
 
The work described in this thesis investigates the regulatory effects of systemic lupus 
erythematosus (SLE) susceptibility factors in B cells, namely risk and protective haplotypes, and 
interferon (IFN)-α stimulation. Firstly, expression quantitative trait locus (eQTL) analyses were 
conducted, using published and newly-generated data sets, in order to investigate whether 
SLE-associated variants within the major histocompatibility complex (MHC) region correlate with 
altered gene expression in healthy individuals of European ancestry. Secondly, gene regulation 
following IFN-α stimulation was characterized in B cells, with particular focus on differential 
expression of disease susceptibility genes.  
 
 
6.1 Cis- and trans-eQTLs arising from MHC haplotypes 
Chapters 3 and 5 describe the identification of several cis-eQTLs for the SLE-associated 
haplotypes DRB1*03:01, DRB1*15:01, rs3117213 (DPB1), rs2071351 (DPB1), and rs409558 
(MSH5), in lymphoblastoid cell lines (LCLs) and ex vivo B cells. Reproducible cis-associations 
identified in different blood cell types include DOM3Z, C6orf48, and HSPA1B for rs409558, and 
HLA-DPB1 and PSMB9 for DRB1*03:01 haplotypes. Furthermore, functional annotation of the 
MSH5 protective haplotype highlighted the best functional single nucleotide polymorphism 
(SNP) candidates, rs409558 and rs4711279. These results implicate a regulatory role for 
disease-associated variants within MHC haplotypes, and pinpoint possible functionally-relevant 
genes implicated in the pathogenesis of SLE. In particular, cis-associations with increased 
DPB1 expression in individuals harbouring DRB1*03:01 haplotypes, as well as rs3117213 and 
rs2071351 minor alleles, suggest an important role for this classical human leukocyte antigen 
(HLA) class II gene in susceptibility to SLE. It can be hypothesised that the functional 
consequence of these disease-associated DPB1 eQTLs in B cells may lead to increased HLA 
class II antigen presentation to CD4+ T cells, thus potentially clarifying the role of DPB1 in SLE, 




6.1.1 The effect of DRB1*03:01 haplotypes on gene regulation 
One other major finding is the trans-association of B*08-DRB1*03:01 haplotypes with down-
regulation of BTN3A2 in resting and IFN-α-stimulated B cells, at both mRNA- and protein-level. 
Since mRNA levels do not always translate to protein, validation of this eQTL at protein-level in 
LCLs is of great functional interest, particularly with regard to the role of the BTN3A2 gene 
product, BT3.2, in T cell inhibition. Down-regulation of BT3.2-mediated co-inhibitory signals in 
DRB1*03:01-homozygous B cells could result in decreased inhibition of T cell activation and/or 
co-stimulation, potentially leading to a state of immune hyper-responsiveness in the presence of 
self-antigens. This scenario is also consistent with the known role of co-inhibitory molecules in 
the prevention of autoimmunity. Furthermore, this is one of a small number of studies that have 
successfully translated trans-eQTLs to protein-level in primary cells. These results implicate 
BTN3A2 as a novel candidate gene underlying the association of the DRB1*03:01 haplotypes 
with autoimmunity, and propose BT3.2 as a potential therapeutic target for disease. 
 
The investigation of gene regulation within the extended B*08-DRB1*03:01 haplotype in SLE-
relevant cellular conditions provided additional insights into the functional effects of this 
important disease susceptibility haplotype. Although no response eQTLs were identified at gene 
level following stimulation of B cells with IFN-α, the data suggested a possible alteration of 
transcript splicing patterns in response to IFN-α stimulation. On an unrelated note, stimulation of 
B cells with IFN-α altered the expression levels of several MHC genes, including those that 
harbour SLE-risk variants present in DRB1*03:01 haplotypes, such as DPB1, TNF, LTA, and 
LTB, as described in Chapter 4; this further supports a functional role for these genes in the 
pathogenesis of SLE.  
 
The presence of eQTLs emanating from the MHC region, particularly from disease-associated 
DPB1 and DRB1 haplotypes, supports a role for HLA haplotypes in regulation of gene 
expression, in addition to their probable effect on HLA amino acid variation. Thus, these data 
support the hypothesis described in Chapter 1, which states that the large effect size of genetic 
associations with disease observed at the MHC may be a result of the combined effect of HLA 





6.1.2 Study design 
The eQTL results here presented also underline the importance of study design, particularly the 
study power and the choice of gene expression platforms, in achieving reproducibility. The 
eQTL study conducted in ex vivo B cells using the Affymetrix Human Exon 1.0 ST Array 
(described in Chapter 5) highlighted the need for large sample sizes in order to corroborate the 
cis- and trans-eQTLs identified in published studies (Chapter 3), as exemplified by the lack of 
significance for the cis-eQTLs at DPB1. This work also highlights the importance of specifically 
targeting homologous genes, such as the butyrophilin 3 (BTN3) genes, in eQTL studies, which 
had not previously been possible using Illumina arrays or RNA sequencing (RNA-seq) 
technologies. The exon array proved to be an effective platform for the specific detection of the 
BTN3 homologs, which allowed the identification of a novel trans-association with BTN3A2. 
However, a major downside of using microarrays for MHC studies is the heterogeneity of MHC 
haplotypes in the population, which results in impaired or inaccurate detection of gene 
expression. Quantitative reverse-transcription polymerase chain reaction (qPCR) was the only 
method that reliably detected the expression of specific MHC genes which failed quality control 
in published array data sets (such as BTN3A2), or in the exon array data (such as the 
polymorphic DPB1 gene). qPCR may therefore be a preferable method for the detection of 
highly polymorphic and/or highly homologous genes, as opposed to commercial or custom 
expression microarrays and RNA-seq. Nonetheless, the exon array study described in Chapter 
5 successfully reproduced the eQTL to BTN3A2 using three different methodologies, i.e. exon 
array, qPCR, and Western blotting, thus supporting the use of a combination of different 
methodologies to validate novel eQTLs. 
 
The work presented in Chapter 3 and Chapter 5 also reiterates the importance of context-
specificity, particularly cell type-specificity, in the detection and validation of trans-eQTLs. The 
novel regulatory effects arising from SLE-associated haplotypes described in the exon array 
study were identified under hormonal, cellular, and environmental conditions relevant to the 
disease, i.e. the selection of female individuals, the use of ex vivo B cells, and stimulation with 
IFN-α. Thus, the identification of eQTLs for SLE susceptibility haplotypes in disease-relevant 
contexts here reported provides new insights into the candidate genes and molecular 




6.1.3 Future work 
One of the caveats of this study was that the SLE-associated SNPs here investigated are not 
necessarily the causal SNPs, which may partly explain why this study failed to identify 
reproducible eQTLs. Furthermore, corroboration of the genetic associations in MSH5 and DPB1 
with Spanish and Filipino SLE is still required in larger studies. These associations were shown 
to be in low linkage disequilibrium (LD) with each other and with classical HLA alleles in Chapter 
3. Thus, the identification of the causal alleles for these associations with SLE may be facilitated 
by the LD breakdown in different populations. To ensure that these SLE signals are truly 
independent from HLA alleles, the correlation between the associated MSH5 and DPB1 SNPs 
and HLA amino acid variation should also be investigated.  
 
The MSH5 and DPB1 eQTLs reported in this thesis require validation in independent studies 
using populations of similar ancestry to those used in the original association study, due to the 
variation of the eQTL landscape across different ancestries. Any of the eQTLs here reported 
may be the result of weak or moderate LD between the tested variant and the peak expression 
SNP (eSNP) for the target transcripts. Therefore, the LD and genetic distance between the SNP 
of interest and peak eSNP of target transcripts need to be assessed. Similarly, BTN3A2 cis-
eQTLs in mild LD with DRB1*03:01 haplotypes are likely to explain the trans-association with 
BTN3A2, and should therefore be investigated in densely-genotyped, well-powered eQTL 
studies in healthy individuals and/or SLE patients, using exon arrays, exon-level RNA-seq, or 
qPCR.  
 
Given the relatively large number of DRB1*03:01-homozygous samples included in the exon 
array data set, the expression data generated for this eQTL study might be incorporated in 
future eQTL meta-analyses conducted in B cells, in order to increase the power to detect 
significant eQTLs for DRB1*03:01 haplotypes. Future validation of cis- and trans-eQTLs at the 
MHC, particularly to DPB1 and BTN3A2, may benefit from being executed using qPCR, in order 
to bypass the aforementioned issues related to highly homologous and/or polymorphic genes. 
The validation of alternative splicing data would ideally be performed in a well-powered qPCR 
study, due to the low true-positive detection rates of splicing algorithms. Lastly, the functional 
role of the variants underlying these eQTLs might be investigated by looking for causal rare 
variants in LD with peak eSNPs, or variants that alter transcription factor binding sites. 
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Investigation of mRNA and protein expression levels of cis- and trans-associated genes in B 
cells from patients may also further our understanding of the molecular mechanisms through 
which eQTLs affect disease susceptibility.  
 
 
6.2 The effect of IFN-α on the regulation of disease-associated 
genes 
Chapter 4 explored the effects of IFN-α stimulation on gene expression in B cells, in order to 
elucidate the mechanism by which type 1 IFNs might confer susceptibility to autoimmunity. 
Acute IFN-α stimulation strongly affected transcriptome modulation, including the triggering of 
differential expression of several B cell markers, which provided some insight into B cell 
phenotypic alterations. Interestingly, IFN-α altered the expression of susceptibility genes for the 
autoimmune diseases SLE, rheumatoid arthritis, inflammatory bowel disease, and multiple 
sclerosis, but not for non-autoimmune diseases. Since relatively few studies have addressed 
the role of type 1 IFN in inflammation and tissue destruction in autoimmune diseases other than 
SLE, these data provide a platform for further investigation of the effects of IFN-α in the 
pathogenesis of these diseases. 
 
IFN-α stimulation altered the expression of several SLE candidate genes involved in type 1 IFN 
signalling, B cell receptor signalling, the classic complement pathway, nucleic acid metabolism, 
and HLA class I and class II antigen presentation. Interestingly, the direction of effect of IFN-α 
on the expression of several genes associated with idiopathic and monogenic lupus mirrored 
the genetic consequences of risk polymorphisms reported in functional studies. In some cases, 
the effects of IFN-α also mirrored the difference in transcript levels between SLE patients and 
controls. Differential expression of SLE candidate genes that had never been functionally 
associated with the IFN-α response (and B cell receptor signalling) suggests that these genes 
play a previously unrecognised role in disease pathogenesis through activation of the type 1 
IFN pathway. IFN-α decreased the expression of regulators of type 1 IFNs, as well as genes 
involved in clearing apoptotic cell debris, immune complexes, and endogenous nucleic acids 
(such as ETS1, ITGAM, FCGR genes, DNASE1L3, and complement component genes), all of 
which are important in the maintenance of immune tolerance during inflammation. Thus, 
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exposure of genetically susceptible individuals to IFN-α may trigger autoimmunity by altering the 
expression of genes involved in maintaining tolerance to self. Furthermore, SLE candidate 
genes were also shown to undergo alternative splicing in B cells following exposure to IFN-α, 
reflecting an additional level of molecular regulation of B cell function. This implicates alternative 
splicing in the control of the response of SLE candidate genes to IFN-α stimulation, in addition 
to gene expression, thus complementing the aforementioned gene-level results. Altogether, 
these data contribute to the ongoing functional investigation of SLE-associated genes in 
disease, by elucidating potential mechanisms through which IFN-α contributes to the initiation 
and perpetuation of autoimmunity. 
 
6.2.1 Future work 
In order to determine whether the alteration in the expression of SLE candidate genes by IFN-α 
translates to protein level, these expression changes need to be validated by fluorescence-
activated cell sorting (FACS) or Western blotting. Investigating protein levels in ex vivo B cells 
from SLE patients and healthy controls, and whether these alterations mirror those induced by 
IFN-α stimulation, would also be of interest and provide further insights into the role of SLE 
candidate genes and IFN-α in disease pathogenesis. 
 
In summary, the eQTL results presented in this thesis implicate a regulatory role for SLE-
associated variants within MHC haplotypes, and identify potential functionally-relevant genes in 
the pathogenesis of SLE, namely BTN3A2 and DPB1. This work also highlights the importance 
of study design in order to achieve reproducibility in eQTL studies. Additionally, the differential 
expression of SLE candidate genes following activation of the type 1 IFN pathway suggests a 
previously unrecognised role for these genes in disease. Taken together, these results have 
helped to further elucidate the mechanisms underlying genetic and environmental associations 






Table A1 Genotype count for seven SLE-associated SNPs in the ex vivo B cell data set from Fairfax et al. 
(2012).  
 
All genomic coordinates are from the NCBI Build 36 genomic assembly. 
 
 
Table A2 Genotype count for seven SLE-associated SNPs in the MuTHER LCL data set (Grundberg et al., 
2012).  
 




















rs2293861 31819103 (MSH5) T 193 77 11 17.62% 
rs2187668 32713862 (HLA-DQA1) T 262 56 3 9.66% 
rs3131379 31829012 (MSH5) A 228 47 3 9.53% 
rs3135391 32518965 (HLA-DRA) A 216 56 9 13.17% 
rs3117213 33172583 (HLA-DPB1) T 145 120 16 27.04% 
rs2071351 33151908 (HLA-DPB1) G 182 93 6 19.45% 
rs2071349 33151498 (HLA-DPB1) G 210 66 5 13.52% 
SNP 
Location on 











rs409558 31816126 (MSH5) G 505 153 10 12.95% 
rs2187668 32713862 (HLA-DQA1) T 525 161 14 13.50% 
rs3131379 31829012 (MSH5) A 526 161 13 13.36% 
rs3135391 32518965 (HLA-DRA) A 503 143 10 12.42% 
rs3117213 33172583 (HLA-DPB1) T 376 261 57 27.02% 
rs2071351 33151908 (HLA-DPB1) G 477 185 28 17.46% 
rs2071349 33151498 (HLA-DPB1) G 535 146 12 12.27% 
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Table A3 Genotype count for seven SLE-associated SNPs in the HapMap CEU LCL data set.  
 




































rs409558 31816126 (MSH5) G 39 17 1 16.67% 
rs2187668 32713862 (HLA-DQA1) T 45 11 0 9.82% 
rs3131379 31829012 (MSH5) A 44 11 0 10.00% 
rs3135391 32518965 (HLA-DRA) A 31 21 4 25.89% 
rs3117213 33172583 (HLA-DPB1) T 28 20 8 32.14% 
rs2071351 33151908 (HLA-DPB1) G 44 11 1 11.61% 





Table B1 Genomic location of rs409558 and proxy SNPs (r2 > 0.80) in the Spanish (IBS) 1000 Genomes 
population.  

























rs409558 - 31816126 intron 1 of MSH5 
rs2293861 1.00 31819103 intron 4 of MSH5 
rs2075788 1.00 31820160 intron 7 of MSH5 
rs3749953 1.00 31821103 intron 9 of MSH5 
rs3828922 1.00 31821433 intron 9 of MSH5 
rs2075801 1.00 31836246 intron 19 of MSH5 
rs6905572 1.00 31839860 exon 3 of SAPCD1 
rs9469051 1.00 31849469 intron 12 of VWA7 
rs4711277 1.00 31877663 intron 3 of LSM2 
rs4711279 1.00 31910444 C6orf48 promoter 
rs116828153 1.00 31912625 intron 3 of C6orf48 
rs116201952 1.00 31915468 3’ UTR of C6orf48 
rs80260075 1.00 31963679 








rs409558 - 31816126 intron 1 of MSH5 
rs2293861 1.00 31819103 intron 4 of MSH5 
rs2075788 1.00 31820160 intron 7 of MSH5 
rs3828922 1.00 31821433 intron 9 of MSH5 
rs2075801 1.00 31836246 intron 19 of MSH5 





Table C1 SLE-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
AFF1 rs340630 4q21.3 1.21 8.00 × 10⁻⁹ 
ARID5B, RTKN2 rs4948496 10q21.2 1.1765 5.00 × 10⁻¹¹ 
BANK1 rs10516487 4q24 1.38 4.00 × 10⁻¹⁰ 
BLK rs7812879 8p23.1 1.45 2.00 × 10⁻²⁴ 
C8orf13 rs13277113 8p23.1 1.39 1.00 × 10⁻¹⁰ 
CD80 rs6804441 3q13.33 1.2658 3.00 × 10⁻¹⁶ 
CDKN1B rs34330 12p13.1 1.1905 5.00 × 10⁻¹² 
CREBL2 rs12822507 12p13.2 1.1628 2.00 × 10⁻⁸ 
DGUOK, TET3 rs6705628 2p13.1 1.3333 7.00 × 10⁻¹⁷ 
DRAM1 rs4622329 12q23.2 1.1905 9.00 × 10⁻¹² 
EDEM3 rs10911628 1q25.3 1.954 2.00 × 10⁻¹³ 
ELF1 rs7329174 13q14.11 1.26 1.00 × 10⁻⁸ 
ETS1 rs6590330 11q24.3 1.37 2.00 × 10⁻²⁵ 
FAM98B, TYRO3 rs11073328 15q14 1.935 1.00 × 10⁻¹⁴ 
GPR19 rs10845606 12p13.1 1.2658 4.00 × 10⁻¹⁷ 
IKZF1 rs4917014 7p12.2 1.39 3.00 × 10⁻²³ 
IRF5 rs4728142 7q32.1 1.43 8.00 × 10⁻¹⁹ 
ITGAM rs9888739 16p11.2 1.62 2.00 × 10⁻²³ 
ITGAX rs11574637 16p11.2 1.33 3.00 × 10⁻¹¹ 
KIAA1542 rs4963128 11p15.5 1.28 3.00 × 10⁻¹⁰ 
LRRC18 rs1913517 10q11.23 1.24 7.00 × 10⁻¹² 
PRDM1, ATG5 rs548234 6q21 1.25 5.00 × 10⁻¹² 
PXK rs6445975 3p14.3 1.25 7.00 × 10⁻⁹ 
RASGRP3 rs13385731 2p22.3 1.43 1.00 × 10⁻¹⁵ 
RNF114 rs11697848 20q13.13 2.115 1.00 × 10⁻¹¹ 
SLC15A4 rs1385374 12q24.33 1.26 2.00 × 10⁻¹¹ 




1.51 5.00 × 10⁻⁴² 
TNFAIP3 rs2230926 6q23.3 1.72 1.00 × 10⁻¹⁷ 
TNFSF4 rs2205960 1q25.1 1.46 3.00 × 10⁻³² 
TNIP1 rs10036748 5q33.1 1.23 2.00 × 10⁻⁹ 
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Reported Gene SNP Region OR P-value 
TNPO3 rs10488631 7q32.1 1.829 2.00 × 10⁻¹³ 
UBE2L3, HIC2 rs131654 22q11.21 1.28 1.00 × 10⁻¹⁶ 
WDFY4 rs7097397 10q11.23 1.3 8.00 × 10⁻¹² 
ZNF184 rs10946940 6p22.1 1.45 8.00 × 10⁻⁹ 
  
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region, intergenic regions, and non-annotated loci are not included. OR – odds ratio. 
 
 
Table C2 Rheumatoid arthritis-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
AFF3 rs11676922 2q11.2 1.12 1.00 × 10⁻¹⁴ 
AIRE, PFKL rs2075876 21q22.3 1.18 4.00 × 10⁻⁹ 
ANKRD55, IL6ST rs6859219 5q11.2 1.28 1.00 × 10⁻¹¹ 
ANXA3 rs2867461 4q21.21 1.13 1.00 × 10⁻¹² 
ARID5B rs10821944 10q21.2 1.16 6.00 × 10⁻¹⁸ 
B3GNT2 rs11900673 2p15 1.11 1.00 × 10⁻⁸ 
BLK rs2736340 8p23.1 1.19 6.00 × 10⁻⁹ 
C5 rs881375 9q33.2 ND 4.00 × 10⁻⁸ 
C5orf30 rs26232 5q21.1 1.14 4.00 × 10⁻⁸ 
CCL21 rs951005 9p13.3 1.19 4.00 × 10⁻¹⁰ 
CCR6 rs3093024 6q27 1.19 8.00 × 10⁻¹⁹ 
CD247 rs864537 1q24.2 ND 2.00 × 10⁻¹¹ 
CD40 rs4810485 20q13.12 1.18 3.00 × 10⁻⁹ 
CD83 rs12529514 6p23 1.14 2.00 × 10⁻⁸ 
CSF2 rs657075 5q31.1 1.12 3.00 × 10⁻¹⁰ 
CTLA4 rs231735 2q33.2 1.17 6.00 × 10⁻⁹ 
DDX6 rs10892279 11q23.3 ND 1.00 × 10⁻¹² 
ELMO1 rs11984075 7p14.1 ND 5.00 × 10⁻⁸ 
GATSL3 rs1043099 22q12.2 1.19 7.00 × 10⁻⁹ 
IL2RA rs706778 10p15.1 1.14 1.00 × 10⁻¹¹ 
IRF5 rs10488631 7q32.1 1.19 4.00 × 10⁻¹¹ 
LBH rs7579944 2p23.1 ND 1.00 × 10⁻⁸ 
NFKBIE rs2233434 6p21.1 1.19 6.00 × 10⁻¹⁹ 
OLIG3 rs10499194 6q23.3 1.33 1.00 × 10⁻⁹ 
PADI4 rs2240335 1p36.13 1.50 2.00 × 10⁻⁸ 
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Reported Gene SNP Region OR P-value 
PDE2A, ARAP1 rs3781913 11q13.4 1.12 6.00 × 10⁻¹⁰ 
PLD4 rs2841277 14q32.33 1.15 2.00 × 10⁻¹⁴ 
PSMA4 rs12901682 15q25.1 135.02 4.00 × 10⁻⁸ 
PTPN2 rs1893217 18p11.21 ND 5.00 × 10⁻¹² 
PTPN22 rs2476601 1p13.2 1.94 9.00 × 10⁻⁷⁴ 
PXK rs13315591 3p14.3 1.29 5.00 × 10⁻⁸ 
RBPJ rs874040 4p15.2 1.14 1.00 × 10⁻¹⁶ 
REL rs13017599 2p16.1 1.21 2.00 × 10⁻¹² 
RTKN2 rs3125734 10q21.2 1.20 5.00 × 10⁻⁹ 
SH2B3 rs653178 12q24.12 ND 3.00 × 10⁻¹⁹ 
SPRED2 rs934734 2p14 1.13 5.00 × 10⁻¹⁰ 
SPSB1 rs11121380 1p36.22 11.11 5.00 × 10⁻⁸ 
STAT4 rs7574865 2q32.3 ND 4.00 × 10⁻¹⁰ 
TNFAIP3 rs6920220 6q23.3 1.22 9.00 × 10⁻¹³ 
TRAF1 rs1953126 9q33.2 ND 4.00 × 10⁻¹¹ 
UBASH3A rs11203203 21q22.3 ND 1.00 × 10⁻⁸ 
UBE2L3 rs2298428 22q11.21 ND 3.00 × 10⁻¹⁰ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 




Table C3 Sjögren’s syndrome-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
GTF2I, GTF2IRD1 rs117026326 7q11.23 2.20 1.00 × 10⁻⁵³ 
STAT4 rs10168266 2q32.3 1.44 2.00 × 10⁻¹⁷ 
TNFAIP3 rs5029939 6q23.3 1.67 8.00 × 10⁻⁹ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region, intergenic regions, and non-annotated loci are not included. OR – odds ratio. 
 
 
Table C4 Idiopathic inflammatory myopathies-associated loci from the GWAS NHGRI database. 
 
Reported Gene SNP Region OR P-value 
PTPN22 rs2476601 1p13.2 1.32 7.22 × 10⁻⁹ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region, intergenic regions, and non-annotated loci are not included. OR – odds ratio. 
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Table C5 Multiple sclerosis-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
AGAP2, CYP27B1 rs12368653 12q14.1 1.10 2.00 × 10⁻⁹ 
AHI1 rs11154801 6q23.3 1.13 1.00 × 10⁻¹³ 
BACH2 rs12212193 6q15 1.09 4.00 × 10⁻⁸ 
BATF rs2300603 14q24.3 1.11 2.00 × 10⁻⁸ 
C1orf106, KIF21B rs7522462 1q32.1 1.11 2.00 × 10⁻⁹ 
C3orf1, TMEM39A rs2293370 3q13.33 1.13 3.00 × 10⁻⁹ 
CBLB rs9657904 3q13.11 1.40 2.00 × 10⁻¹⁰ 
CD5 rs650258 11q12.2 1.12 2.00 × 10⁻¹¹ 
CD58 rs1335532 1p13.1 1.22 3.00 × 10⁻¹⁶ 
CD6 rs4939490 11q12.2 1.30 1.00 × 10⁻⁹ 
CD86 rs9282641 3q13.33 1.21 1.00 × 10⁻¹¹ 
CLEC16A rs7200786 16p13.13 1.15 9.00 × 10⁻¹⁷ 
CLECL1 rs10466829 12p13.31 1.09 1.00 × 10⁻⁸ 
CYP24A1 rs2248359 20q13.2 1.12 3.00 × 10⁻¹¹ 
DKKL1 rs2303759 19q13.33 1.11 5.00 × 10⁻⁹ 
EOMES rs11129295 3p24.1 1.11 1.00 × 10⁻⁹ 
EVI5 rs11810217 1p22.1 1.15 6.00 × 10⁻¹⁵ 
EXTL2, VCAM1 rs12048904 1p21.2 1.09 4.00 × 10⁻⁸ 
GPR65 rs2119704 14q31.3 1.22 2.00 × 10⁻¹⁰ 
HHEX rs7923837 10q23.33 1.10 5.00 × 10⁻⁹ 
IL12B rs2546890 5q33.3 1.11 1.00 × 10⁻¹¹ 
IL22RA2 rs17066096 6q23.3 1.14 6.00 × 10⁻¹³ 
IL2RA rs7090512 10p15.1 1.19 5.00 × 10⁻²⁰ 
IL7R rs6897932 5p13.2 1.11 2.00 × 10⁻⁸ 
IRF8 rs17445836 16q24.1 1.25 4.00 × 10⁻⁹ 
KIF1B rs10492972 1p36.22 1.34 3.00 × 10⁻¹⁰ 
MALT1 rs7238078 18q21.32 1.12 3.00 × 10⁻⁹ 
MAPK1 rs2283792 22q11.21 1.10 5.00 × 10⁻⁹ 
MERTK rs17174870 2q13 1.11 1.00 × 10⁻⁸ 
METTL1 rs703842 12q14.1 1.23 5.00 × 10⁻¹¹ 
MLANA rs2150702 9p24.1 1.16 3.00 × 10⁻⁸ 
MMEL1 rs4648356 1p36.32 1.14 1.00 × 10⁻¹⁴ 
MPV17L2 rs874628 19p13.11 1.11 1.00 × 10⁻⁸ 
MYC rs4410871 8q24.21 1.11 8.00 × 10⁻⁹ 
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Reported Gene SNP Region OR P-value 
NCOA5, CD40 rs2425752 20q13.12 1.11 5.00 × 10⁻¹⁰ 
NFKBIZ rs771767 3q12.3 1.10 9.00 × 10⁻⁹ 
ODF3B, SCO2 rs140522 22q13.33 1.10 2.00 × 10⁻⁸ 
OLIG3 rs13192841 6q23.3 1.10 1.00 × 10⁻⁸ 
PLEK rs7595037 2p13.3 1.11 5.00 × 10⁻¹¹ 
PTGER4 rs4613763 5p13.1 1.20 3.00 × 10⁻¹⁶ 
PTPRK, THEMIS rs802734 6q22.33 1.10 6.00 × 10⁻⁹ 
PVT1 rs2019960 8q24.21 1.12 5.00 × 10⁻⁹ 
RGS1 rs1323292 1q31.2 1.12 2.00 × 10⁻⁸ 
RNASEL rs533259 1q25.3 ND 6.00 × 10⁻⁹ 
SLC15A2 rs4285028 3q13.33 1.10 2.00 × 10⁻⁸ 
SLC30A7 rs11581062 1p21.2 1.12 3.00 × 10⁻¹⁰ 
SP140 rs10201872 2q37.1 1.14 2.00 × 10⁻¹⁰ 
STAT3 rs9891119 17q21.2 1.11 2.00 × 10⁻¹⁰ 
TAGAP rs1738074 6q25.3 1.13 7.00 × 10⁻¹⁵ 
THADA rs6718520 2p21 1.17 3.00 × 10⁻⁸ 
TNFRSF1A rs1800693 12p13.31 1.12 4.00 × 10⁻¹⁴ 
TNFSF14 rs1077667 19p13.3 1.16 9.00 × 10⁻¹⁴ 
ZFP36L1 rs4902647 14q24.1 1.11 9.00 × 10⁻¹² 
ZMIZ1 rs1250550 10q22.3 1.10 6.00 × 10⁻⁹ 
ZNF767, ZNF746 rs354033 7q36.1 1.11 5.00 × 10⁻⁹ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 















Table C6 Inflammatory bowel disease-associated loci from the GWAS NHGRI database. 
 
Reported Gene SNP Region OR P-value 
ADCY3 rs6545800 2p23.3 1.11 6.00 × 10⁻¹⁶ 
ATF4, TAB1, APOBEC3G rs2413583 22q13.1 1.21 4.00 × 10⁻³³ 
C11orf9, FADS1, FADS2 rs4246215 11q12.2 1.08 2.00 × 10⁻¹⁵ 
C1orf53 rs2488389 1q31.3 1.12 8.00 × 10⁻¹³ 
CARD15 rs2076756 16q12.1 ND 5.00 × 10⁻¹⁰ 
CARD9, PMPCA, SDCCAG3, 
INPP5E 
rs10781499 9q34.3 1.19 4.00 × 10⁻⁵⁶ 
CCDC88B, RPS6KA4, TRPT1, 
FLRT1 
rs559928 11q13.1 1.10 4.00 × 10⁻¹¹ 
CCL13, CCL2, CCL11 rs3091316 17q12 1.12 1.00 × 10⁻²⁶ 
CCR6, RPS6KA2, RNASET2 rs1819333 6q27 1.08 7.00 × 10⁻²¹ 
CD226 rs727088 18q22.2 1.08 5.00 × 10⁻⁹ 
CD40, MMP9, PLTP rs1569723 20q13.12 1.09 1.00 × 10⁻¹³ 
CD48, SLAMF1, ITLN1, CD244, 
F11R, USF1, SLAMF7, 
ARHGAP30 
rs4656958 1q23.3 1.06 7.00 × 10⁻⁹ 
CD6, CD5, PTGDR2 rs11230563 11q12.2 1.09 9.00 × 10⁻¹³ 
CEBPB rs913678 20q13.13 1.06 5.00 × 10⁻⁸ 
CEBPG rs17694108 19q13.11 1.10 6.00 × 10⁻¹⁵ 
CISD1, IPMK rs2790216 10q21.1 1.07 8.00 × 10⁻⁹ 
CNTF, LPXN rs10896794 11q12.1 1.08 7.00 × 10⁻¹⁰ 
CREM rs11010067 10p11.21 1.12 2.00 × 10⁻²⁵ 
CRTC3 rs7495132 15q26.1 1.13 9.00 × 10⁻¹¹ 
CXCL5, CXCL1, CXCL3, IL8, 
CXCL6, PF4, CXCL2, PF4V1 
rs2472649 4q13.3 1.10 3.00 × 10⁻⁸ 
CXCR5 rs630923 11q23.3 1.07 7.00 × 10⁻⁹ 
DAP rs2930047 5p15.2 1.07 1.00 × 10⁻⁸ 
DNMT3B rs4911259 20q11.21 1.08 1.00 × 10⁻⁹ 
DOK3 rs12654812 5q35.3 1.07 2.00 × 10⁻⁸ 
EPO rs1734907 7q22.1 1.11 2.00 × 10⁻¹³ 
ERAP2, ERAP1, LNPEP rs1363907 5q15 1.07 6.00 × 10⁻¹³ 
FCGR2A, FCGR2B, FCGR3A, 
HSPA6, FCGR3B, FCRLA 
rs1801274 1q23.3 1.12 2.00 × 10⁻³⁸ 
FOS, MLH3 rs4899554 14q24.3 1.08 3.00 × 10⁻⁸ 
FOSL2, BRE rs925255 2p23.2 1.09 3.00 × 10⁻¹⁵ 
GPR183, GPR18 rs9557195 13q32.3 1.11 2.00 × 10⁻¹⁴ 
GPR35 rs3749171 2q37.3 1.14 3.00 × 10⁻²¹ 
GPR65, GALC rs8005161 14q31.3 1.15 2.00 × 10⁻¹⁴ 
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Reported Gene SNP Region OR P-value 
HCK rs6142618 20q11.21 1.07 6.00 × 10⁻¹⁰ 
ICOSLG rs7282490 21q22.3 1.11 2.00 × 10⁻²⁶ 
IFIH1 rs2111485 2q24.2 1.07 2.00 × 10⁻⁸ 
IFNG, IL26, IL22 rs7134599 12q15 1.10 9.00 × 10⁻³² 
IKZF3, ZPBP2, GSDMB, 
ORMDL3, GSDMA 
rs12946510 17q12 1.16 4.00 × 10⁻³⁸ 
IL10, IL20, IL19, IL24, PIGR, 
MAPKAPK2, FAIM3, RASSF5 
rs3024505 1q32.1 1.21 7.00 × 10⁻⁴² 
IL12B rs6871626 5q33.3 1.18 1.00 × 10⁻⁴² 
IL1R2, IL18RAP, IL18R1, IL1R1, 
IL1RL1, IL1RL2 
rs917997 2q12.1 1.10 3.00 × 10⁻²⁰ 
IL2, IL21 rs7657746 4q27 1.12 3.00 × 10⁻¹³ 
IL23R, IL12RB2 rs11209026 1p31.3 2.01 8.00 × 10⁻¹⁶¹ 
IL2RA, IL15RA rs12722515 10p15.1 1.10 4.00 × 10⁻¹⁰ 
IRF1, IL13, CSF2, SLC22A4, IL4, 
IL3, IL5, PDLIM4, SLC22A5, 
ACSL6 
rs2188962 5q31.1 1.16 1.00 × 10⁻⁵² 
IRF8 rs10521318 16q24.1 1.16 1.00 × 10⁻⁹ 
JAK2 rs10758669 9p24.1 1.17 8.00 × 10⁻⁴⁵ 
KIF21B rs7554511 1q32.1 1.16 1.00 × 10⁻³² 
LIF, OSM, MTMR3 rs2412970 22q12.2 1.08 3.00 × 10⁻¹⁴ 
LOH12CR1 rs11612508 12p13.2 1.06 1.00 × 10⁻⁸ 
LRRK2, MUC19 rs11564258 12q12 1.33 6.00 × 10⁻²⁹ 
MAP3K8 rs1042058 10p11.23 1.08 6.00 × 10⁻¹¹ 
MAPK1, YDJC, UBE2L3, 
RIMBP3, CCDC116 
rs2266959 22q11.21 1.11 1.00 × 10⁻¹⁶ 
MST1, PFKFB4, MST1R, UCN2, 
GPX1, IP6K2, BSN, IP6K1, 
USP4 
rs3197999 3p21.31 1.18 1.00 × 10⁻⁴⁷ 
NFIL3 rs4743820 9q22.31 1.06 4.00 × 10⁻⁹ 
NKX2-3 rs4409764 10q24.2 1.18 1.00 × 10⁻⁵⁴ 
NLRP7, NLRP2, KIR2DL1, 
LILRB4 
rs11672983 19q13.42 1.09 7.00 × 10⁻¹¹ 
NOD2 rs5743289 16q12.1 1.46 4.00 × 10⁻¹⁰ 
PHACTR2 rs12199775 6q24.2 1.13 2.00 × 10⁻⁸ 
PRKCB rs7404095 16p12.2 1.06 1.00 × 10⁻⁹ 
PSMG1 rs2836878 21q22.2 1.41 4.00 × 10⁻¹² 
PTGER4 rs11742570 5p13.1 1.20 2.00 × 10⁻⁸² 
RABEP2, IL27, EIF3C, 
SULT1A1, SULT1A2, NUPR1 
rs26528 16p11.2 1.10 1.00 × 10⁻²¹ 
REL, C2orf74, KIAA1841, 
AHSA2 
rs7608910 2p16.1 1.14 9.00 × 10⁻³² 
RELA, FOSL1, CTSW, SNX32 rs2231884 11q13.1 1.08 3.00 × 10⁻¹⁰ 
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Reported Gene SNP Region OR P-value 
RORC rs4845604 1q21.3 1.14 4.00 × 10⁻¹⁶ 
SLC11A1, CXCR2, CXCR1, 
PNKD, ARPC2, TMBIM1, 
CTDSP1 
rs2382817 2q35 1.07 4.00 × 10⁻¹² 
SMAD3 rs17293632 15q22.33 1.07 6.00 × 10⁻¹⁶ 
SMAD7 rs7240004 18q21.1 1.06 1.00 × 10⁻⁹ 
SMURF1 rs9297145 7q22.1 1.08 8.00 × 10⁻¹² 
SOCS1, LITAF, RMI2 rs529866 16p13.13 1.12 2.00 × 10⁻¹⁶ 
SPRED2 rs6740462 2p14 1.08 2.00 × 10⁻⁸ 
SPRY4, NDFIP1 rs6863411 5q31.3 1.09 4.00 × 10⁻¹⁴ 
STAT1, STAT4 rs1517352 2q32.3 1.08 3.00 × 10⁻¹¹ 
STAT3, STAT5B, STAT5A rs12942547 17q21.2 1.10 6.00 × 10⁻²² 
TNFAIP3 rs6920220 6q23.3 1.10 1.00 × 10⁻²¹ 
TNFRSF18, TNFRSF4 rs12103 1p36.33 1.10 8.00 × 10⁻¹³ 
TNFRSF6B rs2315008 20q13.33 1.36 9.00 × 10⁻¹⁵ 
TNFRSF6B, LIME1, SLC2A4RG, 
ZGPAT 
rs6062504 20q13.33 1.10 1.00 × 10⁻²³ 
TNFRSF9 rs35675666 1p36.23 1.11 1.00 × 10⁻¹⁵ 
TNFSF15 rs2006996 9q32 1.75 4.00 × 10⁻¹⁶ 
TNFSF8, TNC rs4246905 9q32 1.14 3.00 × 10⁻³² 
TNIP1, IRGM, ZNF300P1 rs11741861 5q33.1 1.25 3.00 × 10⁻³⁷ 
TNNI2, LSP1 rs907611 11p15.5 1.07 3.00 × 10⁻¹⁰ 
TRAF3IP2, FYN, REV3L rs3851228 6q21 1.15 1.00 × 10⁻¹³ 
TRIB1 rs921720 8q24.13 1.08 8.00 × 10⁻²⁰ 
TSPAN14, C10orf58 rs6586030 10q23.1 1.12 9.00 × 10⁻¹⁶ 
TUBD1, RPS6KB1 rs1292053 17q23.1 1.08 9.00 × 10⁻¹³ 
TYK2, PPAN-P2RY11, ICAM1 rs11879191 19p13.2 1.14 2.00 × 10⁻¹⁸ 
UBQLN4, RIT1, MSTO1 rs670523 1q22 1.06 6.00 × 10⁻¹¹ 
VDR rs11168249 12q13.11 1.05 8.00 × 10⁻⁹ 
ZFP36L1 rs194749 14q24.1 1.08 3.00 × 10⁻¹⁰ 
ZNF831, CTSZ rs259964 20q13.32 1.09 1.00 × 10⁻¹² 
ZPBP, IKZF1 rs1456896 7p12.2 1.09 7.00 × 10⁻¹⁵ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 







Table C7 Type 1 diabetes-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
BACH2 rs11755527 6q15 1.13 5.00 × 10⁻¹² 
C10orf59 rs10509540 10q23.31 1.33 1.00 × 10⁻²⁸ 
C1QTNF6 rs229541 22q12.3 1.11 2.00 × 10⁻⁸ 
C6orf173 rs9388489 6q22.32 1.17 4.00 × 10⁻¹³ 
CD226 rs763361 18q22.2 1.16 1.00 × 10⁻⁸ 
CD69 rs4763879 12p13.31 1.09 2.00 × 10⁻¹¹ 
COBL rs4948088 7p12.1 1.30 4.00 × 10⁻⁸ 
CTLA4 rs3087243 2q33.2 ND 1.00 × 10⁻¹⁵ 
CTSH rs3825932 15q25.1 1.16 3.00 × 10⁻¹⁵ 
CUX2 rs1265564 12q24.12 1.45 1.00 × 10⁻¹⁶ 
DLK1, MEG3, RTL1, DIO3 rs941576 14q32.2 1.11 1.00 × 10⁻¹⁰ 
EFR3B, 3NCOA1, C2orf79, CENPO, 
ADCY3, DNAJC27, POMC, DNMT3A 
rs478222 2p23.3 1.22 4.00 × 10⁻⁹ 
ERBB3 rs2292239 12q13.2 ND 2.00 × 10⁻²⁵ 
GLIS3 rs7020673 9p24.2 1.14 5.00 × 10⁻¹² 
IFIH1 rs1990760 2q24.2 1.18 2.00 × 10⁻¹¹ 
IL10 rs3024505 1q32.1 1.19 2.00 × 10⁻⁹ 
IL2 rs4505848 4q27 ND 5.00 × 10⁻¹³ 
IL27 rs4788084 16p11.2 1.09 3.00 × 10⁻¹³ 
IL2RA rs12251307 10p15.1 ND 1.00 × 10⁻¹³ 
INS rs7111341 11p15.5 ND 4.00 × 10⁻⁴⁸ 
KIAA0350, CLEC16A rs12708716 16p13.13 1.23 3.00 × 10⁻¹⁸ 
LMO7 rs539514 13q22.2 1.43 6.00 × 10⁻¹¹ 
ORMDL3 rs2290400 17q12 1.15 6.00 × 10⁻¹³ 
PHTF1 rs6679677 1p13.2 1.89 8.00 × 10⁻²⁴ 
PRKCQ rs947474 10p15.1 1.10 4.00 × 10⁻⁹ 
PTPN2 rs1893217 18p11.21 ND 4.00 × 10⁻¹⁵ 
PTPN22 rs2476601 1p13.2 ND 9.00 × 10⁻⁸⁵ 
RAB5B, SUOX, IKZF4, CDK2 rs1701704 12q13.2 1.25 9.00 × 10⁻¹⁰ 
SH2B3 rs3184504 12q24.12 ND 3.00 × 10⁻²⁷ 
LNK, TRAFD1, PTPN11, C12orf30  rs17696736 12q24.13 1.34 2.00 × 10⁻¹⁴ 
TYK2 rs2304256 19p13.2 1.16 4.00 × 10⁻⁹ 
UBASH3A rs11203203 21q22.3 ND 2.00 × 10⁻⁹ 
WDR27, C6orf120, PHF10, TCTE3, 
C6orf208, LOC154449, DLL1, 
FAM120B, PSMB1, TBP, PCD2 
rs924043 6q27 1.35 8.00 × 10⁻⁹ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region, intergenic regions, and non-annotated loci are not included.  OR – odds ratio, ND – no data available. 
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Table C8 Psoriasis-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
ERAP1 rs27524 5q15 1.13 3.00 × 10⁻¹¹ 
FBXL19, POL3S rs10782001 16p11.2 1.16 9.00 × 10⁻¹⁰ 
IFIH1 rs17716942 2q24.2 1.29 1.00 × 10⁻¹³ 
IL12B rs2082412 5q33.3 1.44 2.00 × 10⁻²⁸ 
IL13 rs20541 5q31.1 1.27 5.00 × 10⁻¹⁵ 
IL23A, STAT2 rs2066808 12q13.3 1.34 1.00 × 10⁻⁹ 
IL23R rs2201841 1p31.3 1.13 3.00 × 10⁻⁸ 
LCE3A rs4085613 1q21.3 1.32 7.00 × 10⁻³⁰ 
LCE3D rs4112788 1q21.3 1.29 3.00 × 10⁻¹⁰ 
NFKBIA rs8016947 14q13.2 1.19 2.00 × 10⁻¹¹ 
NOS2 rs4795067 17q11.2 1.19 4.00 × 10⁻¹¹ 
PSMA6 rs12586317 14q13.2 1.15 2.00 × 10⁻⁸ 
REL rs702873 2p16.1 1.12 4.00 × 10⁻⁹ 
SPATA2 rs495337 20q13.13 1.25 1.00 × 10⁻⁸ 
TNFAIP3 rs610604 6q23.3 1.19 9.00 × 10⁻¹² 
TNIP1 rs17728338 5q33.1 1.59 1.00 × 10⁻²⁰ 
TRAF3IP2 rs240993 6q21 1.25 5.00 × 10⁻²⁰ 
TYK2 rs12720356 19p13.2 1.4 4.00 × 10⁻¹¹ 
  
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region, intergenic regions, and non-annotated loci are not included. OR – odds ratio. 
 
 
Table C9 Osteoarthritis-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
DOT1L rs12982744 19p13.3 0.09 1.00 × 10⁻¹¹ 
DUS4L rs4730250 7q22.3 1.15 6.00 × 10⁻⁸ 
GNL3, GLT8D1 rs11177 3p21.1 1.09 5.00 × 10⁻⁹ 
MCF2L rs11842874 13q34 1.17 2.00 × 10⁻⁸ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 






Table C10 Type 2 diabetes-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
ADAMTS9 rs4607103 3p14.1 1.09 1.00 × 10⁻⁸ 
ANK1 rs515071 8p11.21 1.18 1.00 × 10⁻⁸ 
AP3S2 rs2028299 15q26.1 1.1 2.00 × 10⁻¹¹ 
ARF5, SND1 rs10229583 7q32.1 1.14 2.00 × 10⁻¹⁰ 
BCL11A rs243021 2p16.1 1.08 3.00 × 10⁻¹⁵ 
C2CD4A, C2CD4B rs7172432 15q22.2 1.11 9.00 × 10⁻¹⁴ 
C6orf57 rs1048886 6q13 1.54 3.00 × 10⁻⁸ 
CAMK1D rs12779790 10p13 1.11 1.00 × 10⁻¹⁰ 
CDC123 rs11257655 10p13 1.15 7.00 × 10⁻⁹ 
CDKAL1 rs10440833 6p22.3 1.25 2.00 × 10⁻²² 
CDKN2A, CDKN2B rs2383208 9p21.3 1.34 2.00 × 10⁻²⁹ 
CENTD2 rs1552224 11q13.4 1.14 1.00 × 10⁻²² 
CHCHD9 rs13292136 9q21.31 1.11 3.00 × 10⁻⁸ 
DUSP9 rs5945326 Xq28 1.18 7.00 × 10⁻¹⁶ 
FAM58A rs12010175 Xq28 1.21 2.00 × 10⁻⁹ 
FITM2, R3HDML, HNF4A rs6017317 20q13.12 1.09 1.00 × 10⁻¹¹ 
FTO rs9939609 16q12.2 1.25 1.00 × 10⁻²⁰ 
GCC1, PAX4 rs6467136 7q32.1 1.11 5.00 × 10⁻¹¹ 
GLIS3 rs7041847 9p24.2 1.1 2.00 × 10⁻¹⁴ 
GPSM1 rs11787792 9q34.3 1.15 2.00 × 10⁻¹⁰ 
GRB14 rs3923113 2q24.3 1.09 1.00 × 10⁻⁸ 
GRK5 rs10886471 10q26.11 1.12 7.00 × 10⁻⁹ 
HHEX rs1111875 10q23.33 1.21 7.00 × 10⁻¹² 
HMG20A rs7178572 15q24.3 1.09 7.00 × 10⁻¹¹ 
HMGA2 rs1531343 12q14.3 1.1 4.00 × 10⁻⁹ 
HNF1A rs7305618 12q24.31 1.14 2.00 × 10⁻⁸ 
HNF1B rs4430796 17q12 1.19 2.00 × 10⁻¹¹ 
HNF4A rs4812829 20q13.12 1.09 3.00 × 10⁻¹⁰ 
IDE rs5015480 10q23.33 1.18 1.00 × 10⁻¹⁵ 
IGF2BP2 rs1470579 3q27.2 1.08 2.00 × 10⁻¹⁹ 
IRS1 rs7578326 2q36.3 1.11 5.00 × 10⁻²⁰ 
JAZF1 rs864745 7p15.1 1.1 5.00 × 10⁻¹⁴ 
KCNJ11 rs5215 11p15.1 1.14 5.00 × 10⁻¹¹ 
KCNK16 rs1535500 6p21.2 1.08 2.00 × 10⁻⁸ 
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Reported Gene SNP Region OR P-value 
KCNQ1 rs2237892 11p15.4 1.4 2.00 × 10⁻⁴² 
KLF14 rs972283 7q32.3 1.07 2.00 × 10⁻¹⁰ 
LAMA1 rs8090011 18p11.31 1.13 8.00 × 10⁻⁹ 
MAEA rs6815464 4p16.3 1.13 2.00 × 10⁻²⁰ 
MGC21675 rs7656416 4p16.3 1.15 1.00 × 10⁻⁸ 
MIR129, LEP rs791595 7q32.1 1.17 3.00 × 10⁻¹³ 
MTNR1B rs1387153 11q14.3 1.09 8.00 × 10⁻¹⁵ 
NOTCH2, ADAM30 rs10923931 1p12 1.13 4.00 × 10⁻⁸ 
PEPD rs3786897 19q13.11 1.1 1.00 × 10⁻⁸ 
PRC1 rs8042680 15q26.1 1.07 2.00 × 10⁻¹⁰ 
PSMD6 rs831571 3p14.1 1.09 8.00 × 10⁻¹¹ 
PTPRD rs17584499 9p24.1 1.57 9.00 × 10⁻¹⁰ 
RASGRP1 rs7403531 15q14 1.1 4.00 × 10⁻⁹ 
RBM43, RND3 rs7560163 2q23.3 1.33 7.00 × 10⁻⁹ 
RBMS1, ITGB6 rs7593730 2q24.2 1.11 4.00 × 10⁻⁸ 
SGCG, SACS rs9552911 13q12.12 1.49 2.00 × 10⁻⁸ 
SLC16A13 rs312457 17p13.1 1.2 8.00 × 10⁻¹³ 
SLC30A8 rs13266634 8q24.11 1.22 2.00 × 10⁻¹⁴ 
SPRY2 rs1359790 13q31.1 1.15 6.00 × 10⁻⁹ 
SRR rs391300 17p13.3 1.28 3.00 × 10⁻⁹ 
ST6GAL1 rs16861329 3q27.3 1.09 3.00 × 10⁻⁸ 
TCF7L2 rs7903146 10q25.2 1.19 9.00 × 10⁻⁷⁵ 
THADA rs7578597 2p21 1.15 1.00 × 10⁻⁹ 
TP53INP1 rs896854 8q22.1 1.06 1.00 × 10⁻⁹ 
TSPAN8, LGR5 rs7961581 12q21.1 1.09 1.00 × 10⁻⁹ 
VPS26A rs1802295 10q22.1 1.08 4.00 × 10⁻⁸ 
WFS1 rs1801214 4p16.1 1.13 3.00 × 10⁻⁸ 
ZBED3 rs4457053 5q13.3 1.08 3.00 × 10⁻¹² 
ZFAND3 rs9470794 6p21.2 1.12 2.00 × 10⁻¹⁰ 
ZFAND6 rs11634397 15q25.1 1.06 2.00 × 10⁻⁹ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 







Table C11 Schizophrenia-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
AKT3, CEP170 rs14403 1q43 1.10 2.00 × 10⁻⁸ 
BRP44, DCAF6 rs10489202 1q24.2 1.23 1.00 × 10⁻⁸ 
C10orf32, AS3MT, CALHM1, 
CALHM2, CALHM3, 
CNNM2, CYP17A1, INA, MIR1307, 
NT5C2, PCGF6, PDCD11, SFXN2, 
ST13P13, TAF5, USMG5, WBP1L 
rs7085104 10q24.32 1.11 4.00 × 10⁻¹³ 
C12orf65, ABCB9, ARL6IP4, 
CDK2AP1, MIR4304, MPHOSPH9, 
OGFOD2, PITPNM2, RILPL2, 
SBNO1, SETD8 
rs11532322 12q24.31 1.09 2.00 × 10⁻⁸ 
C2orf82, GIGYF2, KCNJ13, NGEF rs778371 2q37.1 1.09 2.00 × 10⁻⁸ 
CACNA1C rs1006737 12p13.33 1.10 5.00 × 10⁻¹² 
CACNB2, NSUN6 rs17691888 10p12.31 1.16 1.00 × 10⁻¹⁰ 
CCDC68 rs12966547 18q21.2 1.40 3.00 × 10⁻⁸ 
CNNM2 rs7914558 10q24.32 1.22 2.00 × 10⁻⁸ 
CSMD1 rs10503253 8p23.2 1.16 2.00 × 10⁻⁸ 
FONG, C2orf47, C2orf69, 
SPATS2L, TYW5 
rs2949006 2q33.1 1.10 1.00 × 10⁻⁸ 
GRIA1 rs17504622 5q33.1 1.24 3.00 × 10⁻⁹ 
HHAT rs7527939 1q32.2 2.63 6.00 × 10⁻⁹ 
ITIH3, ALAS1, ALDOAP1, BAP1, 
C3orf78, DNAH1, GLT8D1, 
GLYCTK, GNL3, ITIH1, ITIH4, 
MIR135A1, MIRLET7G, MUSTN1, 
NEK4, NISCH, NT5DC2, PBRM1, 
PHF7, PPM1M, RFT1, SEMA3G, 
SFMBT1, SPCS1, STAB1, TLR9, 
TMEM110, TNNC1, TWF2, WDR82 
rs4687552 3p21.1 1.09 1.00 × 10⁻⁸ 
LSM1, WHSC1L1 rs16887244 8p11.23 1.19 1.00 × 10⁻¹⁰ 
MAD1L1, FTSJ2, NUDT1, SNX8 rs6461049 7p22.3 1.11 6.00 × 10⁻¹³ 
MAD1L1, SNX8, NUDT1, FTSJ2 rs12666575 7p22.3 1.12 2.00 × 10⁻⁹ 
MAU2, CILP2, GATAD2A, GMIP, 
HAPLN4, LPAR2, MIR640, NCAN, 
NDUFA13, PBX4, SUGP1, 
TM6SF2, TSSK6, YJEFN3 
rs2905424 19p13.11 1.09 3.00 × 10⁻⁹ 
MIR137 rs1625579 1p21.3 1.12 2.00 × 10⁻¹¹ 
MIR137, DPYD rs1198588 1p21.3 1.12 2.00 × 10⁻¹² 
MMP16 rs11995572 8q21.3 1.12 3.00 × 10⁻⁸ 
NRGN rs12807809 11q24.2 1.15 2.00 × 10⁻⁹ 
NT5C2 rs11191580 10q24.33 1.20 3.00 × 10⁻⁸ 
NT5C2, CNNM2 rs11191580 10q24.33 1.23 2.00 × 10⁻⁹ 
PCGEM1 rs17662626 2q32.3 1.20 5.00 × 10⁻⁸ 
QPCT, C2orf56, CEBPZ, PRKD3, 
SULT6B1 
rs2373000 2p22.2 1.09 7.00 × 10⁻⁹ 
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Reported Gene SNP Region OR P-value 
RENBP, ARHGAP4, MECP2 rs2269372 Xq28 1.31 4.00 × 10⁻⁸ 
SDCCAG8 rs1538774 1q43 1.09 3.00 × 10⁻⁸ 
SLC17A1, SLC17A3, BTN3A2, 
BTN2A2, BTN3A1, HIST1H2AG, 
HIST1H2BJ, PRSS16, POM121L2, 
ZNF184 
rs13194053 6p22.1 1.28 1.00 × 10⁻⁸ 
SLCO6A1 rs6878284 5q21.1 1.09 9.00 × 10⁻⁹ 
SNX19 rs7940866 11q25 1.09 2.00 × 10⁻⁹ 
TCF4 rs1261117 18q21.2 1.60 3.00 × 10⁻¹⁰ 
TCF4 rs9960767 18q21.2 1.23 4.00 × 10⁻⁹ 
TCF4 rs4801131 18q21.2 1.08 1.00 × 10⁻⁸ 
TSNARE1 rs4129585 8q24.3 1.09 2.00 × 10⁻¹⁰ 
TSPAN18 rs11038167 11p11.2 1.29 1.00 × 10⁻¹¹ 
ZEB2 rs12991836 2q22.3 1.08 1.00 × 10⁻⁸ 
ZSWIM6, C5orf43 rs171748 5q12.1 1.08 4.00 × 10⁻⁸ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region, intergenic regions, and non-annotated loci are not included. OR – odds ratio. 
 
 
Table C12 Bipolar disorder-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
ANK3 rs4948418 10q21.2 ND 4.00 × 10⁻¹⁰ 
CANCNA1C rs4765913 12p13.33 1.14 2.00 × 10⁻⁸ 
DGKH rs1012053 13q14.11 1.59 2.00 × 10⁻⁸ 
LMAN2L rs2271893 2q11.2 ND 2.00 × 10⁻¹⁰ 
NCAN rs1064395 19p13.11 1.17 2.00 × 10⁻⁹ 
ODZ4 rs12576775 11q14.1 1.14 4.00 × 10⁻⁸ 
PTGFR rs4650608 1p31.1 ND 8.00 × 10⁻⁹ 
RP11-252P19.1 rs1039002 6q27 ND 2.00 × 10⁻⁸ 
TRANK1 rs9834970 3p22.2 ND 1.00 × 10⁻¹² 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 








Table C13 Hypertension-associated loci from the GWAS NHGRI database.  
 
Reported Gene SNP Region OR P-value 
ATP2B1 rs2681472 12q21.33 0.15 2.00 × 10⁻¹¹ 
EDN3, GNAS rs6015450 20q13.32 0.11 4.00 × 10⁻¹⁴ 
FLJ32810, TMEM133 rs633185 11q22.1 0.07 5.00 × 10⁻¹¹ 
GPR39 rs13420028 2q21.2 ND 1.00 × 10⁻¹⁰ 
MACROD2 rs200752 20p12.1 ND 7.00 × 10⁻⁹ 
MYO6 rs3798440 6q14.1 ND 3.00 × 10⁻¹⁰ 
NOV rs2469997 8q24.12 ND 3.00 × 10⁻¹⁶ 
NPR3, C5orf23 rs1173771 5p13.3 0.06 3.00 × 10⁻¹⁰ 
PLCE1 rs932764 10q23.33 0.06 9.00 × 10⁻⁹ 
RANBP3L rs7735940 5p13.2 ND 5.00 × 10⁻¹³ 
UMOD rs13333226 16p12.3 1.15 4.00 × 10⁻¹¹ 
ZFAT rs7827545 8q24.22 ND 2.00 × 10⁻⁴⁴ 
 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 






















Table D1 Genes associated with idiopathic SLE.  
 
Reported Gene SNP Region OR P-value Reference 
STAT4 rs11889341 2q32 1.73 5.59 × 10⁻¹²² Bentham et al. (2015) 
NCF2, SMG7 rs17849501 1q25.3 2.1 3.45 × 10⁻⁸⁸ Bentham et al. (2015) 
TNIP1 rs10036748 5q32 1.38 1.27 × 10⁻⁴⁵ Bentham et al. (2015) 
TNFAIP3 rs6932056 6q23.3 1.83 1.97 × 10⁻³¹ Bentham et al. (2015) 
PTPN22 rs2476601 1p13 1.43 1.10 × 10⁻²⁸ Bentham et al. (2015) 
MIR146A rs2431697 5q33.3 1.26 8.01 × 10⁻²⁸ Bentham et al. (2015) 
CD44 rs2732549 11p13 1.24 1.20 × 10⁻²³ Bentham et al. (2015) 
DHCR7, NADSYN1 rs3794060 11q13.4 1.23 1.32 × 10⁻²⁰ Bentham et al. (2015) 
TNFSF4 (OX40L) rs704840 1q25.1 1.22 3.12 × 10⁻¹⁹ Bentham et al. (2015) 
IRF5, TNPO3 rs12537284 7q32 1.54 3.61 × 10⁻¹⁹ 
International Consortium for 
Systemic Lupus 
Erythematosus et al. (2008) 
IRF8 rs11644034 16q24.1 1.25 9.58 × 10⁻¹⁸ Bentham et al. (2015) 
GPR19 rs10845606 12p13 0.79 3.80 × 10⁻¹⁷ Yang et al. (2013) 
BANK1 rs10028805 4q24 1.2 4.31 × 10⁻¹⁷ Bentham et al. (2015) 
TET3, DGUOK rs6705628 2p13 0.75 6.90 × 10⁻¹⁷ Yang et al. (2013) 
CIITA, SOCS1 rs9652601 16p13.13 1.21 7.42 × 10⁻¹⁷ Bentham et al. (2015) 
UBE2L3, HIC2 rs463426 22q11.21 0.78 1.48 × 10⁻¹⁶ Han et al. (2009) 
CD80 rs6804441 3q13.33 0.79 2.50 × 10⁻¹⁶ Boackle (2013) 
SKP1, TCF7 rs7726414 5q31.1 1.45 4.44 × 10⁻¹⁶ Bentham et al. (2015) 
RASGRP3 rs13385731 2p24.1 0.7 1.30 × 10⁻¹⁵ Vaughn et al. (2012) 
IRAK1, MECP2 rs1734787 Xq28 1.31 1.78 × 10⁻¹⁵ Bentham et al. (2015) 
CSK rs2289583 15q24.1 1.19 6.22 × 10⁻¹⁵ Bentham et al. (2015) 
ABHD6, PXK rs9311676 3p14.3 1.17 3.06 × 10⁻¹⁴ Bentham et al. (2015) 
ATG5, PRDM1 rs6568431 6q21 1.21 5.04 × 10⁻¹⁴ Bentham et al. (2015) 
IKZF1 rs4917014 7p12.2 1.18 6.39 × 10⁻¹⁴ Bentham et al. (2015) 
IKZF2 rs3768792 2q34 1.24 1.21 × 10⁻¹³ Bentham et al. (2015) 
SLC15A4 rs1059312 12q24.32 1.17 1.48 × 10⁻¹³ Bentham et al. (2015) 
TYK2 rs2304256 19p13.2 1.24 3.50 × 10⁻¹³ Bentham et al. (2015) 
FCGR2A, FCGR2B, 
FCGR3B, FCGR3A 
rs1801274 1q23.3 1.16 1.04 × 10⁻¹² Bentham et al. (2015) 
CDKN1B rs34330 12p13 0.84 4.80 × 10⁻¹² Yang et al. (2013) 
WDFY4, LRRC18 rs1913517 10q11.23 1.24 7.20 × 10⁻¹² Vaughn et al. (2012) 
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Reported Gene SNP Region OR P-value Reference 
DRAM1 rs4622329 12q23 0.84 9.40 × 10⁻¹² Boackle (2013) 
IFIH1 rs2111485 2q24 1.15 1.27 × 10⁻¹¹ Bentham et al. (2015) 
KIAA0319L rs2275247 1p34.3 1.49 3.31 × 10⁻¹¹ Martin et al. (2013) 
ARID5B, RTKN2 rs4948496 10q21 0.85 5.10 × 10⁻¹¹ Yang et al. (2013) 
TREX1 rs3135945 3p21.3 44.65 8.50 × 10⁻¹¹ Vaughn et al. (2012) 
JAZF1 rs849142 7p15.1 1.14 8.61 × 10⁻¹¹ Bentham et al. (2015) 
BLK, C8orf13 
(FAM167A) 
rs13277113 8p23.1 1.39 1.00 × 10⁻¹⁰ Hom et al. (2008) 
ETS1, FLI1 rs7941765 11q23.3 1.14 1.35 × 10⁻¹⁰ Bentham et al. (2015) 
KIAA1542 (PHRF1) rs4963128 11p15.5 0.78 3.00 × 10⁻¹⁰ 
International Consortium for 
Systemic Lupus 
Erythematosus et al. (2008) 
IKZF3, ZPBP2 rs1453560 17q21 
1.23-
1.37 
3.48 × 10⁻¹⁰ Boackle (2013) 
ICAM1, ICAM4, 
ICAM5 
rs3093030 19p13 1.16 4.88 × 10⁻¹⁰ Boackle (2013) 
CXorf21 rs887369 Xp21.2 1.15 5.26 × 10⁻¹⁰ Bentham et al. (2015) 
RAD51B rs4902562 14q24.1 1.14 6.15 × 10⁻¹⁰ Bentham et al. (2015) 
TLR7 rs3853839 Xp22.3 1.67 6.50 × 10⁻¹⁰ Vaughn et al. (2012) 
IRF7 rs12802200 11p15.5 1.23 8.81 × 10⁻¹⁰ Bentham et al. (2015) 
LYST rs9782955 1q42.3 1 1.16 1.25 × 10⁻⁹ Bentham et al. (2015) 
PRKCB rs16972959 16p11.2 0.81 1.40 × 10⁻⁹ Vaughn et al. (2012) 
IL12A rs564799 3q25.33 1.14 1.54 × 10⁻⁹ Bentham et al. (2015) 
PLD2 rs2286672 17p13.2 1.25 2.93 × 10⁻⁹ Bentham et al. (2015) 
SH2B3 rs10774625 12q24.12 1.13 4.09 × 10⁻⁹ Bentham et al. (2015) 
IL10 rs3024505 1q24 1.17 4.64 × 10⁻⁹ Bentham et al. (2015) 
LYN rs7829816 8q13 0.77 5.40 × 10⁻⁹ Vaughn et al. (2012) 
UHRF1BP1 rs9462027 6p21 1.14 7.55 × 10⁻⁹ Bentham et al. (2015) 
AFF1 rs340630 4q21 1.21 8.30 × 10⁻⁹ Boackle (2013) 
TMEM39A rs1132200 3q13.33 
0.73–
0.83 
8.62 × 10⁻⁹ Boackle (2013) 
RPEL1 rs4917385 10q24.33 0.72 1.39 × 10⁻⁸ 
Alarcon-Riquelme et al. 
(2016) 
ELF1 rs7329174 13q13 1.26 1.50 × 10⁻⁸ Vaughn et al. (2012) 
IL21 rs907715 4q26 1.16 2.20 × 10⁻⁸ Vaughn et al. (2012) 
CREBL2 rs12822507 12p13 0.86 2.22 × 10⁻⁸ Yang et al. (2013) 
SPRED2 rs6740462 2p14 1.2 2.31 × 10⁻⁸ Bentham et al. (2015) 
ITGAM, ITGAX rs11574637 16p11.2 1.33 3.00 × 10⁻¹¹ Hom et al. (2008) 
All associated loci passed a genome-wide significance threshold of 5 × 10⁻⁸. Associations within the xMHC 
region are not included. OR – odds ratio. 
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Table D2 Genes associated with monogenic forms of SLE.  
 
Reported Gene Variant(s) Region Reference 
ACP5 (TRAP) I89T, G215R, D241N, M264K 19p13 Briggs et al. (2011) 
C1QA Homozygous deficiency 1p36.12 Bryan and Wu (2014) 
C1QB Homozygous deficiency 1p36.12 Bryan and Wu (2014) 
C1QC Homozygous deficiency 1p36.12 Bryan and Wu (2014) 
C1R Homozygous deficiency 12p13.31 Bryan and Wu (2014) 
C1S Homozygous deficiency 12p13.31 Bryan and Wu (2014) 
C2 Homozygous deficiency 6p21.33 Bryan and Wu (2014) 
DNASE1 K5X 16p13 Yasutomo et al. (2001) 
DNASE1L3 W215GfsX2 3p14 Al-Mayouf et al. (2011) 
FASL 84-bp deletion 1q24.3 Wu et al. (1996) 
PRKCD G510S 3p21.1 Belot et al. (2013) 
RNASEH2A L202S 19p13.13 Gunther et al. (2015) 
RNASEH2B K233Q 13q14.3 Gunther et al. (2015) 
RNASEH2C 348 + 1 G>A 11q13.1 Gunther et al. (2015) 
SAMHD1 I201N 20q11 Ravenscroft et al. (2011) 




















Appendix E  
 
Table E1 The effect of IFN-α stimulation on the expression of type 1 interferonopathy susceptibility genes 
in B cells.  












   
   
 
Type 1 interferonopathy-associated genes were obtained from Crow and Manel (2015). Genes 




















IFIH1 2584207 9.82 6.09 × 10⁻¹⁶ 
DDX58 (RIG1) 3203086 8.48 6.00 × 10⁻¹⁵ 
ADAR 2436754 4.57 6.14 × 10⁻¹⁵ 
ISG15 4053534 45.01 7.39 × 10⁻¹⁵ 
PSMB8 2950199 2.49 1.25 × 10⁻¹⁰ 
SAMHD1 3904691 3.76 2.14 × 10⁻⁸ 
TREX1 2621705 1.48 1.23 × 10⁻⁷ 
ACP5 (TRAP) 3851072 2.01 2.56 × 10⁻² 
RNASEH2C 3377826 1.14 6.80 × 10⁻² 
RNASEH2B 3489957 1.10 9.63 × 10⁻² 
TMEM173 (STING) 2877990 -1.07 1.14 × 10⁻¹ 













TAP1 class II 2950214 3.75 8.22 × 10⁻¹⁵ 
TNF class III 2902416 10.00 1.52 × 10⁻¹⁴ 
HLA-DMA class II 2950277 -2.13 1.39 × 10⁻¹² 
PPP1R10 class I 2948425 2.41 6.28 × 10⁻¹¹ 
PSMB8 class II 2950199 2.49 1.25 × 10⁻¹⁰ 
HLA-DMB class II 2950263 -2.25 7.79 × 10⁻¹⁰ 
LOC100507463 class II 2903285 1.91 4.37 × 10⁻⁹ 
HLA-F class I 2900974 2.16 4.75 × 10⁻⁹ 
TAP2 class II 2950167 2.93 6.64 × 10⁻⁹ 
LTA class III 2902407 6.46 7.09 × 10⁻⁹ 
HLA-DOA class II 2950307 -2.55 7.47 × 10⁻⁹ 
NCR3 class III 2949132 -2.78 1.99 × 10⁻⁸ 
ABCF1 class I 2901687 1.56 3.48 × 10⁻⁸ 
GABBR1 xclass I 2947889 -2.34 3.49 × 10⁻⁸ 
HLA-DOB class II 2950145 -2.10 5.24 × 10⁻⁸ 
NRM class I 2948547 -2.57 1.07 × 10⁻⁷ 
BTN2A1 xclass I 2899437 2.03 1.12 × 10⁻⁷ 
TRIM26 class I 2948259 1.87 1.28 × 10⁻⁷ 
ZNRD1 class I 2901333 2.54 1.62 × 10⁻⁷ 
LTB class III 2949118 -2.11 1.65 × 10⁻⁷ 
FKBPL class III 2949760 1.72 2.17 × 10⁻⁷ 
BAG6 class III 2949148 1.45 3.25 × 10⁻⁷ 
AGPAT1 class III 2949801 -1.49 4.52 × 10⁻⁷ 
HIST1H2AK xclass I 2947063 -2.55 5.84 × 10⁻⁷ 
HIST1H1C xclass I 2946232 -3.63 1.40 × 10⁻⁶ 
HIST1H1D xclass I 2946353 -2.76 1.87 × 10⁻⁶ 
TCF19 class I 2902178 -1.61 2.57 × 10⁻⁶ 
TAPBP xclass II 2950629 1.35 3.01 × 10⁻⁶ 
MSH5-SAPCD1 class III 2902633 -1.59 4.64 × 10⁻⁶ 
HSPA1B class III 2902707 3.00 4.97 × 10⁻⁶ 









DHX16 class I 2948485 1.38 5.29 × 10⁻⁶ 
CLIC1 class III 2949330 2.08 6.43 × 10⁻⁶ 
ZNF184 xclass I 2946845 1.59 9.71 × 10⁻⁶ 
RGL2 xclass II 2950590 -1.68 1.13 × 10⁻⁵ 
HIST1H1E xclass I 2899171 -2.60 1.19 × 10⁻⁵ 
HSD17B8 xclass II 2903488 -1.66 1.81 × 10⁻⁵ 
MRPS18B class I 2901818 2.02 1.81 × 10⁻⁵ 
HLA-DPA1 class II 2950329 -1.29 2.18 × 10⁻⁵ 
HIST1H2AC xclass I 2899152 -1.87 2.23 × 10⁻⁵ 
C6orf25 class III 2902609 -2.44 2.65 × 10⁻⁵ 
EHMT2 class III 2949524 -1.49 2.73 × 10⁻⁵ 
LOC554223 class I 2901043 1.62 3.06 × 10⁻⁵ 
WDR46 xclass II 2950561 1.80 3.71 × 10⁻⁵ 
HIST1H3E xclass I 2899233 2.09 5.77 × 10⁻⁵ 
HLA-DPB2 class II 2903435 -1.66 6.54 × 10⁻⁵ 
PPP1R11 class I 2901352 1.61 8.30 × 10⁻⁵ 
HIST2H4B xclass I 2899216 -2.12 9.35 × 10⁻⁵ 
HIST1H2AE xclass I 2899223 -2.42 1.02 × 10⁻⁴ 
AIF1 class III 2902444 -3.08 1.15 × 10⁻⁴ 
BRD2 class II 2903343 1.34 1.42 × 10⁻⁴ 
HIST1H2BN xclass I 2900074 -1.70 2.20 × 10⁻⁴ 
TUBB class I 2948587 -1.42 2.59 × 10⁻⁴ 
TRIM38 xclass I 2899022 1.41 2.82 × 10⁻⁴ 
SLC39A7 xclass II 2903470 1.38 3.45 × 10⁻⁴ 
BTN3A3 xclass I 2899413 1.66 3.95 × 10⁻⁴ 
PFDN6 xclass II 2903588 1.51 3.96 × 10⁻⁴ 
PPP1R18 class I 2948522 -1.78 5.64 × 10⁻⁴ 
LST1 class III 2902427 -1.66 5.75 × 10⁻⁴ 
TRIM27 xclass I 2947572 1.32 5.97 × 10⁻⁴ 
PGBD1 xclass I 2900453 -1.27 9.05 × 10⁻⁴ 
ATAT1 class I 2901841 -1.20 9.21 × 10⁻⁴ 
HLA-E class I 2901620 1.27 1.04 × 10⁻³ 
HIST2H4B xclass I 2899768 1.93 1.24 × 10⁻³ 
BTN2A2 xclass I 2899340 -1.82 1.28 × 10⁻³ 









ZNF187 xclass I 2900423 -1.44 1.60 × 10⁻³ 
C6orf10 class II 2949971 -1.75 1.72 × 10⁻³ 
DOM3Z class III 2949588 -1.31 1.84 × 10⁻³ 
TRIM10 class I 2948239 -1.30 1.96 × 10⁻³ 
ABHD16A class III 2949256 1.24 2.79 × 10⁻³ 
HIST1H3I xclass I 2947077 -1.98 3.44 × 10⁻³ 
NEU1 class III 2949471 1.44 3.96 × 10⁻³ 
PRR3 class I 2901660 1.40 4.33 × 10⁻³ 
HIST1H1B xclass I 2947073 -2.32 4.64 × 10⁻³ 
ZNF323 xclass I 2947248 -1.18 5.25 × 10⁻³ 
HSPA1A class I 2948713 1.26 5.45 × 10⁻³ 
ABT1 xclass I 2899519 1.25 5.86 × 10⁻³ 
ZSCAN16 xclass I 2900269 1.27 6.57 × 10⁻³ 
HCG9 class I 2901312 1.49 7.66 × 10⁻³ 
SLC17A4 xclass I 2898986 -1.46 7.74 × 10⁻³ 
LOC100507547 class III 2949772 1.34 8.71 × 10⁻³ 
HLA-DRA class II 2903189 -1.14 9.89 × 10⁻³ 
HCG27 class I 2902207 1.38 1.11 × 10⁻² 
HIST1H2BO xclass I 2900116 -1.57 1.17 × 10⁻² 
MIR4640 class I 2901970 -1.12 1.20 × 10⁻² 
RXRB xclass II 2950474 1.17 1.56 × 10⁻² 
ZKSCAN3 xclass I 2900497 -1.11 1.70 × 10⁻² 
HIST1H2AM xclass I 2947100 -1.24 1.94 × 10⁻² 
VARS class III 2949380 -1.21 1.94 × 10⁻² 
HIST1H4F xclass I 2899243 1.76 2.04 × 10⁻² 
GPSM3 class III 2949885 -1.22 2.23 × 10⁻² 
STK19 class III 2902935 1.32 2.43 × 10⁻² 
APOM class III 2902531 1.09 2.55 × 10⁻² 
BTN3A1 xclass I 2899372 -1.20 2.57 × 10⁻² 
HSPA1L class III 2949450 1.28 2.66 × 10⁻² 
GPX6 xclass I 2947387 -1.32 2.70 × 10⁻² 
C2 class III 2902804 -1.22 3.00 × 10⁻² 
COL11A2 xclass II 2950384 -1.11 3.24 × 10⁻² 
MAS1L xclass I 2947842 -1.20 3.29 × 10⁻² 









HIST1H2AA xclass I 2946050 -1.32 3.46 × 10⁻² 
HIST1H2BM xclass I 2900059 -1.48 3.54 × 10⁻² 
HIST1H3C xclass I 2899102 -1.20 3.56 × 10⁻² 
PPP1R11 class I 2948188 -1.11 4.03 × 10⁻² 
SLC17A1 xclass I 2946056 -1.15 4.12 × 10⁻² 
SLC17A3 xclass I 2946106 -1.20 4.18 × 10⁻² 
HIST1H2BG xclass I 2946345 -1.33 4.72 × 10⁻² 
BTN3A2 xclass I 2899298 1.38 4.76 × 10⁻² 
C6orf48 class III 2902736 -1.12 4.89 × 10⁻² 
 






























Strong evidence of alternative splicing (FDR < 1%) 
HIST1H2AH xclass I 2899756 3.26 × 10⁻⁹ 
HIST1H2BD xclass I 2899176 8.71 × 10⁻⁸ 
HIST1H2AM xclass I 2947100 1.89 × 10⁻⁶ 
SKIV2L class III 2902884 2.08 × 10⁻⁶ 
HIST1H3D xclass I 2946324 3.78 × 10⁻⁶ 
NOTCH4 class III 2949901 4.77 × 10⁻⁶ 
HCP5 class I 2902326 2.37 × 10⁻⁴ 
PPP1R11 class I 2948188 2.52 × 10⁻⁴ 
SCAND3 xclass I 2947405 6.08 × 10⁻⁴ 
OR11A1 xclass I 2947805 6.59 × 10⁻⁴ 
CSNK2B class III 2902559 1.85 × 10⁻³ 
CYP21A1P class III 2903034 3.28 × 10⁻³ 
MDC1 class I 2948564 4.70 × 10⁻³ 
VWA7 class III 2949352 8.07 × 10⁻³ 
Suggestive evidence of alternative splicing (FDR < 5%) 
COL11A2 xclass II 2950384 1.27 × 10⁻² 
C6orf47 class III 2949197 1.34 × 10⁻² 
GTF2H4 class I 2902013 2.15 × 10⁻² 
ZNF193 xclass I 2900372 3.01 × 10⁻² 
HIST1H2BJ xclass I 2946681 3.52 × 10⁻² 

































2151  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201 - - 
2152 - - - - - - - - - -  - - 
3571  A_0301  A_2301  C_0501  C_0701  B_0801  B_1801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0301 
 DPB1_0101/ 
DPB1_0502 
3572  A_0101  A_2301  C_0501  C_0701  B_0801  B_1801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0101  DPB1_0301 
30301  A_0101  A_0301  C_0401  C_0701  B_0801  B_3501  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0301  DPB1_0401 
30302 - - - - - - - - - - - - 
32331  A_0101  A_2902  C_0501  C_0701  B_0801  B_4402 
 DRB_0101/ 
DRB_0103 
 DRB_0301  DQB_0201  DQB_0501  DPB1_0401  DPB1_0101 
34572 - - - - - - - - - - - - 
45201 - - - - - - - - - - - - 
45202 - - - - - - - - - - - - 
51351 - - - - - - - - - - - - 
51352  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0401  DPB1_0401 
64522  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_1101  DPB1_0101 
73511  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0301  DPB1_0301 
73512  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0301  DPB1_0301 
75591  A_0101  A_6801  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201 - - 
75592  A_0101  A_6801  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201 - - 
81231 - - - - - - - - - - - - 
95711  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0401  DPB1_0401 
95712  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0401  DPB1_0401 
98661  A_0101  A_0201  C_0501  C_0701  B_0801  B_4402  DRB_0301  DRB_0301  DQB_0201  DQB_0201 - - 
98662 - - - - - - - - - - - - 
COX  A_0101  A_0101  C_0701  C_0701  B_0801  B_0801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0301  DPB1_0301 
QBL  A_2601  A_2601  C_0501  C_0501  B_1801  B_1801  DRB_0301  DRB_0301  DQB_0201  DQB_0201  DPB1_0202  DPB1_0202 





BTN3A1      ATGAAAATGGCAAGTTTCCTGGCCTTCCTTCTGCTCAACTTTCGTGTCTGCCTCCTTTTG 
BTN3A2      ATGAAAATGGCAAGTTCCCTGGCTTTCCTTCTGCTCAACTTTCATGTCTCCCTCCTCTTG 
BTN3A3      ATGAAAATGGCAAGTTCCCTGGCTTTCCTTCTGCTCAACTTTCATGTCTCCCTCTTCTTG 
            **************** ****** ******************* ***** **** * *** 
 
BTN3A1      CTTCAGCTGCTCATGCCTCACTCAGCTCAGTTTTCTGTGCTTGGACCCTCTGGGCCCATC 
BTN3A2      GTCCAGCTGCTCACTCCTTGCTCAGCTCAGTTTTCTGTGCTTGGACCCTCTGGGCCCATC 
BTN3A3      GTCCAGCTGCTCACTCCTTGCTCAGCTCAGTTTTCTGTGCTTGGACCCTCTGGGCCCATC 
             * **********  ***  **************************************** 
 
BTN3A1      CTGGCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACCTGTTCCCGACCATGAGTGCA 
BTN3A2      CTGGCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACCTGTTCCCGACCATGAGTGCA 
BTN3A3      CTGGCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACCTGTTCCCGACCATGAGTGCA 
            ************************************************************ 
 
BTN3A1      GAGACCATGGAGCTGAAGTGGGTGAGTTCCAGCCTAAGGCAGGTGGTGAACGTGTATGCA 
BTN3A2      GAGACCATGGAGCTGAAGTGGGTAAGTTCCAGCCTAAGGCAGGTGGTGAACGTGTATGCA 
BTN3A3      GAGACCATGGAGCTGAGGTGGGTGAGTTCCAGCCTAAGGCAGGTGGTGAACGTGTATGCA 
            **************** ****** ************************************ 
 
BTN3A1      GATGGAAAGGAAGTGGAAGACAGGCAGAGTGCACCGTATCGAGGGAGAACTTCGATTCTG 
BTN3A2      GATGGAAAGGAAGTGGAAGACAGGCAGAGTGCACCGTATCGAGGGAGAACTTCGATTCTG 
BTN3A3      GATGGAAAGGAAGTGGAAGACAGGCAGAGTGCACCGTATCGAGGGAGAACTTCGATTCTG 
            ************************************************************ 
 
BTN3A1      CGGGATGGCATCACTGCAGGGAAGGCTGCTCTCCGAATACACAACGTCACAGCCTCTGAC 
BTN3A2      CGGGATGGCATCACTGCAGGGAAGGCTGCTCTCCGAATACACAACGTCACAGCCTCTGAC 
BTN3A3      CGGGATGGCATCACTGCAGGGAAGGCTGCTCTCCGAATACACAACGTCACAGCCTCTGAC 
            ************************************************************ 
 
BTN3A1      AGTGGAAAGTACTTGTGTTATTTCCAAGATGGTGACTTCTATGAAAAAGCCCTGGTGGAG 
BTN3A2      AGTGGAAAGTACTTGTGTTATTTCCAAGATGGTGACTTCTATGAAAAAGCCCTGGTGGAG 
BTN3A3      AGTGGAAAGTACTTGTGTTATTTCCAAGATGGTGACTTCTACGAAAAAGCCCTGGTGGAG 
            ***************************************** ****************** 
 
BTN3A1      CTGAAGGTTGCAGCACTGGGTTCTGATCTTCACGTTGATGTGAAGGGTTACAAGGATGGA 
BTN3A2      CTGAAGGTTGCAGCACTGGGTTCTAATCTTCACGTCGAAGTGAAGGGTTATGAGGATGGA 
BTN3A3      CTGAAGGTTGCAGCATTGGGTTCTGATCTTCACATTGAAGTGAAGGGTTATGAGGATGGA 
            *************** ******** ******** * ** ***********  ******** 
 
BTN3A1      GGGATCCATCTGGAGTGCAGGTCCACTGGCTGGTACCCCCAACCCCAAATACAGTGGAGC 
BTN3A2      GGGATCCATCTGGAGTGCAGGTCCACCGGCTGGTACCCCCAACCCCAAATACAGTGGAGC 
BTN3A3      GGGATCCATCTGGAGTGCAGGTCCACTGGCTGGTACCCCCAACCCCAAATAAAGTGGAGC 
            ************************** ************************ ******** 
 
BTN3A1      AACAACAAGGGAGAGAACATCCCGACTGTGGAAGCACCTGTGGTTGCAGACGGAGTGGGC 
BTN3A2      AACGCCAAGGGAGAGAACATCCCAGCTGTGGAAGCACCTGTGGTTGCAGATGGAGTGGGC 
BTN3A3      GACACCAAGGGAGAGAACATCCCGGCTGTGGAAGCACCTGTGGTTGCAGATGGAGTGGGC 
             **  ******************  ************************* ********* 
 
BTN3A1      CTGTATGCAGTAGCAGCATCTGTGATCATGAGAGGCAGCTCTGGGGAGGGTGTATCCTGT 
BTN3A2      CTATATGAAGTAGCAGCATCTGTGATCATGAGAGGCGGCTCCGGGGAGGGTGTATCCTGC 
BTN3A3      CTGTATGCAGTAGCAGCATCTGTGATCATGAGAGGCAGCTCTGGTGGGGGTGTATCCTGC 
            ** **** **************************** **** ** * ************  
 
BTN3A1      ACCATCAGAAGTTCCCTCCTCGGCCTGGAAAAGACAGCCAGCATTTCCATCGCAGACCCC 
BTN3A2      ATCATCAGAAATTCCCTCCTCGGCCTGGAAAAGACAGCCAGCATTTCCATCGCAGACCCC 
BTN3A3      ATCATCAGAAATTCCCTCCTCGGCCTGGAAAAGACAGCCAGCATATCCATCGCAGACCCC 
            * ******** ********************************* *************** 
 
BTN3A1      TTCTTCAGGAGCGCCCAGAGGTGGATCGCCGCCCTGGCAGGGACCCTGCCTGTCTTGCTG 
BTN3A2      TTCTTCAGGAGCGCCCAGCCCTGGATCGCAGCCCTGGCAGGGACCCTGCCTATCTTGCTG 
BTN3A3      TTCTTCAGGAGCGCCCAGCCCTGGATCGCGGCCCTGGCAGGGACCCTGCCTATCTCGTTG 




BTN3A1      CTGCTTCTTGGGGGAGCCGGTTACTTCCTGTGGCAACAGCAGGAGGAAAAAAAGACTCAG 
BTN3A2      CTGCTTCTCGCCGGAGCCAGTTACTTCTTGTGGAGACAACAGAAGGAAATAACTGCTCTG 
BTN3A3      CTGCTTCTCGCAGGAGCCAGTTACTTCTTGTGGAGACAACAGAAGGAAAAAATTGCTCTG 
            ******** *  ****** ******** *****  *** *** ****** **   *** * 
 
BTN3A1      TTCAGAAAGAAAAAGAGAGAGCAAGAGTTGAGAGAAATGGCATGGAGCACAATGAAGCAA 
BTN3A2      TCCAGTGAGATAGAAAGTGAGCAAGAGATGAAAGAAATGGGATATGCTGCAACAGAGCGG 
BTN3A3      TCCAGGGAGACAGAAAGAGAGCGAGAGATGAAAGAAATGGGATACGCTGCAACAGAGCAA 
            * ***  *** * * ** **** **** *** ******** **      ***   ***   
 
BTN3A1      GAACAAAGCACAAGAGTGAAGCTCCTGGAGGAACTCAGATGGAGAAGTATCCAGTATGCA 
BTN3A2      GAAATAAGCCTAAGAGAGAGCCTCCAGGAGGAACTCAAGAGGAAAAAAATCCAGTACTTG 
BTN3A3      GAAATAAGCCTAAGAGAGAAGCTCCAGGAGGAACTCAAGTGGAGGAAAATCCAGTACATG 
            ***  ****  ***** **  **** ***********   ***  *  ********     
 
BTN3A1      TCTCGGGGAGAGAGACATTCAGCCTATAATGAATGGAAAAAGGCCCTCTTCAAGCCTGCG 
BTN3A2      ACTCGTGGAGAGGAGTCTTCGTCCGATACCAATAAGTCAGCCTGA--------------- 
BTN3A3      GCTCGTGGAGAGAAGTCTTTGGCCTATCATGAATGGAAAATGGCCCTCTTCAAACCTGCG 
             **** ******     **   ** **    *   *  *                      
 
BTN3A1      GATGTGATTCTGGATCCAAAAACAGCAAACCCCATCCTCCTTGTTTCTGAGGACCAGAGG 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      GATGTGATTCTGGATCCAGACACGGCAAACGCCATCCTCCTTGTTTCTGAGGACCAGAGG 
                                                                         
 
BTN3A1      AGTGTGCAGCGTGCCAAGGAGCCCCAGGATCTGCCAGACAACCCTGAGAGATTTAATTGG 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      AGTGTGCAGCGTGCTGAAGAGCCGCGGGATCTGCCAGACAACCCTGAGAGATTTGAATGG 
                                                                         
 
BTN3A1      CATTATTGTGTTCTCGGCTGTGAGAGCTTCATATCAGGGAGACATTACTGGGAGGTGGAG 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      CGTTACTGTGTCCTTGGCTGTGAAAACTTCACATCAGGGAGACATTACTGGGAGGTGGAA 
                                                                         
 
BTN3A1      GTAGGGGACAGGAAAGAGTGGCATATAGGGGTGTGCAGTAAGAATGTGCAGA---GAAAA 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      GTGGGGGACAGAAAAGAGTGGCATATTGGGGTATGTAGTAAGAACGTGGAGAGGAAAAAA 
                                                                         
 
BTN3A1      GGCTGGGTCAAAATGACACCTGAGAATGGATTCTGGACTATGGGGCTGACTGATGGGAAT 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      GGTTGGGTCAAAATGACACCGGAGAACGGATACTGGACTATGGGCCTGACTGATGGGAAT 
                                                                         
 
BTN3A1      AAGTATCGGACTCTAACTGAGCCCAGAACCAACCTGAAACTTCCTAAGCCCCCTAAGAAA 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      AAGTATCGGGCTCTCACTGAGCCCAGAACCAACCTGAAACTTCCTGAGCCTCCTAGGAAA 
                                                                         
 
BTN3A1      GTGGGGGTCTTCCTGGACTATGAGACTGGAGATATCTCATTCTACAATGCTGTGGATGGA 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      GTGGGGATCTTCCTGGACTATGAGACTGGAGAGATCTCGTTCTATAATGCCACAGATGGA 
                                                                         
 
BTN3A1      TCGCATATTCATACTTTCCTGGACGTCTCCTTCTCTGAGGCTCTATATCCTGTTTTCAGA 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      TCTCATATCTACACCTTTCCGCACGCCTCTTTCTCTGAGCCTCTATATCCTGTTTTCAGA 
                                                                         
 
BTN3A1      ATTTTGACCTTGGAGCCCACGGCCCTGACTATTTGTCCAGCGTGA--------------- 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      ATTTTGACCTTGGAGCCCACTGCCCTGACCATTTGCCCAATACCAAAAGAAGTAGAGAGT 
                                                                         
 
BTN3A1      ------------------------------------------------------------ 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      TCCCCCGATCCTGACCTAGTGCCTGATCATTCCCTGGAGACACCACTGACCCCGGGCTTA 










BTN3A1      ------------------------------------------------------------ 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      GCTAATGAAAGTGGGGAGCCTCAGGCTGAAGTAACATCTCTGCTTCTCCCTGCCCACCCT 
                                                                         
 
BTN3A1      ------------------------------------------------------------ 
BTN3A2      ------------------------------------------------------------ 
BTN3A3      GGAGCTGAGGTCTCCCCTTCTGCAACAACCAATCAGAACCATAAGCTACAGGCACGCACT 
                                                                         
 
BTN3A1      --------------- 
BTN3A2      --------------- 
BTN3A3      GAAGCACTTTACTGA 
                            
  
Figure H1 Clustal alignment of the coding cDNA sequences from all three BTN3 genes.  
 
The BTN3A2 exons targeted by the TaqMan qPCR assay are highlighted in yellow (exon 8) and cyan 





























M  K  M  A  S  S  L  A  F  L  L  L  N  F  H  V  S  L  L  L 
 
GTCCAGCTGCTCACTCCTTGCTCAGCTCAGTTTTCTGTGCTTGGACCCTCTGGGCCCATC 
V  Q  L  L  T  P  C  S  A  Q  F  S  V  L  G  P  S  G  P  I  
 
CTGGCCATGGTGGGTGAAGACGCTGATCTGCCCTGTCACCTGTTCCCGACCATGAGTGCA 
L  A  M  V  G  E  D  A  D  L  P  C  H  L  F  P  T  M  S  A  
 
GAGACCATGGAGCTGAAGTGGGTAAGTTCCAGCCTAAGGCAGGTGGTGAACGTGTATGCA 
E  T  M  E  L  K  W  V  S  S  S  L  R  Q  V  V  N  V  Y  A  
 
GATGGAAAGGAAGTGGAAGACAGGCAGAGTGCACCGTATCGAGGGAGAACTTCGATTCTG 
D  G  K  E  V  E  D  R  Q  S  A  P  Y  R  G  R  T  S  I  L  
 
CGGGATGGCATCACTGCAGGGAAGGCTGCTCTCCGAATACACAACGTCACAGCCTCTGAC 
R  D  G  I  T  A  G  K  A  A  L  R  I  H  N  V  T  A  S  D  
 
AGTGGAAAGTACTTGTGTTATTTCCAAGATGGTGACTTCTATGAAAAAGCCCTGGTGGAG 
S  G  K  Y  L  C  Y  F  Q  D  G  D  F  Y  E  K  A  L  V  E  
 
CTGAAGGTTGCAGCACTGGGTTCTAATCTTCACGTCGAAGTGAAGGGTTATGAGGATGGA 
L  K  V  A  A  L  G  S  N  L  H  V  E  V  K  G  Y  E  D  G  
 
GGGATCCATCTGGAGTGCAGGTCCACCGGCTGGTACCCCCAACCCCAAATACAGTGGAGC 
G  I  H  L  E  C  R  S  T  G  W  Y  P  Q  P  Q  I  Q  W  S  
 
AACGCCAAGGGAGAGAACATCCCAGCTGTGGAAGCACCTGTGGTTGCAGATGGAGTGGGC 
N  A  K  G  E  N  I  P  A  V  E  A  P  V  V  A  D  G  V  G  
 
CTATATGAAGTAGCAGCATCTGTGATCATGAGAGGCGGCTCCGGGGAGGGTGTATCCTGC 
L  Y  E  V  A  A  S  V  I  M  R  G  G  S  G  E  G  V  S  C  
 
ATCATCAGAAATTCCCTCCTCGGCCTGGAAAAGACAGCCAGCATTTCCATCGCAGACCCC 
I  I  R  N  S  L  L  G  L  E  K  T  A  S  I  S  I  A  D  P  
 
TTCTTCAGGAGCGCCCAGCCCTGGATCGCAGCCCTGGCAGGGACCCTGCCTATCTTGCTG 
F  F  R  S  A  Q  P  W  I  A  A  L  A  G  T  L  P  I  L  L  
 
CTGCTTCTCGCCGGAGCCAGTTACTTCTTGTGGAGACAACAGAAGGAAATAACTGCTCTG 
L  L  L  A  G  A  S  Y  F  L  W  R  Q  Q  K  E  I  T  A  L  
 
TCCAGTGAGATAGAAAGTGAGCAAGAGATGAAAGAAATGGGATATGCTGCAACAGAGCGG 
S  S  E  I  E  S  E  Q  E  M  K  E  M  G  Y  A  A  T  E  R  
 
GAAATAAGCCTAAGAGAGAGCCTCCAGGAGGAACTCAAGAGGAAAAAAATCCAGTACTTG 
E  I  S  L  R  E  S  L  Q  E  E  L  K  R  K  K  I  Q  Y  L  
 
ACTCGTGGAGAGGAGTCTTCGTCCGATACCAATAAGTCAGCCTGA 
T  R  G  E  E  S  S  S  D  T  N  K  S  A  *  
 
Figure I1 The BTN3A2 coding cDNA sequence (top), and the corresponding BT3.2 amino acid sequence 
(bottom).  
 
Alternating exons are coloured in black and blue, and residues over splice sites are shown in red. The 
boxed region indicates the antigen targeted by the BT3.2 antibody used for Western blotting. The 
corresponding cDNA sequence overlaps the exons targeted by the TaqMan qPCR assay, which are 
highlighted in yellow (exon 8) and cyan (exon 9). The asterisk denotes the stop codon. 
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